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Biomedical research typically relies on data collected from patients in clinical settings. This is currently 
a fraught process due to the diversity and heterogeneity of data management systems, the numerous 
data standards and the sensitivities around the access to and sharing of such data. To tackle this,
international biomedical registries are often established and targeted to specific diseases and 
communities. The quality of the data in such registries is essential to ensure that the clinical research 
findings can be translated into clinical care. However, at present clinical data management systems 
developed for biomedical research rarely perform quality assurance procedures during ongoing data 
collection. Similarly, clinical trials typically perform data quality assessment at the end of the trial. This 
is too late. We argue that data quality assurance procedures for cost reduction and data process 
improvements have to be implemented as an integral and ongoing part of disease registries and the 
data that they are used to collect.
Such an approach requires all aspects of data collection efforts are considered including the intrinsic 
and extrinsic motivational factors of data entry personnel and the organisations in which they work. 
Technical solutions that encourage better behaviour and hence improve data quality are thus 
encouraged.
Hypothesis 
The web-based interactions between data entry users and data management systems can be used to 
improve data quality. Leveraging technological advancement of web-based registries, new feedback 
mechanisms can be used to improve the overall data quality of the data that is captured by registries. 
This should lead to streamlined and improved data capture methods that support the users and 
ultimately benefit the clinical research more generally. This thesis proposes that web-based data 
quality feedback can motivate registry data entry personnel, increase their contributions and 
ultimately improve the quality of registry data and its (re-)use to support clinical trials.
Methods
To explore causes of low data quality and user motivation, a survey and an assessment of quality 
indicators in a multicentre clinical setting was performed. Based on this, we developed and evaluated 
a stage wise framework for web-based feedback and measured data quality trends including the 
factors that can impact user motivation in their data entry. This was explored in the International 
Niemann-Pick Disease Registry (INPDR) and two major international clinical trials associated with the 
European Network for the Study of Adrenal Tumours (ENSAT). We also considered the role of patients 
in data collection through mobile applications supporting data collection with the context of the 
Environmental Determinants of Islet Auto-immunity (ENDIA) clinical study.
Results 
Researchers are motivated when they see the contribution resulting from their data entry and the 
improvement in treatment of patients. The results of the survey and the framework evaluation 
highlight the effectiveness of web-based automated data quality feedback. It was discovered that data 
quality feedback to researchers and the research community improve the data quality. Case studies 
showed an increase of data quality over the period of observation of this research – noting that these 
studies are still ongoing. The stage wise framework to evaluate data entry user behaviour after 
feedback was applied to one trial, which showed that feedback encouraged users to enter both more 
and higher quality data.
III
Conclusions
Recent literature confirms the need for data quality feedback as an ongoing and near-real time activity 
associated with data capture. Centralised data monitoring requires a general framework that can be 
adjusted for a variety of trials and studies. The proposed stage wide research method must be 
improved to measure the outcome of data quality feedback against a control group and/or where 
known benchmarks exist. 
Data quality dimensions need to be adjusted to all research interests. In the age of big data and mobile 
health possibilities, further research needs to be performed with regards to the upcoming challenges 
of data trustworthiness and record eligibility to tackle current and future research objectives. The 
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GLOSSARY
ACC Adrenocortical carcinoma, a malignant adrenal tumour. It secretes 
corticosteroid hormones (Arlt, 2011).
ACTH Adrenocorticotropic Hormone is a hormone measured during a 
Dexamethason Test (DST).
ADDN Australian Diabetes Data Network.
ADIUVO a clinical trial associated with the ENSAT registry.
APA Aldosterone producing adenoma, is an adrenal tumour that causes the 
production of higher levels of aldosterone, which subsequently causes 
lower renin levels that lead to primary aldosteronism (or Conn’s 
Syndrome) (Schirpenbach & Reincke, 2007).
Big Data in the biomedical context, big data is used to describe the increasingly 
voluminous and heterogeneous data that can now be generated by 
sequencing machines, sensors, mobile devices, clinical devices or indeed 
people. Big data often is described by volume, velocity (speed of 
production), variety, and in the clinical domain especially, data often has 
need for veracity (trustworthiness).
Data Mining aggregation and analysis of large (big) datasets to make data more readily 
understandable. Data mining is also used in a range of data-driven 
research approaches (instead of hypothesis-driven research) (Batini & 
Scannapieco, 2006).
DC data completeness.
DIKW Pyramid Data, Information, Knowledge, Wisdom Pyramid. A framework used to 
understand the context and purpose of data collection and its processes 
used to improve research knowledge (Division & Pharmaceuticals, 2001).
DQS data quality score.
DST Dexamethason Test is a test that checks if an adenoma is hormone-
secreting (Nieman, 2010).
eCRF electronic case report forms, a digital data capture system used for trial 
related case/subject information that is stored in a clinical database 
(ECRIN, 2013).
ECRIN European Clinical Research Infrastructure Network.
EHR electronic health record, in this work also referred to as EMR (electronic 
medical record), is a system that captures and stores a digital copy of 
patient related case/subject information – typically in a hospital database.
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EDC electronic data capture, in contrast to manual data entry (MDE) a direct 
feed of patient related information from a medical database to a research 
database (Bacchieri & Della Cioppa, 2012). 
ENDIA Environmental Determinants of Islet Auto-immunity.
ENSAT European Network for the Study of Adrenal Tumours is an international 
leading research network that focuses on adrenal research and on 
improvement of diagnosis and treatment of adrenal tumours.
EURINE-ACT Evaluation of Urine Steroid Metabolomics for the Differential Diagnosis of 
Adrenal Cortical Tumours is a prospective diagnostic trial, focused on 
differentiating benign and malignant adrenocortical tumours.
EU FP7 European Union Framework Program 7, a framework programme for 
research and technological development, which was a funding scheme of 
the European Union between the years 2007-2013. The successor is 
Horizon 2020.
FAMIAN Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal 
Neoplasia is an interventional study performed by ENSAT to verify the 
thesis that a combination of FDG-PET and 123I-Iodometomidate more 
accurately detects adrenocortical adenomas, rather than extracting the 
tumour during surgery and obtaining a diagnosis by a pathologist.
FDA Federal Drug Association, a federal agency in the USA that defines 
standards and provides guidance especially for biomedical research.
FIRST-MAPP a clinical trial associated with the ENSAT registry.
GCP Good Clinical Practise is general standard for the performance of clinical 
trials, defined by the International Conference of Harmonisation (ICH).
Gold Standard Test in clinical research a new diagnostic approach is generally compared to a 
gold standard test, which is defined as the most efficient test, currently 
used in routine care. This test has the highest values of sensitivity 
(probability to detect a disease – true positive rate) and specificity 
(probability to exclude patients that do not have the disease under test–
true negative rate).
h-index is an author-level metric that attempts to measure both the productivity 
and citation impact of the publications of a scientist or scholar. The index 
is based on the set of the scientist's most cited papers and the number of 
citations that they have received in other publications.
HU Hounsfield Units – a quantitative value of radio density of Computer 
Tomography (CT) results. In adrenal research HU supports the 
determination of whether an adrenal tumour is benign or malignant (Arlt, 
2011).
XX
ICC/RICC Intraclass Correlation/Residual Intraclass Correlation is used in clinical 
monitoring to provide a quantified degree “to which observations within 
a cluster differ from those between clusters” (Guthrie et al., 2012). The 
ICC supports the data quality dimension of data comparability. The RICC 
“quantifies the degree of clustering” (Wynants, Timmerman, Bourne, Van 
Huffel, & Van Calster, 2013) and also provides the possibility to visualise 
data inconsistencies for data monitoring purposes.
IF The impact factor (IF) of an academic journal is a measure reflecting the 
yearly average number of citations to articles published in that journal. It 
is frequently used as a proxy for the relative importance of a journal 
within its field.
INPDR International Niemann-Pick Disease Registry.
Interventional 
Informatics
also referred as I2, a novel approach that uses informatics as intervention 
to improve decision making and clinical outcomes of at risk populations 
(Payne, Lussier, Foraker, & Embi, 2016).
Kaplan Meier Survival 
Analysis
A statistical method used to plot the survival rate of a specific disease in 
an observed time period. The time periods are typically plotted 
hierarchically and aggregated. In this model short time periods (more 
critical) are situated on the left side in the graph.
Ki67 is a result of immunohistochemistry, which supports the differentiation 
of a adrenal tumour and whether it is benign or malignant (Fassnacht & 
Allolio, 2009). This is also used in combination with the Weiss Score.
MDE manual data entry, in contrast to electronic data capture (EDC), a direct 
entry of patient/case related information into a clinical (research) 
database.
mHealth an approach to support health related research through mobile devices 
and associated applications. mHealth offers many potential opportunities 
to capture and indeed deliver health-related data (World Health 
Organization, 2011).
NAPACA non-aldosterone producing adrenocortical adenoma, also named 
‘incidentaloma’ a benign form of an adrenal tumour that is commonly 
incidentally detected during routine imaging.
NCI National Cancer Institute, a part of the US National Institutes of Health 
that coordinates the process of cancer related health information to 
conduct research focused on the prevention, diagnosis and treatment of 
cancer.
NPD Niemann-Pick Disease is a rare metabolic disease caused by accumulation 
of fat cells in the liver, spleen, bone marrow and brain. NPD is categorised 
into three types (A, B, C) (Schuchman, 2007)
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pCRF paper case report forms, an analogue of trial related case/subject 





in this thesis, personalised medicine is described as the ultimate goal of 
translational research. Personalised medicine focuses on the detection 
and treatment of a disease specific to an individual using advanced 
knowledge now available since the sequencing of the human genome.
Pheo pheochromocytoma, a benign or malignant adrenal tumor in the adrenal 
medulla, which secretes catecholamines.
PPGL Paraganglioma & Pheochromocytoma, a paraganglima is a 
catecholamine-secreting tumour, which is not located in the adrenal 
medulla (commonly occurring in the head and neck lymphnodes)
PMT Prospective Monoamine Tumour trial is a prospective diagnostic trial 
focused on improving the diagnosis of pheochromocytoma (Pheo).
SDV Source Data Verification is an approach used to detect data 
inconsistencies via re-entering selected data items into eCRFs. In general, 
SDV is used during external audit procedures, e.g. to detect user training 
needs.
Sensitivity see Gold standard test.
SEER Surveillance, Epidemiology and End Results program is a framework of the 
NCI, which provides source data about incidence, prevalence and 
mortality of certain cancer types.
SJR SCImago Journal Rank (SJR indicator) is a measure of scientific influence 
of scholarly journals that accounts for both the number of citations 
received by a journal and the importance or prestige of the journals where 
such citations come from.
SOPs Standard Operation Procedures are procedures defined in a clinical 
context that are used to harmonise processes to improve the 
comparability of diagnostic procedures or treatments.




Translational research has the aim to ‘translate’ findings of basic research 
into clinical routine care. Translational informatics supports this approach 
and provides concepts that move away from general reductionism (where 
problems are broken down to smaller problems) to a move towards 
system thinking (Payne & Embi, 2015). Translational informatics 
promotes data-driven decision making and research, leveraging the 
increasing amount of data available from –omic analytics and information 
about individual phenotypes (Tenenbaum, 2015).
XXII
VRE Virtual Research Environment is an advanced web based research 
environment offering extended functionality to a research community. 
This typically encompasses research databases, analytical capabilities 
with collaboration support.
Weiss score is a system used by pathologists to analyse the morphology of adrenal 
tumour tissues. It consists of 9 parameters. The more parameters that are 
positive, the more likely the tumour is a malignant tumour (Fassnacht & 
Allolio, 2009). The Weiss score alone is not a good diagnostic tool, hence 
it is used in combination with Ki67.
WHO World Health Organisation 
1
1 INTRODUCTION
This chapter provides an overview of the context in which the thesis was developed. Beginning with 
an overview of the current landscape of modern clinical trials and biomedical studies where new 
information technologies are increasingly being applied to obtain increased impact and 
improvements. We consider the way in which big data and especially big data solutions can be applied 
to tackle the challenges of dealing with diverse data holdings. Following this broad overview, we focus 
especially on the specific problems that motivate this research as a whole. Specifically, we consider 
the impact of data quality on clinical research; emphasising the need and the challenges of data quality 
in inter-organisational settings. The chapter introduces the hypothesis for this work. Finally, the 
chapter concludes with a summary of the aims, scope and the significance of this research as a whole.
1.1 Context
Breakthroughs in biomedical research should ideally lead to improvements in clinical care across the 
population in a timely manner. The application of new information technologies in the biomedical 
domain can greatly simplify the work all protagonists involved in clinical research, however such 
technologies give rise to new problems and challenges that must be solved. One of these problems,
which is the focus for the work conducted in this thesis, is the quality of data that is collected and 
analysed during the lifetime of clinical and biomedical research studies. Data quality has a huge impact 
on research outcome and clinical research objectives, especially in the field of rare diseases and in 
multicentre clinical research settings. It is the case that the majority of clinical research studies 
currently rely on data that is manually entered by humans (and not captured and used directly from 
existing clinical healthcare management systems). Patient related information is either entered 
directly into trial databases (or disease registries) where the original source comes from pre-existing 
paper records or electronic hospital records. This process of transferring data into a research study 
database has a huge impact on the quality of the trial data, and ultimately the quality of the research 
that can be undertaken in the clinical trial or research studies more generally. To minimise human 
error, quality assurance procedures such as double data entry are often performed to reduce 
inconsistencies in the data sets that are collected. However, whilst double data entry is an effective 
approach to reduce errors, it is very inefficient with regards to both the time and the costs for the trial 
as a whole. Furthermore, issues with data quality are often only identified after the trial has 
completed, by which it is too late to take any steps to rectify data quality issues. Instead technical 
solutions should be implemented into the data management capture and analysis systems to verify 
and assess the data quality throughout the course of a given clinical trial or biomedical research 
collaboration more generally. 
1.1.1 Research Fields
To understand the context of data quality in a given clinical collaboration whether it is a trial, study or 
a disease registry, the lifecycle of data must be considered. The general process of collecting patient 
related information is often divided into: data collection (question the patient), data capture 
(electronically or manually), optional data transfer and the storage in a clinical database management 
system for research. The Data, Information, Knowledge and Wisdom (DIKW) Pyramid is often used to 
describe the purpose of data capture, which can then be translated into information and knowledge 
for the improvement of patient care. To improve data quality in biomedical research and especially in 
translational clinical research, we argue that research fields in medical data quality assurance and 
clinical research quality assurance must be improved. We show through a range of case studies how 
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and why data quality issues arise and how they can be tackled in a systematic manner that is applicable 
to many research settings. 
It is also important to consider, that such approaches are also taking place during a period of rapid 
evolution in both technology and clinical and biomedical research. 
1.1.2 Translational Informatics
Since the sequencing of the whole human genome in 2002, biomedical research has undergone 
massive changes with regards to education, research and funding (Payne & Embi, 2015). 
Simultaneously, the rapid development of technological advancements provides the possibility of the 
collection of large (big) data sets. Data analytics and data mining now represent major research areas 
that are applicable to many research disciplines. Big data is a buzzword that has captured the 
imagination of many researchers and infrastructure providers alike. With the application of any new 
technologies into research areas, both new opportunities and new challenges arise.
Data aggregation often focuses on the collection of a range of diverse data from potentially distributed 
data holdings to investigate specific phenomenon. This is often used to support a reductionist 
approach. In itself, data aggregation is often essential for many research areas; however translational 
clinical research and translational informatics focus on supporting system thinking, stemming from 
the analysis of such aggregation of data resources. Technological advancement also provides the 
opportunity to investigate research as a whole (Payne, Embi, & Sen, 2009). This data aggregation 
approach often focuses on data-driven research rather than on hypothesis driven research. Shah and 
Tenenbaum identify that data-driven research can enable proactive, predicative, preventive, 
participatory and patient-centred health. They argue that this approach can be used to discover 
patterns of diseases in all patient-related data (Shah & Tenenbaum, 2012).
“Data intensive science allows scientists to analyse bigger and more complete systems efficiently, and 
complements more traditional scientific processes of hypothesis generation and experimental test to 
refine our understanding of the natural world.” (Kelling et al., 2009)
Biomedical research typically starts with a research hypothesis. This hypothesis is drawn from previous 
research or from informed guesswork of researchers about something that needs to be observed
and/or better understood. The researcher defines and investigates a self-defined problem and
explores solutions for this and potentially their influence in other areas. However, in many cases this 
is a simplified (reductionist) view of the way in which research is really undertaken. The counterpart 
of this approach is holism. The advantage of computer-based systems in biomedical research is that 
they offer the opportunity for a shift from hypothesis-driven research to more complex data-driven 
research. 
“Data-driven medicine will enable the discovery of new treatment options based on multi-model 
molecular measurements on patients and learning from the trends hidden among the diagnoses, 
prescriptions, and discharge summaries of millions of patient encounters logged by clinical 
practitioners.” (Shah & Tenenbaum, 2012)
Despite this rhetoric of (big) data–driven research, there is still a great need for hypothesis-driven 
research. Indeed, different approaches are now possible to researchers in allowing freedom for 
defining research questions and a multitude of ways in which such research can be undertaken. 
“The accepted scientific method consists of formulating a hypothesis and then testing it by 
experimentation which, at least in theory, attempts to disprove the hypothesis.” (van Helden, 2013)
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Data-driven research offers an approach that needs to be considered and tested, and ultimately 
validated using more traditional approaches. It is the case that for many biomedical research activities 
it is now only possible to undertake the research through data-driven approaches.
“By contrast, the new ‘omics’ technologies allow us to generate massive quantities of data rapidly and 
thereby enable us to take a far less biased approach to tackle a given problem.” (van Helden, 2013)
Key aspects of new scientific discoveries made possible by access to increasing amounts of biomedical 
information allow tackling areas such as personalised medicine and clinical decision making. For
example, pharmaceutical industries now increasingly develop personalised drugs based on the 
targeted genetic information of the patients (Costa, 2014; Ramsey et al., 2011). 
Such a data-driven approach can potentially transform biomedical science and simplify research more 
generally. Big data-based machine-learning and use of Cloud and high performance computing 
infrastructures are already benefiting many other fields of research (physics, biochemistry). There is 
increased interest in using such data-driven approaches in the clinical and biomedical domains. 
However, more data by itself will not improve research alone and they will not immediately allow that 
research to be translated into a clinical healthcare setting. In the clinical domain especially, data needs 
to be captured and structured in accordance with researcher needs as well as meet a range of 
guidelines for data access and data analysis that are not typically present in other research disciplines 
such as physics and experiments associated with the Large Hadron Collider (as one example). The 
simple aggregation and sharing of data is challenged by the nature of the data that is being shared, 
e.g. due to privacy and confidentiality considerations. 
Irrespective of these challenges, there is a clear need to accelerate the speed of translation of findings 
in clinical research into clinical care. Improvements in data quality is fundamental to drive the process 
of medical discoveries and allow to evolve and sustain biomedical research for all scientists involved
(Martin-Sanchez & Verspoor, 2014).
Importantly high data quality can enhance clinical research and its ability to draw significant 
conclusions out of (digitised) data holdings. The translational domain has hitherto largely focused on 
system thinking, but data-driven research is increasingly possible and there is now a major shift to 
data-driven research more generally.
This thesis focuses on several research areas, most notably: data quality assurance in information 
systems, translational/clinical research informatics, the e-Infrastructures and platforms that underpin 
research collaborations and the impact of Human-Computer Interaction (HCI) on data quality and 
research collaborations more generally. The rest of this chapter provides the motivation and problem 
statement, together with the primary aims and scope of the thesis and its significance in the field as a 
whole. 
1.2 Motivation
According to the World Health Organisation (WHO), 13% of all deaths worldwide are caused by cancer 
and more than 100 cancer types are known that need individual screening and treatment1. However, 
the cause of many cancer types is not yet established and the treatment of the many cancer types is 
currently not established. Cancer research often focuses on monitoring and evaluation accompanied 
by screening programs and associated treatments. For many years, cancer care and cancer research 
more generally focused on investigating the effects of radiation therapy, chemotherapy, targeted 
therapy or surgical removal of primary tumours and understanding the biological processes in cancer 
metastasis. Given their prevalence, research into many forms of cancer (such as prostate cancer, 
1 http://www.who.int/cancer/en/
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malignant melanoma, breast cancer, lung cancer, colorectal cancer) is able to benefit directly from
disease reports from many different institutions and organisations both nationally and internationally. 
These can include reports derived from analysis of data from general practitioners, hospitals and/or
targeted (comprehensive) cancer centres. However, this prevalence can also be a disadvantage. 
Information in such reports is derived from a snapshot of data at a given point in time, yet it is rarely 
the case that the underlying data behind such reports is systematically made available and similarly it 
is not used to automatically update such reports when new data is collected or indeed when issues 
arise and the reports need to be corrected with regards to incidence, mortality, prevalence, survival 
calculations or the effectiveness of treatments. Whilst common cancer diseases such as prostate 
cancer, breast cancer or lung cancer can have an established health reporting pattern and processes 
for data collection and analysis, e.g. data captured and included in regional or national cancer 
registers, this is typically not the case for rarer cancer types. Cancer forms such as adrenal cancer or 
thyroid cancer are not reported because of their low incidence rates in the community. In such 
scenarios, targeted research registries need to be established to aggregate data. Such data typically 
needs to be collected across national boundaries. In such contexts, insights into data processes and 
data quality evaluation are essential to underpin any statistically significant conclusions for these rare 
diseases and importantly, to take steps that can automate the quality of the data that is captured and 
stored in such international disease registries. At present the collection and quality of data in such 
resources is largely based on best effort. Up to now there has been little systematic (automated) 
support for improvements in the quality of data that is entered.
1.2.1 Data Processes of Clinical Registries
Data captured and stored within clinical data registries can serve many different purposes: health 
reports, health protection, research and for the evaluation of preventive and therapeutic processes 
(Hentschel, Pritzkuleit, Schmid-Höpfner, & Katalinic, 2011). The data process is often divided into 
three general areas: data entry, data processing and data assessment (see Figure 1-1 for the example 
of cancer registries). 
Data process Analysis criteria Frame






Data processing Reporting procedures
Coding
Record linkage
Comparison of mortality 
rates
Data assessment Data quality
Figure 1-1 Assessment criteria of data processes
The development of epidemiological and clinical registries can improve the quality of reporting. 
Epidemiology is focused on the health of populations and therefore, epidemiological registries have 
the primary purpose to publish reports applicable to the population. For cancer this can be calculations 
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and reports of cancer prevalence, incidence and mortality. The distribution of mortality is often a 
special case, since official death certificates as source documents are typically needed. Clinical cancer 
registries monitor the cancer progress of individuals or smaller cohorts to evaluate diagnostic, 
treatment, rehabilitation and follow-up care of cancer patients based upon general established 
guidelines and standards (Hofstädter & Klinkhammer-Schalke, 2011). To improve data quality, region 
and/or nationwide registration of cancer patients is important, because different regions and 
countries can have many different factors that should be considered in relation to their own cancer 
patients (chemical industry, socio-economic indicators, smoking rate, etc.) (Katalinic & Hentschel, 
2008).
To improve the outcome of clinical trials, every step in the data process needs to be understood,
monitored and potentially improved with quality control methods. In every step the process and the 
source documents have to be assessed. Such patient-specific data can be either generated by devices 
(biochemical assessments, blood pressure, weight, etc.), from reports of other medical institutions 
(pathology report, genetic assessments, etc.) or indeed contributed by the patient themselves. In 
terms of data quality, it is assumed that devices provide less error than the recall of humans (recall 
bias). Therefore, data from devices or other documents should be preferred or assumed to have higher 
quality and trustworthiness. It is possible that this information is entered into hospital records directly 
and re-used (recycled) into research registries through manual or automated mechanisms. If the 
patient data is written to paper, then it often requires manual data entry into the registry by 
individuals within the hospital setting. If the patient data is included in electronic health records, then 
in principle it is possible to directly export it into clinical registries (electronic data capture). 
Irrespective of the mechanisms used, the implementation of quality assurance procedures to assess 
and evaluate the data processes is essential, especially in a clinical setting. Data and patient-related 
information must be accurate at the stage where it is created and added to paper or electronic 
records. The steps taken to transfer it to registries should also be monitored and improved wherever 
possible. The question that drives this research is, what influences the overall data quality of data 
entered into such registries and what is the impact on future reuse in clinical trials and studies and 
their associated outcomes? 
1.2.2 Example of Cancer Registry Data Analysis and undocumented Data Quality
To understand the challenges that arise we consider an explorative study involving a German dataset 
of malignant melanoma that was used to calculate 5-year survival rates (Kaplan-Meier survival). This 
data was collected from epidemiological cancer registries across Germany in 2011. The study used the 
variables for the calculation set out in Table 1-1. 
Table 1-1 Variables of Survival Calculation
Variable Description
Date of Birth Calculation of age (adjustment with relative survival) 
Date of Death Calculation of survival
Date of First Diagnosis Data for reliable diagnosis (pathology report)
Date of Follow-up Every data of clinical examinations that confirm that the patient 
is still alive
Date of Events Example: patients moves from one registry cover region to an 
other
Date of Final Report Last status of the patient (alive or dead)
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With a tumour size greater than 1mm, the tumour and the adjacent sentinel lymph node were
removed (SLNE). In case a tumour cell was discovered in the extracted sentinel lymph node a total 
lymphadenectomy was performed (LAD). Patients with both interventions have a poor survival rate. 
Based on this, every patient was assigned to a special tumour stage (Balch et al., 2009). Patients with 
a very pathogenic and lethal form of skin cancer were classified in stage IV, while patients with a not 
so malignant form were classified in stage III as shown below in Table 1-2. 









The first step of the analysis involved a comparison of SLNE patients with SLNE and LAD patients 
stratified by gender. The five-year survival rate of male patients with SLNE and LAD was 0.48 whilst 
male patients with SLNE had a survival rate of 0.56. In other words, a male person diagnosed with
malignant melanoma and a treatment combination of SLNE and LAD had a 48% chance of survival 
within the first 5 years after initial diagnosis. Female patients with SLNE and LAD had a calculated 
survival rate of 0.54 and those with only SLNE had a survival rate of 0.71. This indicates that males 
with LAD and SLNE have the worst prognosis compared to males with just SLNE or female patients 
with LAD and SLNE (see Figure 1-2 & Figure 1-3). 
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Figure 1-2 Kaplan-Meier male Patients with LAD and LAD & 
SLNE
Figure 1-3 Kaplan-Meier male Patients with LAD and LAD 
& SLNE
The graph shows a smooth curve up to 8 years, since there are fewer patients to follow up after 8 
years. What is not shown in the graphs is the completeness and quality of the data that was provided 
for the analysis. As described, cancer registries often receive their data from many different 
stakeholders and organisations such as comprehensive cancer centres, hospitals, organ cancer centres 
or pathology laboratories. These stakeholders typically don’t report directly to single established 
national cancer registries but to population-based registries at the regional or country level. The steps 
for collecting and checking the data that goes into such registries can vary greatly and standardisations 
must be improved. Similarly, the analysis that is undertaken by institutions and individuals using the 
data in cancer reports is often specific to the needs and demands and quality of the data. However, 
not every source of information reports on the correct and/or complete information required to 
address such efforts. We argue that a quality assurance instrument has to be continuously 
implemented into cancer and other disease registries focused on the continuous and systematic
evaluation of data, and ultimately on the ongoing improvement of data quality.
In 2009, Bray and Parkin published two articles focused on the evaluation of data quality in cancer 
registries. Their work included the primary research areas of data quality, medical informatics and 
epidemiology (Bray & Parkin, 2009; Parkin & Bray, 2009). The researchers identified that the
application of tools for the data management of cancer registries provided possibilities to measure 
data quality and raise discussions on how to improve data collection processes to underpin cancer 
reports. The authors described four primary quality dimensions for the evaluation of data quality in 
cancer registries: completeness, validity, timeliness and comparability. Every dimension has its own 
approach to provide quantitative values, graphs and visualisations used to show cancer researchers 
whether the data has high or low quality based on these dimensions.
For the measurement of completeness for cancer registries, they regarded completeness as “the 
extent to which all of the incident cancers occurring in the population are included in the registry”
(Parkin & Bray, 2009). Comparing the completeness of a given cancer registry, they assumed that 
incident and mortality values for every type of cancer should be similar worldwide. As an example, for 
mortality to incidence ratio (MIR) of deadly cancer types like lung cancer, they assumed that this
should be near 1, while cancer types with a good prognosis (e.g. breast cancer) would have a much 
lower ratio. The M:I ratio is considered as an observed/expected age adjusted rate (Parkin & Bray, 
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2009). The authors compared national registries with the worldwide data and discovered that the 
investigated cancer registry in Japan had a reported 82.8% completeness, in contrast to a cancer 
registry in Korea that only achieved 50.7% data completeness levels.
In a pre-project for this thesis, a completeness analysis was performed of available data for the five 
most common types of cancer (stomach, prostate, lung, breast and colorectal cancer). Scandinavian
cancer registries (Norway, Sweden, Denmark) were assumed to have the most complete dataset for 
all reported cancer types (Bray & Parkin, 2009; Parkin & Bray, 2009) since every person was identified 
with an 11 digit identification number assigned to the person at birth (Larsen et al., 2009). This helps 
minimise the possibility of duplicates and gives the advantage of better follow-up possibilities. The 
evaluation of data completeness was performed using age adjustments (European standardized age). 
For the evaluation of data completeness the calculation of a MIR suggested from Bray & Parkin (2009) 
was used. The MIR is a quantitative method to estimate data completeness. In this case, all reported 
deaths of patients from cancer were divided by the calculated incidence of the cancer type. 
The Surveillance, Epidemiology and End Results Program (SEER) of the National Cancer Institute (NCI)
provides standardized, age, sex and region adjusted incidence and mortality rates of cancer. Cancer 
of the pancreas, oesophagus or liver are often fatal diseases and therefore have a very high MIR rate. 
SEER focuses on defining such rates and using MIR as a quality indicator for registry completeness. 
Comparison of cancer registries should be based on having a similar MIR in relation to case
completeness. In a hypothetic case of a MIR for prostate cancer with the value 0.95, a complete 
epidemiological cancer registry needs to have the MIR of 0.95 (defined by SEER). The calculated
completeness rates are related to this value. The calculation of record completeness of cancer 
registries is shown in Equation 1-1. 
Equation 1-1 Calculation of Record Completeness in Cancer Registries
The European Cancer registry data is available online at http://eco.iarc.fr/EUREG/Default.aspx. In a 
comparison of Norway (assumed complete coverage) versus all German cancer registries in 2010, the 
data shows that Norway has more complete data for stomach, prostate and colorectal cancer, whilst 
Germany has a higher level of completeness with regards to lung and breast cancer (see Figure 1-4).  
 
Figure 1-4 Registry Completeness Germany vs. Norway calculated with Mortality-Incidence Ratio
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This calculation shows that no general conclusion can be made regarding Scandinavian countries (in 
this example Norway) over other countries. Similarly the data collection and data processes often 
differ between registries (Bray & Parkin, 2009; Larsen et al., 2009; Parkin & Bray, 2009). Importantly, 
the MIR is only one method used to calculate the data quality dimension of registry completeness. 
There are many other quantitative and qualitative methods that can also be used to calculate data 
quality dimensions. Other dimensions like validity, timeliness and comparability have their own 
methods to quantify the overall data quality (from these dimensions) of disease registries. The case 
studies outlined here have focused on cancer, but the same approaches and methodologies for 
comparison of data is applicable to many other diseases areas such as diabetes, mental health and 
other non-chronic diseases. 
1.2.3 Data Quality Feedback
One major challenge of data quality is dealing with complexity. Ideally the mean of all data quality 
dimensions should be expressed in a single score, which describes the overall data quality (see Table 
1-3). However not all dimensions can be applied equally in clinical research. General data quality 
dimensions can include (registry) completeness, data comparability, data validity and data timeliness 
for registries and data completeness, data correctness (accuracy), data concordance, data plausibility 
and data currency (timeliness) for clinical research more generally (Weiskopf & Weng, 2013). There 
are other quality dimensions that can be applied for other research purposes depending upon need 
and focus. For example, the trustworthiness of source documents is often essential for data mining as 
explained in Nurse, Agrafiotis, Goldsmith, Creese, & Lamberts (2014).
Table 1-3 Example Overall Data Quality Score
Validity Comparability Completeness Timeliness Trustworthiness … Data 
Quality
80% 95% 90% 95% 70% = 86%
The overall data quality (Quality Score – QS) is the arithmetic mean of all used quality dimensions (QD) 
defined by Equation 1-2. The overall data quality of a registry is a quantitative value that expresses 
the quality of processes, reports and data contained within that registry. This thesis explores whether 
this score can be used to motivate individuals to increase their own overall data quality and hence the 
data quality of the registry as a whole? Specifically, we consider whether combining the data quality 
score with feedback to researchers can potentially influence the quality of the data as a whole. Care 
must be taken to ensure that the feedback does not demotivate the individuals tasked with data entry. 
Instead approaches should seek to inspire them to improve their own data quality related processes
and practices. 
Equation 1-2 Calculation of the overall Data Quality
In conclusion, data processes are an important aspect of data quality since they have a large influence 
on the quality of data. Poor quality data can lead to erroneous conclusions. Even high quality data that 
does not document how the quality of the data has been achieved and measured can lead to 
challenges in understanding and reusing the data. The established methods of evaluating data quality 
in disease registries have to be applied across the wider clinical context. Solutions that work with 
single disease or isolated registries should be avoided (if possible). Too many data inconsistencies can 
lead to a lower research impact. Therefore, data quality dimensions have to be defined to transform
the data to the needs of the researcher and the intended use of the data by the community involved.
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1.2.4 Usefulness of Improving Data Quality
Data quality dimensions such as trustworthiness can lead to questions such as, are the data reported 
by these institutions reliable and believable (trustworthy)? Are reports provided by national 
institutions, the EU or even the WHO actually correct and based on data of high quality?
There are many types of disease registries. One type of registry that has directly impact on individual 
patients and can lead to discovery of new conclusions are clinical trial-related registries. Compared to 
registries more generally, databases for clinical research cannot often use a comparison database that 
was collected by other institutions. MIR or other quality indicators that are applied on cancer registries 
for example can’t be transferred to research registries. However, clinical research registries need to 
visibly demonstrate and measure data quality to ensure the validity and repeatability of insights 
gained from any studies that have used the data. What quality dimensions and statistical assessments 
can an evaluation of data quality in clinical research registries include?
Only a few research groups worldwide have investigated the possibilities to increase data quality in 
clinical research. In contrast to the previous described research about the evaluation of data quality 
in cancer registries, research regarding the evaluation of data quality in research registries more 
generally tends to focus on clinical research informatics, human-computer interaction and data quality 
research. As noted, data quality evaluation normally happens at the end of a clinical trial and its values 
are not often reported, since it is assumed that ‘high-quality’ and positive research based on rigorous 
and high quality data is published. At the end of a given trial, the principal investigator or data-
manager typically ‘cleans’ the data, which typically involves adding average values for missing data or 
deleting data items that were used for the final analysis. Such late-stage data amendments can 
significantly weaken the overall quality and results of the clinical trial. Instead data quality evaluation 
should be conducted throughout the lifetime of the clinical study.
Previous work leading to this research focused on data monitoring, on-site monitoring and the 
application of quality assurance procedures in clinical trials, however these are often rejected by the 
clinicians and study sponsors, because they make the trial more expensive and can lead to discovery 
of problems that may not actually arise or be directly related to the study in question. 
There is no direct measure related to the impact of low data quality on the outcome of clinical trials, 
however data from surveys of business companies showed that the estimated average costs that are 
associated with ‘dirty data’ are around $8 Million USD2. It was identified that with the implementation 
of data quality assurance methods, overall costs could be reduced by 10-40% and the outcome 
(revenue and sales) increased by around 20%. Similar rates were estimated by the Federal Drug 
Agency (FDA) with regards to clinical research. It was identified that through implementation of risk-
based monitoring and data quality assessment by the FDA, trial costs could be reduced by 20-25% 
(Franco, Hronec, & Slizgi, 2013). 
Ongoing procedures for evaluating data quality during clinical trials have to be implemented into the 
data management system. Compared to other more general data quality research activities, clinical 
trials have other quality dimensions. Research registries do not need record completeness, but they 
may often need eligibility checks to determine whether records meet the minimum criteria for a given 
study or trial objectives. Often this is to determine if the patients meet inclusion and/or exclusion 
criteria for the study.
On the other hand, evaluating data quality or applying quality methods in research does not directly 
increase data quality. Factors that directly influence data quality often include environmental factors 
like the software, hardware and especially the human element. Indeed, the human factor often has 
2 https://halobi.com/2015/02/infographic-data-quality-in-bi-the-costs-and-benefits/
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the highest impact on data quality. Considerations such as whether the registry user (data entry 
personnel) has been trained or is actually motivated to enter research related data are important 
factors. The complexity of the data to be entered and indeed whether the information required is 
actually available are all important factors to consider with regards to data quality along with the 
processes that should be taken to improve data quality. 
1.2.5 Summary
Clinical research informatics face numerous challenges with regards to capturing heterogeneous data 
in a single registry (J. Chen, Qian, Yan, & Shen, 2013). Quality control procedures to achieve high data 
quality are rarely established or implemented in data management systems, especially those that 
cross organisational and jurisdictional boundaries. This thesis explores the reasons for low data quality 
and develops a general framework that supports clinicians, investigators and researchers in capturing
higher quality data that can make an impact on their research. We consider the requirements for 
technological features that support the collection of high quality data during clinical trials with specific 
focus on web-based feedback mechanisms during data entry.
1.3 Research Hypothesis
The aims of this thesis are to explore and develop a framework for the automation of a web-based 
tool to increase the quality of data in clinical research registries. Authorities in clinical research 
informatics have previously concluded that there is no general approach or tool that could fit all 
clinical research needs (Nahm, 2012). However, the need for high quality data collection in rare 
diseases especially, requires an approach to systematically provide support to improve data quality.
This requires a framework that can be applied in many disease areas and in many scenarios. As such 
the primary goal of this research is to develop such a framework for data quality that assesses user 
motivation, which can be applied in web-based data management applications for clinical research 
across a range of (rare) disease areas. 
To ground this work, an important point to consider is the range of disease registries that are selected 
for clinical research and the experiments that can be considered for web-based feedback. Every 
registry has different users and intentions for research. Users can be researchers, investigators or in 
some cases patients. Some registries work in a national setting, whilst others are based on 
international needs and demands, with associated language issues. Furthermore, research can be 
driven by data or based on specific research hypotheses. These dimensions are important to consider 
in how feedback mechanisms can work. 
There has been a profusion of translational tools and data processing pipelines that have been created
for clinical and biomedical research, yet there has been a limited amount of detailed assessment 
regarding the application of these to establish best practice and specifically, recommendations and 
practices that ensure that they meet the rigorous requirements demanded when translating research
findings into clinical care settings. Translational clinical research faces problems of patient 
recruitment, evaluation of tools, lack of academic-industry cooperation, low proof of efficiency and 
effectiveness, and a need for training of researchers (Bornstein & Licinio, 2011). The field of basic 
science requires improvement for independent reproducibility of science which in turn depends upon 
simplified access to clinical data from increasing numbers of patients through targeted disease 
registries that include rich phenotypic information that contextualise any biological insights that might 
be made. The era of just dealing with information is nearly over, now it should focus on knowledge 
derived from data that can be used and trusted to improve clinical decision-making and care for the 
patient and the population more generally. 
With the support of basic research, information pipelines and general frameworks must be developed 
to expedite knowledge transfer from the bench to the bedside to support improved clinical decision-
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making (Cantor, 2012). Implicit in this is a need for improved data quality in clinical and translational 
trials. 
The hypothesis of this work is that 
“web-based feedback should be an integral part of data collection processes in disease registries that 
demonstrably improves the overall quality of data that is entered into such registries”.
We explore this through a range of case studies related to a variety of disease registries utilising a 
variety of feedback mechanisms.
1.4 Significance
The first intended outcome of this work is to provide an overview of data quality and whether data 
quality feedback can be applied to clinical research scenarios or not. 
Clinical research quality assurance practices will be explored and a data quality framework developed. 
This will explore and update guidelines that are now, we argue, outdated, e.g. the GCP-Guideline from 
1996. Aspects of user motivation are tackled while exploring the interactions of data entry personnel, 
and we consider specific extrinsic and intrinsic motivational factors that can impact on data quality. 
Furthermore, data quality dimensions and their weightings and overall impact on clinical research will 
be investigated. 
Multicentre trials about rare diseases benefit from the implementation of new technologies in clinical 
research, because clinical data management systems have several features to support data quality 
assurance and simplify data entry. However, not all funding schemes for clinical research support 
multicentre trials. This thesis will investigate the impact of funding schemes on research success, 
measured in publications with high bibliometric scores (impact factor or h-index). The outcome of that 
investigation will show the importance to enhance clinical data management systems and to support 
the research intentions of multicentre trials.
On a practical level, the intended outcome of this research is to explore data quality measures in the 
context of diseases, however we focus predominantly on rare diseases since they are the most 
demanding with regards to high quality data collection due to the rarity of the conditions and 
sparseness of such data more generally. In this research, we consider adrenal tumours and Niemann-
Pick disease as key case studies and different aspects of rare disease related research (data driven vs. 
hypothesis driven). As noted, the measurements of data quality during clinical trials are rarely 
published or reported. Rather the literature provides overviews and review articles about the 
measurement of data quality and common inconsistencies, but little in the way of practical techniques 
to improve data quality. Through the application of data quality assurance mechanisms in disease 
registries and their impact in supporting clinical trials and related studies, we show and quantitatively 
measure the impact that these web-based feedback tools can make. We also consider more common 
conditions including type-1 diabetes mellitus and the role of the patient as the data entry personnel.
The third outcome of this thesis is the development of a framework that can be applied across a range 
of clinical research registries to improve data collection processes. This enables future studies to 
benefit from the mechanisms and framework proposed, and subsequently allows performance of
other observational studies focused on an investigation of the effectiveness of data quality feedback
in clinical data collection in inter-organisational settings. Data quality feedback is rarely researched, 
but all authorities describe the need for improvements in the quality of data to expedite the 




In undertaking this research it is important to review possible background information that might 
impact on data quality feedback approaches. We consider related research in the field in chapter 2 
and the extent that this work related to other fields. Building on this knowledge, a data quality 
feedback assessment exercise is considered based on several cohort studies to demonstrate the 
validity of the approach, i.e. does feedback work (chapter 3). This work focuses primarily on direct 
face-to-face feedback with multiple centres across Europe tasked with performing data entry into an 
international disease registry. To better understand the more detailed insights and working 
mechanisms of data quality feedback, a survey that investigates data processes and user motivation 
with regards to data quality processes is performed (chapter 4). This data quality feedback approach 
is considered in a research network based on a rare disease (Niemann-Pick Disease Types A, B and C 
and the international registry that has been established to support global research into this condition) 
to compare differences between research-driven and quality-driven research intentions (chapter 5). 
Chapter 6 focuses on the patients themselves and how they can be data providers through use of 
targeted mobile applications. We consider whether they are more diligent in data entry and ultimately 
provide better quality data. Chapter 7 investigates other motivational factors that can influence data 
entry and especially the quality of data entered into international disease registries. Specifically, we 
investigate whether centres involved in particular clinical trials associated with the disease registry 
have better quality data for those data items that are required for the studies associated with the 
registry. Ultimately we consider the overall impact of data processes and user motivation on data 
quality and whether web-based feedback can help improve data quality. We conclude the work as a 
whole and the extent that the research hypothesis has been met. 
This thesis is structured into seven further chapters within four parts. These parts are: Introduction, 
Exploration, Application and Discussion/Conclusions (see Figure 1-5). Following the introduction, 
three chapters explore data quality feedback with various recommendations identified based on
preliminary results (chapters 2-4). Following this, the gained knowledge will be applied to develop and
explore a general framework to detect if web-based feedback can be applied to improve the quality 
of data in clinical research registries. We consider data quality evaluations with regards to weights and 
quality dimensions to gain more insights into data quality issues and user motivation (chapters 5-7).
The final chapter contains the conclusions and suggestions of further research opportunities. 
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Figure 1-5 Thesis Structure
PART I
 Introduction – states the contexts, the motivation, hypothesis, research significance and 
structure of this thesis
PART II
 Chapter 2 – gives an overview of Quality Assurance in Clinical Research. In addition, the 
associated methods to improve quality are discussed and the significance and impact of 
clinical research informatics identified. Related research to actions that might improve data 
quality in clinical trials is discussed. Methods like centralised data monitoring, double data 
entry or electronic data capture are discussed. 
 Chapter 3 – Focuses primarily on a demonstration that investigator feedback and community 
feedback can work within the setting of two major diagnostic cohort trials associated with an 
adrenal tumour disease registry.
 Chapter 4 – Explores the challenges that must be overcome to support automated feedback. 
For this, a survey within the ENSAT-CANCER research network was performed to investigate 
user motivation in relation to data quality.
PART III
 Chapter 5 – Focuses on applying web based feedback to support the data quality of a data-
driven research registry. We show how usage through log analysis can identify user behaviour 
and patterns in access and use of a registry, and subsequently consider aspects that might 
improve data collection and data entry processes.
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 Chapter 6 – Considers the role of patients and empowering them to enter their own data. We 
focus specifically on use of mobile technologies within the context of a large diabetes related 
clinical study. 
 Chapter 7 – Explores data quality evaluations with applied knowledge to a range of data 
quality dimensions. We consider specifically whether actual clinical trials improve the data 
quality of research registries. To address this, we consider whether researchers are more 
motivated to undertake better quality data entry to disease registries if they are direct 
beneficiaries of the data being entered, i.e. they are involved in a clinical study that requires 
the data that is being entered into the disease registry.
PART IV
 Conclusion/Future work – draws conclusions from the thesis as a whole and identifies areas 
for future research.
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2 STATE OF THE ART
Clinical research relies on information and data. Often such data is captured in clinical research 
registries. This chapter provides background on clinical research data management procedures, 
processes and mechanisms and introduces important aspects of clinical research informatics for this 
thesis. We describe how the quality of data captured in registries and their associated databases can 
have a huge impact on the outcomes of clinical studies and trials. We provide an overview of common 
quality assurance procedures adopted in clinical research with specific focus on those that focus on 
evaluation of data quality and the different data quality dimensions described in chapter 1. This 
chapter provides the contextual background that underpins the research conducted in this thesis.
2.1 Clinical Research Informatics
2.1.1 Introduction
The primary objective of biomedical research is to improve the knowledge, understanding and 
decision making of clinicians in clinical care. Ideally biomedical research should lead to guidelines that 
improve the diagnosis and treatment of patients with particular diseases. The transfer of research 
outcomes from basic science combined with the extraction of knowledge from clinical research is the 
primary objective of translational research. Translational biomedical research uses systemic 
approaches for hypothesis and knowledge generation. Such approaches commonly investigate the 
relationship and/or interactions between systems with one another, rather than for example, 
considering a single part of the body. 
As an example, the capacity of the human brain is limited. A clinician typically creates a treatment plan 
based on around a small number of different facts that are discovered in the clinical phenotype (Stead, 
Searle, Fessler, Smith, & Shortliffe, 2011). Since the Human Genome Project completed in 2003 
(International Human Genome Sequencing Consortium, 2004), more and more information for 
decision making is now available (see Figure 2-1). Data regarding structural genetics, gene expressions 
or information about proteomics should, depending on the disease, ideally be taken into account by 
clinicians. Today, it has been identified that around 1000 facts per patient typically needs to be 
considered (Tenenbaum, 2015). With the support of information systems and the increasing collection 
of human genotype and phenotype data, even more complex interactions can be studied through 
massive amounts of data supported by diverse modelling and analysis approaches (I. Buchan & 
Bischop, 2009). Translational informatics has the ability to deal with and expand the role of “big data”; 
improve individual decisions; increase capacity by offering learning health care systems with dynamic 
information transfer and take results and apply/embed them into a clinical care or research setting 
(Payne & Embi, 2015).
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Figure 2-1 Clinical Decision Making (Tenenbaum, 2015)
Health research can be split into several different domains: the understanding of the human genome; 
the understanding of the underlying biology; understanding of diseases; the continually evolving 
advancements in the science of medicine and improvement of healthcare (Green, Guyer, & National 
Human Genome Research Institute, 2011). Genomics are fundamental data sources for the 
understanding of the biology and underlying basis of diseases that can lead to improved human health
and patient management. It is now the case, that generating the genome is cheaper than the 
generation of knowledge derived from it (Border, 2011). However, there are still problems in 
transferring knowledge from one domain to another. Similarly, there are still weaknesses in data 
collection in biomedical trials and discoveries of novel molecules and their potential role in human 
health. These are often not transferred into the clinical domain due to the complex inter-disciplinary 
nature of biomedical research (Clinical Research Society, 2014).
These issues suggest that there is a need for mature, validated and interoperable tools, combined with 
processes and services to address this situation. Translational research, especially in the clinical 
domain, relies on the quality of collected data. Given this, it is crucial to develop tools that improve 
data quality and raise awareness on the research and research processes required to collect high 
quality data that is most useful for diverse clinical research efforts. 
This research focuses on how automated feedback mechanisms for data entry and data review can 
improve this situation. It suggests a novel approach that can be adjusted during particular trials to 
deliver fundamental information to investigators at the onset of data collection and throughout the 
course of a given study. The hypothesis of this research is that automating real-time feedback on the 
quality of data can help improve this situation. To support this, a range of clinical solutions have been 
developed and used across a range of biomedical research areas.
2.1.2 Problem Statement
Since the beginning of the 21st century, the paradigms of translational medicine, research and 
informatics has continually evolved and are now fully established and widely adopted (Sung et al., 
2003). Translational research moves away from general reductionism and the associated steps to 
system thinking (Payne & Embi, 2015). The main paradigm of the translational research cycle includes 
translational blocks (see Figure 2-2). Translational block 1 (T1) is supported by bioinformatics and 
translational block 2 (T2) is supported by medical informatics. This cycle covers knowledge transfer 
including evaluation of the effectiveness of the approach across both individual and population-wide
health (Khoury et al., 2007). 
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Figure 2-2 Translational Research Cycle (Sung et al., 2003).
The main problem this approach encounters is the slow transfer of findings from basic science into 
clinical research and beyond (Contopoulos-Ioannidis, Alexiou, Gouvias, & Ioannidis, 2008; 
Contopoulos-Ioannidis, Ntzani, & Ioannidis, 2003). Additionally this area often has inconsistencies of 
data, especially in multicentre collaborations where barriers exist for beneficial knowledge sharing of 
patient data with institutions and indeed transferring discoveries into industrial and/or commercial 
settings (Bornstein & Licinio, 2011; Kuchinke et al., 2010).
Translational informatics has the aim to increase the speed of newly developed medical entities from 
the lab to patients with specific diseases (Sarkar, 2010; Woolf, 2008). However it has been identified 
that over the last decade, the development of new treatments has decreased, but the money spent 
on research and development of new therapies has actually increased (Woodcock & Woosley, 2008). 
Furthermore, it was shown that new findings in genomics often shows no increase in late phase clinical 
trials (Clinical Research Society, 2014; Green et al., 2011). Currently an average drug development 
costs of the order of $1 billion USD and the whole process takes around 10 years. Only 15% of new 
therapies ever get into phase 3 trials and 50% of the novel therapeutics that pass this barrier actually 
get approved (Ledford, 2011). As such it has been identified that present clinical trials are woefully 
inefficient for drug development (Allison, 2012) and translational research has to evolve to tackle such 
problems (N. S. Buchan et al., 2011).
As an example, research in neuroscience showed a drastic shift of R&D funding in 2014 compared to 
2009. Far less drug development programs (-52%) were processed by the pharmaceutical industry 
(Choi et al., 2014). This reduction of neuroscience drug development was caused by high drug costs 
and the extensive time periods that are taken until a drug actually gets approved (Brady & Insel, 2012). 
In 2011, the NIH (National Institute of Health) funded the National Center for Advancing Translational 
Science (NCATS) to counter these slow translational processes. The primary goal of NCATS was to 
expedite the transfer of newly discovered diagnostics and/or therapeutics to improve human health. 
It was identified that this should be achieved by promoting collaborative research and partnerships 
(Colvis & Austin, 2014) so that (inter-)national societies and/or collaborating institutions should be 
able to accelerate drug development processes. The ability to achieve this depends on both the 
financial support and importantly the way such support is delivered. 
To obtain significant conclusions for new medical hypotheses especially in rare diseases, multicentre 
clinical studies are needed (Gatta, Capocaccia, Trama, & Martinez, 2010). Multicentre studies offer
benefits of an increased sample size and associated improvements in the statistical power leading to 
better outcomes, however they must tackle the heterogeneity of the performance of the trial 
procedures to ensure an overall improved generalizability of the results (Guthrie et al., 2012). 
However multicentre clinical trials also face challenges: the heterogeneous performance of trials can 
be caused by changes of study protocols or complex protocol designs and diverse patient information 
that is collected within the individual institutions (Brandt et al., 2006). Other problems include data 
propagation; errors through wrong randomization or in some cases erroneously calibrated equipment 
can make a multicentre comparison of values difficult (Venet et al., 2012). A literature review also 
showed that Randomized Clinical Trials (RCTs) in single centre settings have larger treatment effects, 
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than intervention trials in multicentre settings (Dechartres, Boutron, Trinquart, Charles, & Ravaud, 
2011).
Despite these problems, every genomic discovery and associated new medical development must be 
proven in a late phase clinical trial to show evidence of the effectiveness and efficacy of the new 
invention (Green et al., 2011). To prove this, a comparison trial against the gold-standard test or a 
standard of care treatment vs a placebo must be conducted (Vaidyanathan, 2012). In short, there is a 
great need for faster translation of research and trials into the clinical environment. New methods in 
clinical research must be cheap, fast, adaptable and more in tune with genomics (Ledford, 2011). To 
support this, electronic health records (EHR) or phenotypic information must be observed in relation 
to genotype data, and biomarkers must be used on study populations that can subsequently be shown 
to lead to new stratified study designs for biomarker trials (Jensen, Jensen, & Brunak, 2012). 
Translational blocks (T1 & T2 and above) urgently need improved data validation processes to achieve 
rapid knowledge transfer between the lab and the patient (McShane et al., 2013).
An important step to consider is the form of data collection. While -omics analyses are mainly driven 
by data sets from targeted machines, e.g. spectrometers, clinical trials are predominantly manual data 
entry methods. Remote Data Entry (RDE) or Electronic Data Capture (EDC) are used in many academic 
institutions (ECRIN, 2007), however there is no evidence as to whether these methods provide an 
advantage in reducing errors (Nahm, Pieper, & Cunningham, 2008). Organizations/institutions need 
better knowledge about the conduct of trials and the user interfaces used for data entry (K. Chen,
Chen, Conway, Hellerstein, & Parikh, 2011). Furthermore, since double data entry (DDE) is often too 
costly, it has been suggested that instead of DDE, randomly selected records must be checked (ECRIN, 
2010). Finally, the use of new mobile devices for data entry is considered to improve the data quality 
and motivation of the staff to enter more and better quality data more often, but has not shown 
significant beneficial results (K. Chen et al., 2011; Paulsen, Overgaard, & Lauritsen, 2012; Walther et 
al., 2011). 
Human motivational affordances are a very important aspect for the consideration of the 
improvement of data entry and subsequent improvement of data quality. Besides feedback tools, this 
research presumes that the reason for low data quality can be due to low staff motivation, and 
especially those staff actually undertaking data entry. To increase user motivation it was shown that 
gamified processes in non-game contexts were useful but not well studied within the biomedical 
domain (Deterding, Sicart, Nacke, O’Hara, & Dixon, 2011). Adding features of community 
competitions, badges and achievements through web-based data entry, may increase the drive of the 
user for improved contributions and better quality data entry (Hamari, Koivisto, & Sarsa, 2014). 
2.2 Data Quality Assurance Dimensions and Statistics
The term ‘quality’ is often used in different kind of contexts. It could be used as label for an item, a 
final mark of a review or a description of lifestyle. Whilst “Quality-Food”, “Quality-of-Life” and 
“Quality-Time” have different usages, but one common purpose: to describe an aspect that something 
is better than something else. Quality doesn’t explicit refer to something expensive, rather it describes 
whether there is a balance between the usefulness of an object and the related costs/resources that 
are spent. Quality can also be construed as an attribute that describes an item or process as fit for its 
purpose. 
An accepted general definition of quality is from Joseph Juran, who defined quality as the “Degree to 
which an inherent characteristic fulfils requirements” (Juran & De Feo, 2012). In regards to the medical 
domain, the Institute of Medicine (IOM) defines quality “as the degree of which health serves increase 
the likelihood of desired health outcomes and are consistent with current professional knowledge” 
(American College of Medical Quality, 2010). Clinical research relies on data captured during clinical 
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trials, so collected data must represent and be ‘fit’ for the needs of the scientist (Abate, Diegert, & 
Allen, 1998). 
Another important aspect is that quality is assumed to describe different attributes of a product or 
trial: design, conformance and useability (Ottevanger et al., 2003). This indicates that all users who 
are in contact with the product need to participate in the development on the product. 
“Quality is everyone’s responsibility.” W. Edwards Deming
In 1950, Deming adapted and improved a method for quality control from Walter A. Shewhart for 
consistent quality improvement. Through an iterative process, he provided the interaction of four 
domains: design (plan), production (do), sales (study) and research (act) (Moen & Norman, 2010). This 
process is called the PDSA or Deming-Cycle (see Figure 2-3) and due to the general approach proposed 
for quality improvements, it can be applied to health care as well as many other domains (Deming, 
2000). In general, this concept checks the current status of a product or process and compares it with 
the standard that should be or was achieved, i.e. it is a comparison of a target and the current actual 
performance. 
Figure 2-3 Deming Cycle (PDSA)
Furthermore, Deming defines product dimensions: design, development process, time of delivery and 
price. These dimensions have a huge impact on what the customers will spend to buy or use the 
product being developed. The Deming Ratio of quality is the ratio between effort and cost:
Equation 2-1 Quality Equation
The larger the usefulness of an item or process and the lower the resources, the higher is the quality. 
On the other hand, most people expect that something has high quality only when the most expensive 
available resources are used (implemented). Quality is a term that everyone describes differently, but 
for quality assurance purposes, high value is easily explained by the ratio of quality and resources (see 
Equation 2-2). It is important to gain the best value while investing the least possible resources. 
Equation 2-2 Value Equation
In conclusion, usefulness equals value. This thesis assumes, that usefulness in clinical research 
informatics is data that can be used directly for research-oriented clinical trial objectives as well as for 
other research purposes (in protocol amendments, follow up trials, new clinical studies). Resources in 
this context are the efforts of all human interactions (software engineers, data managers, principal 
and local investigators, data entry users) that directly influence data quality. Factors that have 
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negative impact on data quality will be explored in chapter 3. In general, these factors are explored 
with the definition of quality indicators.
2.2.1 Data Quality Indicators
Avedis Donabedian provided an insight of quality indicators in health care that influence the quality 
of a product and its development processes (Donabedian, 1988). He separated quality indicators into 
three categories: structure quality, process quality and outcome quality. To detect possible indicators 
for the quality of an object, all categories must be investigated. With the identified problems and 
resources, improvements can be planned and executed, e.g. in a PDSA Circle (Donabedian, 1988). 
The requirement for a Data Quality framework in clinical research needs to address the following 
aspects: 
- Active improvement of quality from every user (not only management);
- Assess quality levels and improve data processes (Donabedian), and
- Ongoing improvement of data during the data collection process (Deming).
Nonnemacher, Nassek, & Stausberg (2014) adapted the Donabedian model for data quality in cohort 
registries and clinical research registries. The authors applied categories of structure quality, process 
quality and outcome quality into the monitoring and data management setting. They labelled 
structure into data ‘plausibility’ (which was renamed in the 2nd data quality version to ‘integrity’), 
processes into ‘organisation’ and outcome into ‘correctness’.
The researcher defined for each of these levels, several quality indicators with a definition, source of 
literature, clinical context, comments and the ratio, i.e. how the indicator could be quantified. Table 
2-1 provides an overview of all quality indicators of the 2nd version assigned to their recommended 
weight and threshold. Weights are scaled from 1-9, where 9 reflects the highest importance to be 
considered for the evaluation of data quality in cohort studies. Thresholds provide an overview of the 
range of calculated values the quality indicator should achieve. For example, overall data accuracy has 
to be around over 95%.
Table 2-1 Quality indicators in cohort registries (adapted from Nonnemacher et al., 2014)
Weighting Threshold
Plausibility/Integrity (Structure quality)
Accordance to a reference value 1 > 5%
Concordance 1 > 5%
Consistency 3 > 5%
Records without follow up information (infinite living patients) 2
Implausible entries 2
Possible implausible entries (alerts) 1
Values distribution 1 > 10%
Data fraud (detection of wrongly entered values) 1 > 10%
Value distribution of parameter (medical devices) 1
Value distribution of parameter (examiner) 2
Value distribution between results 1
Value distribution between centres 2
Examinations at the weekend and public holidays 1 > 2%
Missing records 1
Missing record items 2
Missing compulsory items 3 > 5%
Missing optional items 1 > 5%
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Unknown items 1
Items with non-related item entry (e.g. ‘unknown’, ‘na’) 2
Outliers in biochemical and diagnostic procedures 2 > 0%
Values that are out of range 1
Values of standards 2
Unpermitted values of qualitative items 1
Unpermitted values of qualitative items for coding and missing records 1
Unpermitted values for coding and missing records 1
Unpermitted values of quantitative items for coding of outlier of ranges 1
Items with non-specified units 1
Observations with unknown primary tumour 2
Evidence of known correlations 1
Amount of metadata of examinations 1
Organisation (Process quality)
Timeliness 6
Double entered items 4 > 5%
Recruitment rate 5 < 90%
Death certificate rate 6
Refusals of examinations 4
Refusals of records 4
Refusals of single items 4
Early cleaned data items 5 > 1%
Synonyms 4
Homonyms 4 > 5%
Items per record 4 >2%
Reports of pathologists 5
Rejected reports 5
Data sources per record 4
Count of Follow-up data 6
Correctness (Outcome quality)
Data accuracy 8 < 95%
Results of SDV regarding items 9 > 5%
Results of SDV regarding records 8 > 5%
Completeness 7 < 95%
Accordance to SOPs and study design 7 > 5%
Representativeness of items 7 < 100%
Here, the data quality dimensions of accuracy and completeness have the highest ratio of threshold 
and weighting, which indicates the importance of their evaluation for data quality in clinical 
research/cohort registries. Other important quality indicators of data quality are recruitment rates 
and results of Source Data Verification (SDV). In version 1.0 of this approach, the professional 
qualification of data entry users was also part of the process quality with a threshold of < 100%. All 
these indicators provide the opportunity to calculate an overall data quality score (as described in 
Equation 1-2 on page 9). However, not all indicators can be applied directly to clinical research 
registries. It is important to consider that indicators like death certificate rates are only compulsory 
for cancer registers and not as important for other clinical research registries. To improve data quality 
as part of a rigorous ongoing process, these indicators must be addressed in every data quality 
assurance activity throughout the course of a clinical trial. The research group of Nonnemacher et al. 
(2014) clustered the final data quality score into 5 groups with 100%-81% receiving the grade ‘very 
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good’, 80%-61% - ‘good’, 60%-41% - ‘moderate’, 40%-21% - ‘poor’ and below 20% receiving the grade 
‘very poor’.
To obtain very good data quality grades, ongoing data quality procedures need to be implemented in 
the quality assurance activities of the study.
2.2.2 Data Quality Assurance
Since the Nurnberg Code 1947, clinical research and research ethics have been jointly developed. The 
primary reason for this was that after World War II, it was identified that subjects have the 
fundamental right to be protected against involuntary participation in medical experiments. It is now 
widely accepted that it is essential that the enrolment of a new patient in the clinical trial is entirely 
voluntary. This is accomplished when the subject has had enough time to think about participating 
after reading the informed consent and consequences of being involved in a given study. The 
Declaration of Helsinki refined the clinical research ethics in accordance to “informed consent based 
on prospective research design, independent protocol review, confidentiality, and data integrity 
(Rock, Molloy, & Humphrey, 2010). 
Quality assurance for trials is regulated in the Good Clinical Practice (GCP) guidelines. These guidelines 
include a variety of sections to ensure patient safety and data integrity. GCP was published and 
declared compulsory for all clinical trials in 1996. To understand the impact of GCP interactions with 
trial quality assurance (QA), quality control (QC) and monitoring, the following sections provide an 
overview of the key definitions and suggested practises.
Quality Assurance
Quality Assurance (QA) comprises all actions that improve data. It is defined by:
„All those planned and systematic actions that are established to ensure that the trial is performed and 
the data are generated, documented (recorded), and reported in compliance with Good Clinical Practice 
(GCP) and the applicable regulatory requirement(s).” (International Conference on Harmonization, 
1996)
In case of an independent audit (external), auditors must have the possibility to gain insights into all 
performed QA procedures that involve data management processes. All documents (CRFs, study 
protocols, amendments) should be accessible and QA actions need to be traceable (Campbell & 
Sweatman, 2002).
Quality Control (QC)
The QC definition in the GCP-Guidelines states:
„The operational techniques and activities undertaken within the quality assurance system to verify that 
the requirements for quality of the trial-related activities have been fulfilled.” (International Conference 
on Harmonization, 1996)
Therefore, QC is an instrument of QA. QC is more an active action of trial personnel involved in data-
related processes. These staff members carry out actions to improve data quality and data integrity. 
As such, audits of every action used to assess data quality is not part of QC, but it is part of monitoring 
procedures (Campbell & Sweatman, 2002).
Monitoring
Monitoring as instrument for the evaluation and assessment of data quality is defined as:
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„The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and 
reported in accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice 
(GCP), and the applicable regulatory requirement(s).“ (International Conference on Harmonization, 
1996)
In short, monitoring as a QA tool focuses on controlling and assessing the actual information (data)
quality.
A major concern for quality in clinical trials is data monitoring. English, Lebovitz & Griffin (2010) noted 
in a cost breakdown that 30% of all trial costs are spent on monitoring purposes to improve the quality 
of collected clinical data (R. Califf, 2009; English, Lebovitz, & Griffin, 2010). Site and data monitoring 
has drawn strong criticism because of their high inefficiency (Baigent, Harrell, Buyse, Emberson, & 
Altman, 2008). The FDA recommended using a risk-based approach to monitoring that used 
centralized techniques to detect data errors, that can subsequently reduce overall trial costs by 20-
25% (Franco et al., 2013) and detecting 90% of data issues (J. M. Bakobaki et al., 2012; U.S. Department 
of Health and Human Services et al., 2013). A key question is whether the high cost is incurred to 
detect around 95% of all issues or whether a lower cost and a data error detection ratio are feasible 
for conducted clinical trials? Ideally we would like 100% of data issues to be identified, but if this comes 
at a cost that is unrealistic, then what rate of errors might be acceptable?
Monitoring in clinical trials is a good example about issues that appear during the performance of 
medical research. If data monitoring can be performed more efficiently and utilising generally 
accepted standards, subsequent problems can be reduced and transferral of knowledge to other 
domains can be expedited. It is essential to apply general accepted standards in healthcare and clinical 
research with regards to data quality frameworks. Bespoke solutions are unlikely to work in the large.
2.2.3 Data Quality Dimensions
‘Quality’ is a multidimensional term. In industrialised nations, customers generally want more quality 
of a product or service for less money. Thus quality is often associated with cost. A customer wanting 
to purchase a mobile phone has to answer the question, whether he/she is interested in buying a 
product with high costs and (one assumes) high quality or a product with lower costs and (one 
assumes) less quality. What is the intention and motivation of buying this product? What features are 
okay to dismiss for the purpose of saving money?
Quality in healthcare settings has exactly the same intention. Implementing quality control methods 
that incur extensive resources often leads to high quality (in most cases). However, investing fewer 
resources can often provide only slightly lesser quality than the higher cost version. Is it possible to 
find a balance? To answer this question, it is mandatory to evaluate the actual quality and compare it 
with the targeted quality (target-actual comparison). Following this, the cost for implementing quality 
control methods must be calculated, to assess if quality assurance of the product or process is worth 
the actual overall improvement obtained. 
Every quality dimension should capture different aspects. The combination of quality dimensions will 
give a judgement about data quality. Not all dimensions are useful in every project or completely 
generalizable in a single framework. However, there are concepts that support the development of 
quality aspects and overall quality assurance with regards to data quality. Data quality dimensions 
should be separated from data models (schemata) during the development of an information system 
(Batini & Scannapieco, 2006).
In a review by Bray & Parkin (2009) several key criteria for the evaluation of data quality in cancer 
registries were explored. These criteria included Completeness, Comparability, Timeliness and Validity 
(Bray & Parkin, 2009; Parkin & Bray, 2009). However, as explained in the introduction, cancer registries 
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differ to research databases in several aspects regarding data collection including the purposes of the 
registry itself. While cancer registries often have several data sources and focus on public health 
reporting, health protection, grading of prevention and treatment and epidemiological research 
(Hentschel et al., 2011), research registries typically focus on achieving an answer to individual 
research hypotheses. In their review, registry completeness is mainly used for the calculation of 
incidence and survival rates. However, registry completeness in trial databases have a different 
priority to cancer registries. The described dimensions are equally adaptable to research registries. Of 
high importance for clinical trials are data validity including data completeness, data plausibility and 
data accuracy (Arts, De Keizer, & Scheffer, 2002).
Weiskopf & Weng (2013) proposed similar dimensions in the clinical research domain. They performed 
a literature review focused on the reusability of EHRs and they identified five criteria for the 
assessment of data quality: Completeness, Correctness, Concordance, Plausibility and Currency. In 
their study they determined major terms of data quality dimensions with correctness equal to 
accuracy and currency equal to timeliness. Additionally, the authors assessed methods of how the 
data quality dimensions could be calculated. They identified seven main methods: gold standard tests 
(registry data compared to sources other than the original source data), data element agreement 
(random items selected and compared with the EHR), elements present (completeness of data 
elements), data source agreement (data compared to the source data), distribution comparison 
(statistical analysis compared with key clinical concepts), validity checks (application of item rules) and 
log reviews (analysis of data entry practises). Table 2-2 shows the total number of review studies 
clustered in quality dimensions and evaluation methods (Weiskopf & Weng, 2013). They identified 
that data completeness and accuracy are commonly used dimensions for the evaluation of data quality 
in EHRs. It is interesting to note the generally low count of log-review methods used for the 
assessment of any data quality dimension.
Table 2-2 Studies related to data quality dimensions and evaluation methods (adapted from Weiskopf & Weng 2013) 
Dimension/
Method
Completeness Correctness Concordance Plausibility Currency Total
Gold Standard 24 35 37
Data Element 
agreement






4 1 6 11
Distribution 
comparison
4 3 4 10
Validity checks 5 2 7
Log review 1 4 5
Total 63 59 16 8 4
Other authors referred to correctness, plausibility, organisation (Nonnemacher et al., 2014) and 
reliability (Hong et al., 2013; Le Jeannic, Quelen, Alberti, & Durand-Zaleski, 2014; Rostami, Nahm, & 
Pieper, 2009). The European Clinical Research Infrastructure (ECRIN) standard indicates that every 
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centre needs to perform quality processes to evaluate accuracy and consistency for data collection 
(ECRIN, 2013). In 1996, Wang and Strong published a data quality framework for general information 
systems with the following dimensions: completeness, accuracy, timeliness, ease of understanding, 
reputation, reliability, availability, price, (representational) consistency, response time, relevancy and
amount. Every dimension was labelled with a scale, e.g. reputation with 1 (bad) to 10 (very good) 
(Naumann, Leser, & Freytag, 1999; Wang & Strong, 1996).
In the following sections, important dimensions of biomedical data quality will be explained and 
discussed. These dimensions include completeness, accuracy, comparability, reputation, timeliness
and eligibility.
Data Completeness
Generally, data completeness (C) is measured in combination with data accuracy (validity) checks. 
Scores are typically calculated as a quotient of the relation between the sum of incomplete items (r) 
compared to all items (Batini & Scannapieco, 2006).
Equation 2-3 Completeness Calculation (adapted from Batini & Scannapieco, 2006)
Completeness is a quality dimension measured in many trials and data management systems 
performing data quality assurance. It is recognised that high data completeness shows strong evidence 
that trial results are useful (and truthful). However even if an item is complete (e.g. filled out in a web 
form), then this doesn’t necessarily mean that the item is correct. Other dimensions need to be 
applied to check whether the data is actually correct and useful.
Data Accuracy 
Batini & Scannapieco (2006) define inaccuracy as a state such that “the information system represents
a real world state different from the one that should have been represented” (Batini & Scannapieco, 
2006). Arts, De Keizer & Scheffer (2002) provide a simplified definition in the context of clinical 
research, where they define accuracy as “the extent to which registered data are in conformity to the 
truth” (Arts et al., 2002). According to the data quality definition of Wand & Wang (1996) data can be 
incomplete, ambiguous, meaningless or incomplete (see Figure 2-4) (Wand & Wang, 1996).
Correct Mapping
Incomplete Mapping Ambiguous Mapping Meaningless Item
Figure 2-4 Data Quality Representation Deficiencies
Even if the mapping of an item is correct, it doesn’t necessarily imply that the value actually represents 
the truth. Accuracy must include dimensions of timeliness, completeness, reliability, consistency and 
validity (Batini & Scannapieco, 2006). Accuracy can be distinguished between internal (related to the 
data) and external (related to the further use of the data) views (Wand & Wang, 1996). Applying range 
checks on values is one method to improve the internal aspects. Checking if the item represents the 
most recent value is an external view characteristic.
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Arts, De Keizer & Scheffer (2002) performed a case study where they performed a Source Data 
Verification (SDV) to evaluate the completeness and accuracy of data in a research registry compared 
to information in hospital records. For every data process (data entry, data extraction, data transfer) 
they calculated an accuracy score and a completeness score. Accuracy was based on whether the 
values of the registry were shown in the paper records or the selected category (e.g. yes/no) was 
correctly selected (Arts et al., 2002). 
SDV can be very expensive and time consuming (Tantsyura et al., 2010; Venet et al., 2012). Data 
accuracy checks without availability of electronic source data is reduced to range checks and cross 
validation methods. Venet et al. (2012) suggested an approach of evaluating data quality in trials 
where paper based sources (pCRFs) are in use. The group addressed four main errors: abnormal, 
infrequent, fabricated and falsified data values. They identified these errors with statistical analyses 
these errors could be readily detected (Venet et al., 2012). 
Data Comparability 
For international multicentre trials, every study site should have procedures and processes of how to 
implement standardized operation procedures (SOPs) for routine care and associated data 
management. To harmonize SOPs between centres, on-site data monitoring can be performed to 
investigate local processes and subsequently discover issues that may lead to low data quality. A 
statistical evaluation provided by clinical data management processes should ideally support visits to 
reduce costs and time efforts. This approach must also be transferable to other situations and data 
comparability checks. 
Comparability as a data dimension is known in the literature by the terms interoperability, agreement, 
consistency, reliability and variation. All are collected under the topic of concordance (Weiskopf & 
Weng, 2013). Guthrie et al. (2012) describe a quality control approach of collected values using the 
calculation of the intra-class correlation coefficient (ICC). With ICC it is possible to detect performance 
differences between centres in multicentre clinical trials. In a case study, the authors calculated the 
ICC and detected 2 significant performance differences. They reported the ICC in a table and looked 
at the identified values in box plots to easily detect the centre with the highest variations in their 
measurements compared to other centres (Guthrie et al., 2012). Calculation of the ICC can be used to 
detect data clustering, e.g. if the same physician performs a measurement more than once. This 
dependence can be skipped with the use of the residual ICC (RICC). The RICC can provide a direct 
percentage or degree of data clustering (Wynants et al., 2013).
ICC and RICC can detect data clustering and are therefore very useful for investigators during clinical 
trials to detect data inconsistencies and subsequently plan actions to reduce them (Guthrie et al., 
2012; Wynants et al., 2013).
Reputation 
Data reputation is also found in the literature as data provenance or data trustworthiness (Batini & 
Scannapieco, 2006; Dai, Lin, Bertino, & Kantarcioglu, 2008; Wang & Strong, 1996). Data standards 
demand that datasets are exchangeable particularly in the biomedical domain where information 
must be rapidly transferred from basic science to clinical trials and beyond (Richesson & Krischer, 
2007). Data provenance is define as “description of the origins of a piece of data and the process by 
which it arrived in the database” (Buneman, Khanna, & Wang-Chiew, 2001). With a trust score, the 
scientist can choose whether they wish to use the data directly or send data inquiries to the data 
provider (Dai et al., 2008).
Nurse, Agrafiotis, Goldsmith, Creese, & Lamberts (2014) explored an approach to measure data 
trustworthiness of online information using sources such as Facebook, Twitter and Google. The 
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authors developed a calculation that was dependent on the source competence, the timeliness of the 
information (recency), the user closeness to the event/information (proximity) and 
integrity/quality/provenance of the source. Every item was assigned with a weight to calculate a 
trustworthiness score. Other authors discussed radar graphs, traffic lights and stars to display the 
trustworthiness of data for users that need to “make informed decisions” based on the data (Nurse et 
al., 2014). 
In biomedical research this score is effective when methods like remote data entry or electronic data 
capture are in use. In the case of manual data entry, if the data source is electronic, then the original 
data can be checked with the entered data directly (at least in principle). 
Timeliness 
Time-related dimensions like timeliness, currency or volatility provide information on whether data is 
captured and/or updated in (near) real-time or more generally, if the data represents the most recent 
values (Batini & Scannapieco, 2006; Lane, Heddle, Arnold, & Walker, 2006). Batini & Scannapieco 
(2006) provide definitions for terms of time-related dimensions. These include:
 Currency is “the sum [of] how old data are when [they are] received (Age), plus a second term 
that measures how long data have been in the information system (DeliveryTime –
InputTime)” (Batini & Scannapieco, 2006)
Equation 2-4 Currency Calculation (adapted from Batini & Scannapieco, 2006)
 Volatility is “the length of time data remains valid” (Batini & Scannapieco, 2006) and
 Timeliness represents a value of “how current data [is] for [a] task” (Batini & Scannapieco, 
2006).
Equation 2-5 Timeliness Calculation (adapted from Batini & Scannapieco, 2006)
Here a value of 0 represents poor timeliness and a value of 1 represent good timeliness (Batini & 
Scannapieco, 2006).
In the biomedical domain, timeliness scores often represent efficient data capture. The more time 
between the original data collection and that data entry into a database for example, results in a lower 
data quality (Richesson & Andrews, 2012). For clinical data management, this score is often combined 
with a schedule feature that reminds the researcher of certain events and provides 
indications/notifications to improve timely data entry, e.g. in the biomedical domain, follow up visits 
of a patient (Brandt et al., 2006). Established tools can provide warnings of pending values or remind 
researchers that special events may occur in the future (Herzberg, Rahbar, Stegger, Schäfers Michael, 
& Dugas, 2011). Generally, a cut-off will be set by the data scientist to classify the data as either timely 
or untimely (Mathers, Fat, Inoue, Rao, & Lopez, 2005). 
A narrative literature review of RCTs found that there is an increased efficiency in timeliness of data 
capture by hand-held computers compared to paper-based approaches (Macefield, Beswick, Blazeby, 
& Lane, 2013). In the literature, timeliness is reported as either a score, a percentage or a histogram, 
where it is correlated with completeness or count of errors (Hills et al., 2010; Krzych et al., 2011; 
Laberge & Shachak, 2013; Mathers et al., 2005; Weiskopf & Weng, 2013). This indicates that timeliness 
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can always be used in combination with a logging information approach that provides time stamps for 
entered, changed or deleted values/records in a research registry.
Record Eligibility 
Nahm (2012) argues that there is no data quality framework that can be labelled with ‘one size fits 
all’. The reason for this is the heterogeneity of statistical analysis caused by data inconsistencies 
(Nahm, 2012). Eligibility is a data dimension that is hard to measure. Every clinical trial defines 
different requirements that need to be matched by all study participants. These criteria are not only 
the inclusion and exclusion criteria of subjects, but they can also include the minimum required 
information for the study objective. A proposal for computable protocol-driven research was 
presented in Sim & Niland (2012).
There are two main approaches for confirming clinical records as eligible for a trial. Firstly, compulsory 
data items can be defined for an ongoing trial and/or they can be defined in the set up of a new study 
for eligibility criteria to help find records in an existing data registry that can be re-used. Both purposes 
are used for computer-based clinical trial recruitment (Köpcke, Kraus, et al., 2013; Köpcke, Trinczek, 
et al., 2013). 
During an ongoing clinical trial, confirmation of record eligibility and defining related eligibility scores 
to records is an indicator of how much compulsory information has been entered for trial subjects. It 
is the responsibility of the investigator to determine whether mandatory trial items should be 
weighted. Through such an approach, tools can support users and/or investigators, e.g. by error flags 
and warnings (important data is missing) or reminders (less important data is missing).
In contrast to Nahm (2012), this leads to the conclusion that in every trial the assessment of data 
completeness and record eligibility is mandatory to monitor trial performances. 
Data Thresholds
Another key aspect for quality assurance and subsequent accreditation of a quality score is the 
definition of thresholds of items and the weight of the assessed quality dimensions. With regards to 
thresholds, this limit gives an indicator as to whether the quality of a selected item is adequate or 
insufficient. It is suggested that this threshold must be defined for all values in a data repository 
(JCAHO, 1990).
Little research has been done that shows whether thresholds on quality scores/scales are actually 
effective. In the literature, thresholds are usually subjectively predefined values or limits calculated 
by linear regression models to predict the likelihood of an event, process or decision procedure. They 
are typically defined a priori to a trial although they can be dynamically adjusted during the trial 
(Bacchieri & Della Cioppa, 2012; Batini & Scannapieco, 2006; R. M. Califf, Karnash, & Woodlief, 1997).
The (important) role of thresholds is related to the motivation of individuals in reaching particular 
goals. Goals can be part of games, or in the context of biomedical research as gamified objects. A goal 
can encourage a user to reach a certain percentage of data quality (Deterding, 2012).
How this goal (score) is actually calculated can be a generic requirement in the medical context and 
subsequently used for auditing purposes. Additionally, we argue that this threshold can serve as 
motivation for the user to achieve better data quality scores.
Data Quality Scores
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Generally, scores are used in the medical domain as a grade. This grade is often an arithmetic mean 
of at least two components that support the assessment of an item (Holle, 1995). In many situations 
it is a combination of considered quality dimensions, e.g. accuracy and completeness (Wang & Strong, 
1996). As described, not every score needs a simple threshold. Some scores need a weight, e.g. 
whether it is more or less important for the selected research hypothesis. Nonnemacher, Weiland & 
Strausberg (2007) used in their evaluation of data quality in cohort trials a scale of values between 1 
and 9 (Nonnemacher, Weiland, & Stausberg, 2007). They considered that data quality dimensions can
be distinguished into four different aspects: 
(a) intrinsic aspects, that states that data quality needs to achieve a high amount of accuracy 
and completeness in its own right;
(b) contextual aspects, that describe data quality itself and considers quality of data in the 
frame of the research objectives;
(c) the representational aspects, that describe the format (concise and representation) and 
meaning (interpretability and ease of understanding) of the data, and 
(d) accessibility data quality aspects, that define data as a construct that should be sharable 
and exchangeable between domains, with the highest standards of privacy and security 
(Wang & Strong, 1996) (see Figure 2-5).
Figure 2-5 Data Quality Dimension Framework (adapted from Wang & Strong, 1996)
Conclusions
Given all of these possibilities of data quality dimensions that need to be considered, a general 
approach for clinical trials cannot be overly prescriptive. Every trial needs to select their own criteria 
that are useful to measure data quality that is specific to that trial. This research considers criteria that 
are possible to capture, measure and report during data entry through web-based feedback. Data 
quality dimensions need to be reported (feedback) to three different users: the data entry user, the 
(principal) investigator and the research community. The data entry user needs data quality feedback 
to achieve better quality, to avoid data cleaning at the end of a trial. Literature shows that feedback 
of data completeness and data accuracy is usually reported in research papers after a clinical trial has 
concluded. However, web-based databases and associated information systems now have the 
possibility to capture, show and we hypothesise, improve this data quality assessment in real-time. 
Data completeness and data accuracy can be reported during data entry as real-time feedback. 
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Procedures for data monitoring can also be performed, e.g. centralized monitoring, that can be 
reported to staff members and investigators on a regular basis. Investigator feedback must include 
all-important information so that an investigator can start interventions to improve local data 
processes to collect higher quality data earlier in the trial lifecycle. Important examples are eligibility 
scores and timeliness scores. Finally, community feedback must include all information needed to 
challenge the user to be better than others and to set up individualised motivations to improve data 
quality. Examples considered include leaderboards for overall data quality rankings with suggestions 
on how to increase data quality scores targeted to the individuals.
To implement feedback tools in data management systems, it is important to investigate what 
procedures are currently used in clinical trials and what specific requirements new tools should 
address.
2.3 Web-based Feedback Systems
Participants in clinical trials have to sign and understand the consequences of their involvement 
through clinical research consent (or parental assent). One part of this consent includes information 
about what happens with information collected during the trial. In most cases, this information is 
pseudonymised, i.e. every subject is assigned with a unique computer-generated identification code 
that only internal staff at the specific centre where the patient was recruited can use to subsequently 
re-identify the subject. The patient information often needs to be provided to other researchers 
outside of the immediate healthcare/research unit. The issue here is that local data is primarily stored 
in paper-based records whilst data that is exchanged between centres is stored in digital repositories. 
It is generally known, that data transfer from paper-based records to electronic records results in a 
loss of accuracy and completeness (Arts et al., 2002; Glöckner, Arlt, Bancos, Stell, & Sinnott, 2015; Le 
Jeannic et al., 2014). To increase the usefulness of captured data for clinical research, data quality 
feedback is needed to improve the transfer of such information into a translational research context 
and thereby provide information that can be used to draw statistically significant conclusions in clinical 
research.
In 2002, Simon De Lusignan and co-workers investigated the impact of feedback on data quality in 
medical records. In their study they defined ‘useful data quality markers’ and investigated whether 
feedback increases these marker’s statistical significance. Their literature review concluded, that 
feedback had been used to improve “clinical outcomes rather than on changes in data quality” (S. de 
Lusignan, 2002). They discovered that just 3 of their 10 defined markers improved. These items were 
the READ code, prescriptions linked to diagnosis and acute prescriptions linked to diagnosis. Other 
prescription items and follow up information was not improved through feedback. They concluded 
their research with identification of motivational factors that could have had an impact on data entry 
users.
Data quality feedback has already been implemented by the research group of Brouwer, Bindels & 
Weert (2006) in clinical data management systems and seemed “to have some positive effect” 
(Brouwer, Bindels, & Weert, 2006). However, with the improvement of technology and the availability 
of new (cheaper) devices, novel tools for data quality feedback are far more readily accessible. We 
consider the background of recent literature that address new approaches for data quality feedback 
with focus on different data entry domains including manual data entry and electronic data capture
mechanisms. 
2.3.1 Feedback Realisation
Main origin of errors in data collection is in the original source to registry or trial database transfers 
(Day, Fayers, & Harvey, 1998). The hospital patient record is considered as the most accurate source 
of clinical information and the manual double data entry of patient information into a trial registry is 
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considered as the gold standard of data accuracy (R. M. Califf et al., 1997; Paulsen et al., 2012). Data 
quality relies on the quality of the original (source) data and the subsequent transcription of this into 
the registry databases or clinical trial case report forms (CRF). Generally, the collection of patient 
information and trial-related data are performed in parallel (dual source information system – see 
Figure 2-6). Due to policy and security regulations, it is not always possible to collect research data 
directly from patient information systems (single source information systems – see Figure 2-7). There 
are a multitude of data collection and data sharing models and systems, each with a different purpose 
and design goal established to meet the demands of the associated stakeholders (Sinnott, Stell, & 
Jiang, 2011).
Figure 2-6 Dual Source Information System Figure 2-7 Single Source Information System
To tackle issues of data exports, EDC supports the process of information collection and reduces the 
error rates (Nahm et al., 2008). Research has shown that EDC transfers data with an equal accuracy 
compared to human data entry, but the time is significantly reduced hence the trial costs are reduced 
(Walther et al., 2011). It has also been shown that capturing data in electronic CRF (eCRFs) is only 
effective if it is used in the framework of multicentre trials (Le Jeannic et al., 2014).
Mobile applications (apps) and real-time notifications
In 2014, it was identified that the sales of mobile devices have been increasing each year and are now 
more widely used to access web-content than desktop PC/Macs (Fulgoni, 2015). During the 2016 
Google I/O Keynote CEO Sundar Pichai informed the audience that 50% of all Google queries were 
now made by mobile phones and every 5th query is a voice query (Pichai, 2016). Even third world 
countries have an increased mobile device usage (Ibukun, 2014). The mobile phone is now a key part 
of (almost) everyone’s life. Almost everyone now uses such devices for checking social networks, for 
news or email more than once a day (Fulgoni, 2015). One feature of mobile applications is the ongoing 
alerts, reminders and notifications that can pop-up on the home screen, reminding everyone of 
specific events.
The term that describes the use of mobile devices in public health setting is often called mobile health 
or mHealth. Systematic reviews concluded, that mHealth is beneficial, but less research has been 
conducted to show significant improvements of such applications on health generally (Aranda-Jan, 
Mohutsiwa-Dibe, & Loukanova, 2014; Catalani, Philbrick, Fraser, Mechael, & Israelski, 2013; Hamine, 
Gerth-Guyette, Faulx, Green, & Ginsburg, 2015).
mHealth can be used to improve local data processes as shown in a mobile and web-based approach 
like SORMAS (Surveillance and Outbreak Response Management System). Here a data management 
systems using mobile phone apps was implemented into local data processes to improve the 
reporting/surveillance of an Ebola outbreak for epidemiological purposes in 2014/2015. Patient 
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information from suspected Ebola patients was captured on paper-based forms, however SORMAS 
developed a mobile app that improved and simplified the data capture for local medical personal 
(Fähnrich et al., 2015). Furthermore, with regards to data quality feedback, another research group 
implemented data quality feedback into a food questionnaire-based trial. They distinguished between 
data input feedback and data analysis feedback. This data quality tool could be dynamically adjusted
by the user, who could define their own data quality requirements with assigned weights (Weber, 
Presser, & Norrie, 2015). 
Another group investigated the increase in data quality achieved through mobile apps as part of a 
randomised controlled trial (Joos et al., 2016). The improvement of health information can also be 
accomplished with the help of motivational short message service (SMS) or by the combination of 
motivational SMS and data quality feedback. The author discovered no differences between the two 
groups, but mentioned that the study was underpowered (Joos et al., 2016).
Importantly for data capture is the role of the patients themselves. It is now possible to develop mobile 
applications for patients that allow them to enter their own self-reported data. This offers new 
possibilities for data capture that extend beyond the kinds of data that is typically collected in a clinical 
healthcare setting, e.g. real time reporting of quality of life issues that impact patients with particular 
ailments, or indeed on their general life issues more generally, e.g. the exercise they take or their 
dietary intake (Sinnott, Han, Hu, Ma, & Yu, 2015).
An important aspect of data accuracy arises from the data source. The ideal situation is a single source 
system, where data errors can easily be tracked and reminders automatically sent to researchers 
and/or data entry personnel (Herzberg et al., 2011). In the case of dual source systems, a human will 
typically transfer the information into a disease registry or a clinical trial database. This can be 
undertaken manually or through automated data extraction systems. In the former scenario, which is 
by far the most prevalent existing across the healthcare landscape, data quality relies on the 
motivation and accuracy of the user. Therefore, mechanisms that encourage a user to enter high 
quality data must be investigated. mHealth applications whilst promising for public health, are not 
well researched with regards to data quality and challenges around the trustworthiness of the data.
2.4 Enhanced Web-based Solutions and the Move to Complete Virtual Research
Environments
As explained, over the last years funding into R&D for new medical entities has increased, but the 
number of actual developed medical solutions has actually decreased. Web technologies have now 
evolved to provide more all-encompassing solutions that can increase the amount and quality of data 
that is collected. 
2.4.1 Web-based Frameworks
Ideally, all tools and processes must be developed and used in accordance with GCP Guidelines and 
all applicable regulations. Quality assurance in clinical research is defined as: 
“[…] all planned and systematic actions that are established to ensure that the trial is performed and 
the ‘clinical’ data are generated, documented (recorded), and reported in compliance with GCP and 
applicable regulations.” (International Conference on Harmonization, 1996). 
To ensure these aims, a variety of Quality Control methods have been developed to assess and 
improve the quality and integrity of the collected data. One of these methods that assesses the quality 
of trial performances is (Data-) Monitoring (Campbell & Sweatman, 2002; International Conference 
on Harmonization, 1996). 
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Monitoring needs to be an on-going process in Quality Control that continuously aims to decrease 
inconsistencies. In general, monitoring is a continuous process that can be used to avoid specific errors 
(Arts et al., 2002). Historically, monitoring has been time-consuming, inefficient, problem-focused and 
cost-intensive (Baigent et al., 2008). To tackle this, the US Food and Drug Administration (FDA) 
published guidance documents for efficient (risk-based) approaches to clinical monitoring. This 
approach recommended a centralized data monitoring approach, that allows to discover critical data 
and data anomalies and then perform on-site monitoring, thereby allowing local site staff to improve 
data processes in the selected items (U.S. Department of Health and Human Services et al., 2013).
Arts, Keizer & Scheffer (2002) conducted a literature review about quality control methods for the 
improvement of data quality in the context of biomedical research. They described procedures that 
improve the quality of data at the setup of the registry, during data collection and general actions for 
data analysis. Unfortunately, data cleaning is a method currently established by the database 
community that has not been targeted to the specific needs of the translational biomedical 
community (Batini & Scannapieco, 2006; K. Chen et al., 2011). The authors conclude that quality 
assurance in clinical trials needs to be an ongoing process and not simply involve data cleaning at the 
end of a given trial. This ongoing systemic process needs to not only ensure that high data quality is 
collected, it also represents the need for GCP compliant data management and improved data 
integrity and subject protection (Bhatt, 2011).
Nonnenmacher, Weiland & Strausberg (2007) adapted this framework and developed an 
infrastructure for quality control in cohort trials. They created a recommendation for a quality score 
that could report on the quality of the collected information. In comparison to the established quality 
indicators (structure quality, process quality and outcome quality) from Donabedian (1988), they 
suggested 24 scores divided into three categories (plausibility, organisation and correctness ) 
(Nonnemacher et al., 2014). 
2.4.2 Heterogeneity of Data Management in Biomedical Research
One major challenge with translational research is data heterogeneity (E. A. Zerhouni, 2005; E. a 
Zerhouni, 2007). Translational research is supported by translational informatics that aims to “enable 
high-throughput research” (Payne et al., 2009; Payne, Johnson, Starren, Tilson, & Dowdy, 2005). There 
remain many issues in the diverse landscape of health IT systems with numerous standards and data 
formats. Of particular importance for the performance of clinical data management systems (CDMS) 
for clinical trials are GCP Guidelines and standards related to GCP (International Conference on 
Harmonization, 1996; Ohmann et al., 2011).
One of these documents is the Good Clinical Data Management Practise (GCDMP) Guideline. This 
industry standard proposes standards for ongoing data quality assurance of CDMS. Among other “best 
practise” requirements, it suggests calculating error rates, assessing the comparability of data 
between sites and conducting evaluations on the impact of data quality measurements and associated 
processes to improve data integrity (Society for Clinical Data Management, 2005).
Unfortunately, hitherto there have been no widely accepted standards for GCP-compliant data 
management of multicentre trials associated with the underpinning IT-Infrastructure. Results of a 
survey in a European research consortium showed a significant heterogeneity of CDMS used in clinical 
trials. The survey showed that in 66 centres, 20 different commercial and 7 open-source CDMS were 
in use. Furthermore, more than half of all centres were identified as not performing data management 
according to GCP, FDA or GAMP Guidelines (Kuchinke et al., 2010).
To tackle this, the ECRIN Working Group suggest a general CDMS framework with use of a structured 
communication techniques comprised of a board of data management experts and discussion groups 
35
(Ohmann et al., 2011). This standard is divided into three parts: standards for IT, standards for data 
management and general standards (see Figure 2-8). Every group of standards has criteria that are 
classified as “essential”, i.e. they represent the minimal recommended requirements for a clinical trial 
(Ohmann et al., 2013).
Figure 2-8 List of ECRIN standards (Ohmann et al., 2013)
In essence, one aim of translational informatics is to increase the information flow and knowledge 
transfer that are caused by, amongst other things, the heterogeneity of data management systems. It 
was stated that data management systems need ongoing data quality checks. Limited research has 
been published in this specific area. This suggests that data quality control could be improved through 
implementing features such as performing feedback in the data management system and encouraging 
users to improve their data quality and the processes that might impact on their, and hence the overall 
system, data quality.
2.5 Diversity of Funding Schemes
In the US, Australasia and most other nations the majority of biomedical funding involves single 
investigator initiatives: the NIH RO1 grant in the US is a prime example (Yin et al., 2015). In 2015, the 
NIH provided a total of $30 Billion USD for research grants. Most of the NIH budget goes to R01 grants, 
which fund single investigator initiated initiatives. There are now Clinical Translation Science Awards
(CTSA) and National Cooperative Drug Discovery Groups (NCDDG) awards for group efforts, but these
are a minor part of the overall NIH budget (<2%) and they are only awarded through NCATS (Collins, 
2011). Some smaller NIH institutes are also now moving to partnership awards and providing minor 
budgets for more cooperative/collaborative-oriented research.
On the other hand, research elsewhere is much more collaboratively oriented. As two examples, 
Germany is supported by three large sources of funding: the German Research Foundation (DFG); the 
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Federal Ministry of Education and Research (BMBF), and the EU through the Horizon 2020 initiative. 
In France, the French National Research Agency (ANR) funds increasingly interdisciplinary and 
collaborative research projects. In contrast to the US, in the EU there is much more effort on 
cooperative multi-project and multicentre grants. In 2014, 21% (~$683 Million USD) of the DFG budget 
was used for Collaborative Research Centres (SFBs), but there are other multicentre funding grants 
including Clinical Research Groups (KFOs) (DFG, 2016a). Around 35% of this budget is used for Life 
Science research (DFG, 2016b). The BMBF similarly funds partnerships. The third major source of 
funding is the EU through the Horizon 2020 initiative. These grants are explicitly targeted to large-
scale multinational research endeavours. It should be noted that EU funding has gone up dramatically 
since the mid 90’s from less than 1 Billion Euro to estimated 80 Billion Euro for the package 2014-2020 
(Grove, 2011). Despite this growth of funding, many challenges related to the volume, the veracity 
and the variability of data (often called big data) still need to be addressed by biomedical research 
networks if they are to achieve a higher overall impact. 
To overcome these issues, interdisciplinary research and improved communication (feedback) is 
needed. Research activities, that provides education for researchers and infrastructures that allow for 
rapid and accurate knowledge sharing are essential (Wild et al., 2015). It is assumed that international 
teams and interdisciplinary research enhances the quality of research and ultimately the impact of the 
resultant conclusions, however this assumption needs to be considered in more detail. 
2.5.1 Multicentre clinical collaborations
As mentioned previously, to achieve significant breakthroughs especially in rare diseases, multicentre 
trials that involve many centres and multidisciplinary teams are required (Gatta et al., 2010; E. A. 
Zerhouni, 2003). One of the primary benefits of multicentre trials are increased sample sizes that offer 
increased statistical power leading to improved research outcomes. 
However, multicentre clinical trials also face a number of challenges: diverse performance of trials can 
be caused by ongoing changes of the study protocols or complex protocol designs and impacts on 
associated data collection (Brandt et al., 2006). Other problems include data propagation; fraud and 
erroneous randomization or in some cases incorrectly calibrated equipment, which can make the 
conduct and comparison of studies difficult (Venet et al., 2012). A literature review showed that 
Randomized Clinical Trials (RCTs) in single centre settings have larger treatment effects than 
intervention trials in multicentre settings (Dechartres et al., 2011). 
As argued, multicentre research depends on tackling data management challenges. With the existence 
and adoption of data processing standards, the usefulness and quality of collected data can be 
increased to improve the findings and conclusions of collaborative research. This is especially 
important in the area of rare diseases such as adrenal tumour research. Rich research-oriented 
infrastructures – often called Virtual Research Environments (VRE) - allow exchange of patient 
information to support multiple trials. VREs can now be established across many targeted areas that 
augment basic databases and support targeted data collection and support the interconnectedness of 
data related to multiple trials and studies (Sinnott & Stell, 2011; Sinnott et al., 2011). 
The technical software solutions that can now be achieved depend on the funding models that allow 
them to be created, adopted by multiple organisations and centres, and ultimately used to influence 
research and clinical outcomes. In this context, we consider how diverse funding schemes in Europe 
are allowing investigators and centres to work more collaboratively and in so doing, having a more 
positive impact on biomedical research productivity. 
One way to measure collaboration and research success is through actual research publications that 
are generated as a result of data sharing. However, research success is not the only impact, 
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nevertheless it is often a major factor in how funding is delivered. Successful submitted research 
articles are often a key determinant in the allocation of funding that subsequently shapes the activities 
in the clinical, biomedical and indeed many other research domains.
2.5.2 Measuring Clinical Research Collaborations
International societies, research networks and/or individual scientists often use bibliometrics to 
measure research success, e.g. impact factors of papers that are successfully published. Traditionally, 
bibliometrics typically offers scores that characterise a journal by calculating the count of citations 
from other articles that refer to a paper in that journal. Bibliometrics are used to capture an expression 
of citation quantity not quality of the article/journal, however they are often used as a tool to show 
the influence of a journal in a particular field of research. 
Commonly used and well-established bibliometrics are the impact factor (IF), the Eigenfactor or h-
index. The IF is calculated through the average number of citations from articles in a given journal over 
a 2-year period. The IF shows the impact of a journal in a particular field of research. In contrast, the 
h-index measures the total number of articles and the associated citations. The h-index is provided by 
major research index providers including Scopus and Thomson Reuters. Scopus also provides the 
SCImago Journal Rank (SJR) that measures the prestige of a particular journal. Scopus has the 
advantage that new journals and journals not listed in more mainstream Thomson Reuters Journal 
Citation Reports. Different bibliometrics are used for different purposes. Exploring the impact of 
funding and software solutions on research success implies that an analysis of articles and journals 
must be performed using more than just one metric (Bollen, Van de Sompel, Hagberg, & Chute, 2009; 
Bornmann, Marx, Gasparyan, & Kitas, 2012; Falagas, Kouranos, Arencibia-Jorge, & Karageorgopoulos, 
2008). It is noted that this is just one aspect of research success; novel treatments, drug therapies or 
patient management therapies are other clinical outcomes that are obvious alternative measures of 
research success.
To measure the impact of collaborative research networks, it is mandatory to explore whether the 
research networks funded by the EU have made an impact. Specifically, an exploration is needed to 
determine whether the establishment of research networks with support software infrastructures has 
galvanised the research community, and determine how this has changed on a global scale. To prove 
this hypothesis, we describe a representative case study focused on the adrenal tumour research 
community – specifically through the European Network for the Study of Adrenal Tumours (ENSAT3). 
It is argued that investigating the impact of ENSAT in adrenal research, the findings can be applied 
more generally to other clinical domains, or indeed to other domains and disciplines. ENSAT is an 
example of a large European network of scientists, clinicians, software engineers and quality 
controllers that takes advantage of European funding schemes to perform international research. If 
the research success of ENSAT is significant higher compared to other research initiatives of non-
European funding schemes, conclusions and discussions about the general practicability of single 
centre funding must be initiated. The enhancement of technologies in clinical research assists large 
research networks to collaborate, exchange knowledge and promote young scientists in the field of 
research. Data management tools that provide audit and support data entry are general expected by 
authorities that provide funding for clinical research.
2.5.3 The European Network for the Study on Adrenal Tumours (ENSAT)
Luke et al. (2015) conducted an investigation into collaborative research of an academic institute in 
the US between 2007 and 2011. Here, the networks of scientists were analysed. It was shown that 
3 www.ensat.org
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studies involving scientist with higher numbers of collaborations and more interdisciplinary team 
activities over time were identified as being more successful. The authors concluded that 
interdisciplinary collaboration is key to obtaining higher impact of research conclusions by the 
scientific community. By promoting collaboration between basic scientists and clinical researchers, 
collaborative research achieves a higher impact than individual researcher-driven or individual centre-
driven science (Barker-Haliski, Friedman, White, & French, 2014; Wuchty, Jones, & Uzzi, 2007). To 
validate this hypothesis, it was suggested that network analyses should be used to evaluate diverse 
developments in collaborative research (Luke et al., 2015). 
Research into collaborative studies and their outputs, has been explored in the field of the Science of 
Team Science (SciTS). It was identified that multidisciplinary teams are advantaged and able to find 
conclusions on complex diverse objectives that are often not possible through single 
investigator/single centre research efforts. The phenomenon of so called “team-based research” or 
“team science” is supported by international online resources that focus on exploring and improving 
knowledge sharing within and across research communities. One example of this is the team science 
toolkit from the National Cancer Institute (NCI) (Vogel et al., 2013). 
Over the last 20 years there has been increased emphasis in Europe, compared to the US and other
nations, in supporting collaborative, multicentre research that has spurred the formation of 
international multicentre biomedical research networks. This thesis claims that this has resulted in 
accelerated translational research productivity in Europe compared to the US and other nations. 
ENSAT is an example of a research network that is conducted by international researchers who want 
to make an impact onto adrenal research. Investigating the impact of ENSAT in the context of the 
adrenal research community will help to gain an insight into the impact of collaborative funding 
schemes on research success that can potentially be generalised to other research areas.
ENSAT was founded in 2002 with the aim to improve the prediction and management of specific types 
of adrenal tumour. The network was merged from three existing but largely independent, adrenal 
tumour research networks in France, Germany and Italy, with research teams from the UK. ENSAT was 
originally developed for clinical researchers across Europe but has since grown to include member 
centres in Japan, USA, Brazil, Canada and Australia. The process of the development of the ENSAT VRE 
in close cooperation with the ENSAT network and the empowerment that it supports has been a key 
to its global success. Thus clinicians are not obliged to send physical bio-specimens or offer further 
information on patients other than what is in the registry. This model of collaboration has overcome 
many of the concerns of the clinical community that are involved. 
ENSAT investigates four primary types of adrenal tumours including: adrenocortical carcinomas (ACC), 
pheochromocytoma and paragangliomas (Pheo/PGL), non-aldosterone producing adrenocortical 
adenoma (NAPACA) and aldosterone-producing adenoma (APA) - all of which are relatively rare (e.g. 
for ACC this is 1.5: 1million) and have typically poor survival rates (Golden, Robinson, Saldanha, Anton, 
& Ladenson, 2009; Kebebew, Reiff, Duh, Clark, & McMillan, 2006). All clinical information entered into 
the ENSAT VRE is categorized into one of four related sets of tables in a database with four associated 
(international) working groups (see Figure 2-9). 
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Figure 2-9 Patient Information from ENSAT-trials categorised into work groups
The information technology and data management solution of the ENSAT platform itself is offered 
through a security-oriented, web-based VRE. This VRE provides a variety of functions for clinical 
researchers (Stell & Sinnott, 2012). The VRE supports a portfolio of coordinated translational studies 
(basic science/genetics and clinical trials/diagnostic & treatment) of adrenal tumour patients that can 
be used to reveal new molecular mechanisms of the growth of these tumour types and provide insight 
into associated clinical research areas, e.g. their role in hypertension (Beuschlein, 2013). 
A key aspect of the ENSAT VRE is the re-usability and classification of the captured clinical data. This 
is accomplished through centralized data monitoring for data completeness (Glöckner et al., 2015). 
An audit tool allows for measurement of the completeness of data and record eligibility in the registry. 
This can be used for research centres data completion rates, associated trial data completeness rates 
as well as the tumour type data completeness rates.
Based on the above, we consider the impact of collaborative funding with regards to the publication 
success of adrenal research between 1995 and 2015. It is assumed that only some of the highlighted 
funding goes to biomedical research and only some to endocrine efforts and an even smaller fraction 
to the adrenal tumour research domain. Nevertheless, the discovered patterns in the data analysis 
are compelling and representative, and we argue a key overall barometer to measure the success of 
clinical research collaborations. This in turn has dependencies on the quality of the data within the 
ENSAT registry.
2.5.4 Assessment of Research Success
To explore ENSAT as collaborative research network funded by European grant and its impact into 
adrenal research globally, published work related to adrenal research and health care from MEDLINE 
was considered. To cover the primary topic of adrenal research the search terms: “primary 
aldosteronism”, “Cushings Syndrome” (including the various spellings), “pheochromocytoma”, 
“paraganglioma”, “incidentaloma”, “adrenal cortical cancer”, “adrenocortical carcinoma”, ”adrenal 
cancer” and for general articles “adrenal tumour” (including the various UK/US spellings) were used. 
The search was restricted on titles between the years 1995 to the end of 2015. All types of publications 
and languages were included. Reviews papers were not considered as research success. To exclude 
reviews, all articles with fewer than two authors were excluded from the final analysis.
40
In total, the search identified 9275 publications that were indexed in MEDLINE. The search was 
subsequently exported into an XML (Extensible Markup Language) file to use an XML reader library of 
Python to automate the process of data mining to create a CSV spreadsheet (for source code see 
Appendix: Python Code for Data Extraction). With this CSV (Comma-Separated Values) file details of 
the publications were categorized into article name, PubMed identifier (PMID), name of the first and 
last author along with their institutional affiliation, number of authors, International Standard Serial 
Number (ISSN) and year of publication. The nation of the author was assigned based on the author 
institute affiliation. After the exclusion of review papers, 7856 articles were identified for the final 
analysis.
Here publication success was characterized as the total count and average yearly increase of 
successful submitted papers in journals with high influence and reputation. The data analysis was 
based on three journal metrics: the SJR, the h-index and the IF. These metrics were chosen to evaluate 
the success from multiple aspects: the prestige of the journal (SJR), the productivity of the journal (h-
index) and the average number of citations of the journal within a given 2-year period (IF). 
To review the impact of multicentre research versus single centre funding on publication success, a 
comparison of publications and metric trends between North America (NA) and Europe (EU) in the 
years 1995 to 2015 was conducted. For NA data from the US and Canada was used in the analysis. 
Mexico and other North/Central American countries were investigated separately. 
To confirm the thesis of different regions and related research funding schemes, nations/regions with 
the highest gross domestic spending (GDP) on R&D in the year 2013 were also separately analysed 
regarding their submitted publications and bibliometric scores. The identified nations/regions 
selected were: US, Japan, Italy, France, Germany, Korea, Israel, Nordic Countries (Island, Denmark, 
Norway, Sweden, Finland), China/Taiwan (OECD, 2016). To show the outcome of related research 
networks, the identified regions were compared to the publication success of ENSAT. Research articles 
where first or last author were affiliated with ENSAT were marked as an ENSAT article. 
The observed years were clustered over the periods 1995-1999 (baseline data), 2000-2004 (start of 
ENSAT research network funding in Europe), 2005-2009 and 2010-2015 (following the establishment 
of the ENSAT research networks and the implementation of the ENSAT-VRE) and the shift of funding 
in the US vs. EU. The data analysis was categorised by:
(a) general publication overview; 
(b) the yearly increase of the SJR per paper per continent/nation;
(c) the yearly increase of the h-index per paper per continent/nation, and
(d) the yearly increase of the IF per paper per continent/nation.
A linear regression analysis for the years 2000 and beyond was used to compare the period 1995-
1999. The SJR and h-index data was obtained through the Scopus database4. The IF was obtained via 
the Journal Citation Reports5. Bibliometrics were available to 2014. To include publications for 2015 
in the data analysis, the articles from 2015 were assigned with the same scores as 2014. This was 
similar to the SJR and h-index, which could not be obtained before 1999, hence articles published 
before 1999 were assigned with the same score as those of 1999. Also the IF was not available before 
1997, hence articles from 1995 and 1996 were assigned the 1997 IF scores. For a concluding overview 




During the data collection, it was discovered that author affiliations were rarely included in the 
MEDLINE export, therefore data was reviewed and in the majority of cases author affiliation manually 
added. This research and the data processing elements could be extended to include an investigation 
including more than just first and last author affiliation. However, the last author affiliation is often 
not available via MEDLINE and in many cases just the first author has information given. Furthermore, 
due to license restrictions, it was not possible to access the full text of all articles and all named 
authors. This was an issue especially for articles available in other languages besides English where no 
author affiliation was given. During the manual review of the articles it was discovered that some non-
English articles needed special review, e.g. Spanish articles were checked to determine whether their 
origin was Mexico or Spain, similarly for French articles (Morocco, Switzerland or France), Portuguese 
articles (Brazil or Portugal) and German articles (Germany, Austria or Switzerland). All non-English 
articles with no author affiliation were assigned with the nationality of the language used in the paper.
This analysis also included conversations/comments that were indexed in MEDLINE. It is questionable 
whether a comment has the same weight of influence in the research community as a peer-reviewed 
article in a highly cited journal.
To assign every article with the SJR, h-index and IF, the ISSN exported from MEDLINE was matched 
with the ISSN information exported from Scopus and Thomson Reuters Journal Citation Ranking. 
MEDLINE exports the eISSN (electronic ISSN) or ISSN-L (linking ISSN), however the bibliometric 
databases provide the p-ISSN (print ISSN) and this does not always match with the general ISSN of the 
journal. Therefore, where required, the ISSN was manually added to obtain an appropriate journal 
metric value for every article. Some papers were also discovered that had changed the name and ISSN 
within the observed period of years.
2.5.5 Discoveries
In the observed period, first authors affiliated with institutions from the USA published nearly 18% of 
all articles in the field of adrenal tumours. Notably countries with higher R&D per capita like Japan, 
Korea, Taiwan or Israel scored 2nd, 12th, 15th and 20th. In total 78 countries published 7856 papers 
within the 21 observed years (see Table 2-3).
Table 2-3 Nations (First Author affiliation) with the most published papers between 1995 and 2015











Rest of the World 2170
Total 7856
The EU published 3605 research articles between 1995 and 2015. Asian countries published 2425 and 
North America published 1526 articles. The Journal of Clinical Endocrinology & Metabolism was the 
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journal with by far the most successfully submitted and published articles from all analysed journal 
papers between 1995 and 2015 (see Table 2-4). The highest non-UK/USA journal was Hinyokika Kiyo 
(Japan) with 83 articles (place 9).
Table 2-4 Top 5 Journals of successfully submitted articles
Journal Publications 
The Journal of Clinical Endocrinology & Metabolism 400
Clinical Endocrinology (Oxf) 164
European Journal of Endocrinology 161
Journal of Endocrinological Investigation 105
Endocrine Journal 102
SJR
In the observed years, NA achieved the highest SJR values per paper per year. In contrast, the EU had 
the highest regression rate, which indicates that - if the trend continues - the EU will overtake NA with 
regards to SJR per paper per year in 2025. It is also notable that NA had a very high fluctuation of SJR 
values in the observed time period (R2=0.2) (see Figure 2-10).
Figure 2-10 SJR per paper per year of EU and NA
The analysis of individual nations and regions with a higher GDP on R&D shows that France, Germany, 
the USA and Italy have the highest SJR scored per articles per year. The negative regression of Japan 
is explained by the fact that Japan started with a very high average SJR in 1995 (SJR=0.74). This 
contrasts to significantly lower values in the following years. ENSAT, as an example of international 
research cooperation, scored the highest average SJR values together with a steady regression rate 
(see Table 2-5). 
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Table 2-5 SJR per paper per year in selected nations/regions
1995-1999 2000-2004 2005-2009 2010-2015
USA
SJR per paper per year 1.19 1.37 1.36 1.44
Regression coefficient -0.01 0.02 0.02 0.01
Japan
SJR per paper per year 0.60 0.57 0.87 0.75
Regression coefficient -0.06 -0.02 0.03 0.02
Italy
SJR per paper per year 0.71 0.98 1.34 1.32
Regression coefficient 0.06 0.05 0.06 0.04
France
SJR per paper per year 0.76 0.81 1.35 1.78
Regression coefficient -0.08 -0.01 0.04 0.06
Germany
SJR per paper per year 0.70 1.24 1.22 1.51
Regression coefficient 0.11 0.10 0.06 0.05
Korea
SJR per paper per year 0.37 0.86 0.73 0.74
Regression coefficient 0.23 0.11 0.04 0.02
Israel
SJR per paper per year 1.14 0.82 1.32 1.20
Regression coefficient 0.00 -0.03 0.02 0.01
Nordic Countries
SJR per paper per year 0.72 0.85 0.87 1.17
Regression coefficient -0.09 0.03 0.01 0.03
China/Taiwan
SJR per paper per year 0.56 0.67 0.86 0.90
Regression coefficient 0.09 0.02 0.03 0.02
ENSAT
SJR per paper per year 1.45 1.42 1.69 2.05
Regression coefficient 0.25 0.03 0.03 0.04
In 2014, the Journal Nature Reviews Genetics had one of the highest SJR sores in the biomedical 
domain. Journals with higher SJR are Ca: A Cancer Journal for Clinicians (SJR 2014: 37.4), Annual Review 
of Immunology (SJR 2014: 28.6) and Nature Reviews Molecular Cell Biology (SJR 2014: 24.3). Adrenal 
articles with the highest SJR between 1995 and 2015 are shown in Table 2-6. 
 
44
Table 2-6 Top 3 articles with the highest SJR Score
Place Article FA Nation Score
1. Qin, Y., … Dahia, P. L. M. (2010). Germline mutations in TMEM127 
confer susceptibility to pheochromocytoma. Nature Genetics
USA 22.4
2. Comino-Méndez, I., … Cascón, A. (2011). Exome sequencing identifies 
MAX mutations as a cause of hereditary pheochromocytoma. 
Nature Genetics
Spain 20.5
3. Goh, G., … Lifton, R. P. (2014). Recurrent activating mutation in 
PRKACA in cortisol-producing adrenal tumors. Nature Genetics
USA 19.6
Assié, G., … Bertherat, J. (2014). Integrated genomic characterization 
of adrenocortical carcinoma. Nature Genetics
France 19.6
h-index
NA and EU showed a decrease of h-values over the observed period. The EU kept the h-values 
relatively constant over the observed years. The predicted intersection of the EU and NA regression 
will be the year 2019, i.e. when the EU will have a similar h-index. Similar to the SJR analysis, h-values 
show a drastic fall between 2006 and 2008 (see Figure 2-11).
Figure 2-11 h-index per paper per year of EU and NA
Similar to the EU vs NA evaluation, the general h-index downward trend can also be observed in the 
national/regional analysis. France and Germany scored higher h-values than the USA, while France 
also achieved an upward trend regarding the h-index in the observed year periods (see Table 2-7).
45
Table 2-7 h-index per paper per year in selected nations/regions
1995-1999 2000-2004 2005-2009 2010-2015
USA
H value per paper per year 124.98 138.59 112.54 97.27
Regression coefficient 5.46 2.19 -1.00 -2.01
Japan
H value per paper per year 76.09 67.33 62.62 57.41
Regression coefficient -5.38 -2.33 -1.56 -1.09
Italy
H value per paper per year 91.93 113.22 113.33 90.36
Regression coefficient 8.64 4.19 1.91 -0.30
France
H value per paper per year 88.75 88.43 124.94 123.10
Regression coefficient -9.24 -1.68 2.26 2.18
Germany
H value per paper per year 89.41 121.00 113.46 113.42
Regression coefficient 15.39 6.19 2.84 1.49
Korea
H value per paper per year 63.90 98.13 65.87 45.06
Regression coefficient 32.35 10.18 1.46 -1.43
Israel
H value per paper per year 145.99 74.27 126.63 67.14
Regression coefficient 6.53 -9.58 -1.86 -3.73
Nordic Countries
H value per paper per year 97.26 90.34 79.13 93.69
Regression coefficient -12.27 -2.84 -2.58 -0.62
China/Taiwan
H value per paper per year 62.28 78.19 71.75 65.59
Regression coefficient 11.51 2.60 1.00 0.01
ENSAT
H value per paper per year 166.81 151.23 136.84 138.31
Regression coefficient 29.76 0.69 -1.93 -1.47
The journals with the highest h-index in 2014 were Nature (h-index 2014: 890), Science (h-index 2014: 
851) and the New England Journal of Medicine (h-index 2014: 757). The best three papers with the 
highest h-index between 1995 and 2015 are shown in Table 2-8. 
Table 2-8 Top 3 articles with the highest h-index Score
Place Article FA Nation Score
1. Baysal, B. E., … Devlin, B. (2000). Mutations in SDHD, a mitochondrial 
complex II gene, in hereditary paraganglioma. Science
USA 851
Sato, Y., … Ogawa, S. (2014). Recurrent somatic mutations underlie 
corticotropin-independent Cushing’s syndrome. Science 
Japan 851
Hao, H.-X., … Rutter, J. (2009). SDH5, a gene required for flavination of 
succinate dehydrogenase, is mutated in paraganglioma. Science
USA 851
Cao, Y., … Ning, G. (2014). Activating hotspot L205R mutation in 




In the first 6 years of the 21st century, the average IF of all published NA papers dropped steadily. 
However, it was noted that the IF went up in the following years leading to their peak in 2009 with an 
average IF of 3.9 per paper per year. The EU significantly increased the IF from 2004 to 2008. Following 
this period, the EU held this trend and achieved a slight increase in 2011 onwards. If the trend 
continues, the EU will overtake NA in 2019 (see Figure 2-12). 
 
Figure 2-12 IF per paper per year of EU and NA
Like in the h-index evaluation, France and Germany have the highest IF scores, followed by the USA. 
The USA had a rapidly increasing trend between 1995 and 1999, but only a gentle increase from 2000 
onwards. In 2005-2009, France, Italy, Germany and Israel scored significant higher IF scores than the 
USA, however Israel could not continue the high IF trend between 2010-2015 (see Table 2-9).
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Table 2-9 IF per paper per year in selected nations/regions
1995-1999 2000-2004 2005-2009 2010-2015
USA
IF value per paper per year 2.55 3.00 2.94 3.30
Regression coefficient 0.20 0.08 0.05 0.04
Japan
IF value per paper per year 1.19 1.26 1.32 1.68
Regression coefficient -0.11 -0.01 0.00 0.03
Italy
IF value per paper per year 1.69 2.40 3.60 3.02
Regression coefficient 0.25 0.13 0.16 0.09
France
IF value per paper per year 1.84 1.82 3.74 4.69
Regression coefficient -0.08 -0.02 0.16 0.19
Germany
IF value per paper per year 1.72 3.11 3.47 4.07
Regression coefficient 0.39 0.24 0.17 0.15
Korea
IF value per paper per year 0.79 1.75 1.65 1.14
Regression coefficient 0.67 0.25 0.11 0.02
Israel
IF value per paper per year 2.08 1.67 4.73 1.56
Regression coefficient 0.62 0.06 0.25 0.01
Nordic Countries
IF value per paper per year 1.72 2.27 2.42 2.96
Regression coefficient -0.08 0.13 0.08 0.08
China/Taiwan
IF value per paper per year 1.10 1.30 1.50 2.03
Regression coefficient 0.26 0.06 0.05 0.07
ENSAT
IF value per paper per year 4.30 3.48 4.17 5.11
Regression coefficient 1.08 -0.01 0.02 0.08
The journals with the highest IF in 2014 were: CA: A Cancer Journal for Clinicians (IF 2014: 144.8), New 
England Journal of Medicine (IF 2014: 55.87) and Chemical Reviews (IF 2014: 46.57). Table 2-10 shows 
the highest IF scored in the period between 1995 and 2015.
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Table 2-10 Top 3 articles with the highest IF Score
Place Article FA Nation Score
1. Beuschlein, F., … Allolio, B. (2014). Constitutive Activation of PKA 
Catalytic Subunit in Adrenal Cushing’s Syndrome. The New 
England Journal of Medicine
Germany 55.9
Teo, A. E. D., … Brown, M. J. (2015). Pregnancy, Primary 
Aldosteronism, and Adrenal CTNNB1 Mutations. New England 
Journal of Medicine
UK 55.9
3. Assié, G., … Bertherat, J. (2013). ARMC5 mutations in macronodular 
adrenal hyperplasia with Cushing’s syndrome. The New England 
Journal of Medicine
France 54.4
Baudry, C., Paepegaey, A.-C., & Groussin, L. (2013). Reversal of 
Cushing’s Syndrome by Vandetanib in Medullary Thyroid 
Carcinoma. New England Journal of Medicine
France 54.4
Conclusions
The results clearly show that the publication success of the EU and other single nations/regions like 
Korea, Nordic Countries, China/Taiwan, Israel will likely challenge the bibliometric scores of the USA 
in the not too distant future. The USA still has very high bibliometric values that have largely remained 
constant since 1995. On the other hand, countries like France, Germany and Italy have shown a drastic 
increase in their bibliometric scores with higher regression coefficients than the USA, especially over 
the last few years. Also these countries have all increased their baseline scores significantly since 2000. 
The findings support the argument that this is caused directly by the paradigm shift in more 
collaborative funding schemes provided by the EU and individual European national funds (such as the 
ANR, DFG and the BMBF).
The evaluation of publication success also indicates that research networks enhance the form of 
adrenal research and hence translational research worldwide. In our example, ENSAT will surpass the 
USA and NA with regards to publication success based on articles published in highly influential and 
heavily cited journals. Even though ENSAT started with higher scores in 1995-1999 compared to other 
nations, the regression analysis showed that these scores improved in comparison to the USA.
Furthermore, the results show that after the establishment of the ENSAT VRE in 2010, the publication 
success has improved greatly. This was caused by the ongoing and strategic improvement of the 
ENSAT patient registry – a key part of the ENSAT VRE and more importantly by its adoption by the 
wider adrenal tumour research community. With the focus on data quality improvements, further 
trials with new objectives are increasingly being identified thus consolidating the data quality and the 
grants and activities that are now possible through a larger critical mass of patient data and associated 
research opportunities. These subsequent grants build on and consolidate the collaborations and the 
community of researchers and clinicians that are engaging in ENSAT.
It is recognised that the used search terms don’t cover the whole research field of adrenal tumours. 
However, with the focus on targeted terms associated with adrenal tumours the majority of published 
papers are covered and hence we would expect to see a similar trend using other related search terms. 
The assessment has shown that research funding supporting collaborative networks to enhance 
biomedical research can and indeed has made a clear difference, at least in the adrenal tumour 
domain. However, that evaluation of research success requires consideration beyond the analysis of 
publications and their associated bibliometrics. To tackle the major impediments to translational 
research depends upon financial support for multidisciplinary and multi-organisational activities. Such 
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investments should ideally be aligned with established societies and networks. The ongoing tracking 
of research success and associated impact should also be increasingly considered. A key aspect of this 
that has been successful in ENSAT has been the realisation and adoption of the VRE and the associated 
data management tools that are used for continued monitoring and improvement of data quality, 
which has to be taken into account in every research evaluation (Hicks, Wouters, Waltman, de Rijcke, 
& Rafols, 2015). It was possible to determine which sites are truly collaborating and sharing data, and 
this information is made available across the ENSAT network. Such transparency is essential to 
facilitate research collaborations, especially those involving collaborations with often competing 
organisations.
Besides this, interviews with NIH researchers have revealed that the crucial elements for team success 
and effectiveness are focused on setting up the correct roles for each individual researcher in a team 
and showing the overall purpose of research. This in turn depends upon the objectives and 
transparency in the research. One of the most important elements in collaboration is trust. Trust in 
individuals that they will work with the same motivation and work load to achieve the same goal as 
those of collaborating team (Bennett & Gadlin, 2012). In our example, transparency and trust are 
supported through direct feedback in the ENSAT VRE that enables the research to continually improve.
This research has shown that there is a notable increase in influential research articles that have been 
published and indexed in MEDLINE by EU and ENSAT researchers between the years from 2000 to 
2015. To continue to increase the publication and research success, it is essential to continue to 
support such international research networks. Furthermore, all networks should leverage web-based 
e-Infrastructures as typified through the ENSAT VRE to strengthen research findings and support new 
hypotheses. Collaborations, especially those that are facing challenges of big data depend upon 
multiple teams with mutually beneficial areas of expertise that can work on common research 
problems.
Since 2010 multicentre research funding that has been invested into ENSAT has galvanised 
international research in the area of adrenal tumours. Evaluation of the publication metrics 
substantiates this claim. Increasing numbers of patient records and information, combined with 
multiple features to manage the data continually improves the usefulness and quality of data. Rare 
diseases often struggle to achieve a critical mass of data and coordination of international research 
community. The ENSAT community and associated VRE is certainly the exception to the rule in this 
regard. The ENSAT network has also received follow on funding as part of the Horizon2020 ENSAT-HT6
that will continue to build upon and support the ENSAT research community. 
New dimensions to the work of ENSAT are the involvement and support of patients and patient 
support groups. To this end, the ENSAT VRE is growing with a range of new mobile applications that 
allows patients to enter their own data. This will offer new dimensions that will help better understand 
the daily challenges and issues of patients with adrenal tumours and their treatment and 
management.
Given all of this, one would assume that ENSAT has excellent high quality data. As we shall see, the 
capture and improvement of data quality continues to be an ongoing process. We show in later 
chapters how technology can be used to help support this process.
2.6 Chapter Conclusions
This chapter has systematically explored the many challenges associated with the capture of clinical 
data in disease registries to support clinical trials and studies, and thereby improve healthcare as a 
whole. We focused on the many dimensions of data quality that can impact on the overall usefulness 
6 http://www.ensat-ht.eu
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of data entered into such registries. A key part of this is implicitly connected with the motivational 
aspects of the protagonists that are involved. This in turn impacts upon the funding models that are 
associated with the clinical collaborations, e.g. if researchers are paid to enter data then one assumes 
that the data will be of better quality. 
We have systematically explored the research impact of the ENSAT registry to support clinical research 
into adrenal tumours and the international network that has been funded to establish and use the 
registry. We have demonstrated how such collaboration drives research output and how this can 
subsequently inform and improve clinical trials through the statistical power that increased amounts 
of data can imbibe. Data quality remains a major challenge however, especially when multiple centres 
are coordinating their efforts through web-based international collaborations. 
The following chapter explores the extent that direct (face-face) feedback to the data entry personnel 
can improve the quality of data entered into disease registries such as ENSAT. If we can improve the 
quality of data in such a manner, then we hope to demonstrate that web-based (automated) feedback 
can also improve the quality of data in disease registries. This is the focus of subsequent chapters.
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3 CASE STUDY OF DIRECT DATA QUALITY FEEDBACK
The previous chapter provided insights into quality assurance regulations in clinical research, data 
quality measurements and data quality feedback. Key to the investigation of the research hypothesis 
is that feedback can improve the quality of data in clinical data registries. Before exploring web-based 
approaches for automated feedback, a precursor investigation is whether feedback works at all. This 
chapter describes the empirical basis by which we demonstrate that we can measure data quality and 
understand why low data quality can occur through direct, face-to-face feedback with data personnel 
involved in entering data into clinical research registries.
For this exploration, a case study was performed within the ENSAT-CANCER consortium. Prospective 
evaluation of data quality was performed for two multicentre diagnostic trials EURINE-ACT (Evaluation 
of Urine Steroid Metabolomics for the Differential Diagnosis of Adrenal Cortical Tumours) and PMT-
Study (Prospective Monoamine-producing Tumour Study). A diagnostic trial has the aim to improve 
current diagnostic procedures (also called gold standards tests) that can include finding new 
biomarkers or procedures or evaluating the sensitivity and specificity of particular approaches. In the 
case of diagnostic trials in cancer research, this means that newly developed tests will have the best 
possible true positive rate and best possible false negative rate with regards to the evaluation of 
whether the patient has an adrenal tumour or not. 
The following chapter introduces the background in relation to adrenal tumours and the empirical 
work that was performed for the exploration of data quality assessment within ENSAT-CANCER. These 
assessments involved an initial centralised data monitoring (data quality evaluation of EURINE-ACT), 
a survey to explore commonly used data processes in the participating trial centres and a report about 
findings from six face-to-face on-site monitoring visits.
3.1 European Adrenal Research
3.1.1 Adrenal Tumours
It is assumed that three in 100 of all 40-year-old humans carry an adrenocortical tumour. The majority 
of all adrenal tumours are discovered incidentally during the diagnosis for another condition. For this
reason, the tumour is often called an ‘incidentaloma’. The prevalence rate of incidentaloma results in 
a categorization of benign tumours as a common disease (Arlt, 2009; Kapoor, Morris, & Rebello, 2011).
Due to hormonal inactivity and their typically slow size growth, the majority of incidentaloma remain 
undetected during an individual’s lifetime. However, in rare situations, this tumour can be hormonally 
active and the tumour tissue can secrete adrenal hormones. In around 1-2 per 1 million healthy 
humans, such tumours can have a malignant character, causing back pain because of the rapid size 
growth, with infiltration of adjacent tissue and potentially the spread of cancer cells in other organs 
(metastasis) (Fassnacht & Allolio, 2009). The treatment often depends on the location, the patient 
themselves, e.g. their demographic details, and the tumour behaviour including for example whether 
the tumour is secreting hormones or not.
To understand the rareness of adrenocortical cancer, it is useful to consider the prevalence rates. 
Considering the population of Melbourne (4 million people), around 40,000 people could have an 
incidentaloma, while just 4 people in Melbourne could have an adrenocortical cancer. Other adrenal 
tumours like malignant pheochromocytoma have even lower prevalence rates.
This low sample size requires not only a multicentre approach for collaboration, but also an 
international effort to recruit sufficient numbers of patients. It is often the case that statistically 
significant evidence of new therapies or diagnostic tools can only be shown through large sample sizes 
(Gatta et al., 2010). The ‘Levels of Evidence’ provided by the Centre of Evidence Based Medicine 
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(CEDM) located at the University of Oxford consider that only the results and conclusions of 
randomised controlled trials (RCTs) or systematic reviews have enough power to be transferred into 
clinical care and influence clinical guidelines (Phillips et al., 2009). However for RCTs, large populations 
are required and the correct trial performance is mandatory. The patient sample size (cohort) and 
study more generally can also have ethical issues regarding the performance of RCTs, which challenge 
clinical care and patient management. One example is the FIRST-MAPP trial 7 , the first RCT for 
malignant pheochromocytoma. Here the success rate of the cancer drug Sunitinib, an oral treatment 
for adrenal cancer was tested. Through the trial, the randomisation step required that some patients 
with malignant pheochromocytoma would not receive appropriate treatment for the tumour. 
Whilst adrenal tumours can be relatively common diseases, some forms, especially malignant 
tumours, are very rare. Given this, clinical trials have to be performed on an international base and 
meet a range of requirements to provide conclusions that can be rapidly transferred into clinical care. 
In such contexts and given the previous discussions on data quality, infrastructures that support data 
management have a very high impact on the trial performance. Every collected data item needs to 
meet appropriately high standards. One standard is defined by the GCP and relates to the collection 
of high quality data. In multicentre trials, external auditors typically need to understand how rare 
tumours can be diagnosed. This can lead to the definition of compulsory data items that have to be 
collected during particular trials. To show how high data quality can support adrenal research and how 
data inconsistencies can be improved, the general pathophysiology of adrenal tumours needs to be 
understood. We summarise the most pertinent aspects here. A richer discussion on this is available at 
Arlt (2011).
The adrenal is an endocrine gland on each pole of the kidneys. The gland consists of two hormone-
secreting regions: the adrenal cortex and adrenal medulla. The adrenal cortex is differentiated into 
zona glomerulosa, zona fasciculata and zona reticularis. Each zone produces specific hormones that 
include glucocorticoids, mineralocorticoids, androgens and catecholamines.
Zone Hormone Example
Adrenal Cortex:
Zona glomerulosa Mineralcorticoids (Aldosterone)
Zona fasciculata Glucocorticoids
(Cortisol, Corticosterone, Cortisone)




The secretion of the hormone aldosterone influences blood pressure. An endocrine tumour in the 
zona glomerulosa increases the aldosterone production, which causes primary hyperaldosteronism 
(or Conn Syndrome) and consequently causes high blood pressure (Beuschlein, 2013). High levels of 
cortisol can be caused by a hormone-secreting tumour in the zona fasciculata. Not all causes of 
Cushing’s syndrome (or hypercortisolism) are adrenal tumours, however there are specific diagnostics 
that can lead to the indication that higher cortisol levels are caused by an adrenal tumour. Typical 
symptoms are central adiposity, proximal myopathy, striae or hirsutism in women (Arlt, 2011). 
Hyperandrogenism can be caused by a tumour in the zona reticularis, which can lead for example to 
7 https://clinicaltrials.gov/ct2/show/NCT01371201
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polycystic ovarian syndrome (PCOS) in woman. The symptoms of PCOS include menstrual disorders, 
infertility or high levels of male hormones that can lead to acne and hirsutism (Teede, Deeks, & Moran, 
2010).
The adrenal medulla secretes catecholamines including adrenalin, noradrenaline and dopamine. 
Hormone-secreting tumours in the adrenal medulla are called pheochromocytoma. To diagnose a 
pheochromocytoma the gold standard test is the collection of 24-hour urine, where the levels of 
metanephrine and normetanephrine (metabolites of adrenaline and noradrenaline) are measured. 
When these levels are higher than the defined reference intervals, a pheochromocytoma is suspected. 
With a cortisol test, which should reduce levels of catecholamines in the blood, the tumour in the 
adrenal can be confirmed or excluded (Därr et al., 2014; Eisenhofer, 2004).
In all cases detailed information on the patients themselves (including their phenotypic information) 
needs to be captured to contextualise the biomedical information related to the adrenal glands and 
subsequent tests that can be applied.
3.1.2 ENSAT
In 2002, the European Network for the Study of Adrenal Tumours (ENSAT) was founded with the aim 
to improve the prediction and management of specific types of adrenal tumours. In particular, the 
community focuses on the tumour types: adrenocortical carcinomas (ACC), pheochromocytoma and 
paragangliomas (Pheo/PGL), non-aldosterone producing adrenocortical adenoma (NAPACA) and 
aldosterone-producing adenoma (APA) - all of which are relatively rare, e.g. for ACC the annual 
prevalence is 1.5 per 1 million population. Malignant adrenal tumours have typically poor survival 
rates (Arlt et al., 2011; Eisenhofer, 2004; Golden et al., 2009). To improve diagnostics and treatment 
of malignant adrenal tumours, the ENSAT-CANCER project8 was funded as part of the EU Framework 
Program 7 (FP7) initiative in 2011. The web-based data management systems were delivered through 
a security-oriented, web-based virtual research environment (VRE). This VRE provides a variety of 
functions for clinical research (Stell & Sinnott, 2012; Stell, Sinnott, & Jiang, 2010). The VRE supports a
portfolio of coordinated translational studies (basic science/genetics and clinical trials/diagnostic & 
treatment) of adrenal tumour patients that is used to reveal new molecular mechanisms related to 
the growth of these tumour types and provide insight into associated clinical areas, e.g. their role in 
hypertension (Beuschlein, 2013).
The ENSAT-CANCER VRE was built using a standard n-tier web application setup with a MySQL back-
end database, business logic programmed in Java rendered to a JSP front-end. The front-end web 
application was hosted in a Tomcat container – with various libraries used to provide additional 
feature support (Apache POI, iTextPDF, Guava). Parameter rendering was achieved using a separate 
database listing the available parameters for the central forms and the subsidiary “one-to-many” 
forms implemented for treatments, biomaterials and follow-up. The VRE included a variety of features 
that enabled collection and validation of high quality data: 
 consolidated databases reflecting the international community needs and consensus on 
adrenal tumour data;
 consolidation of international security policies on access and use of data that meets 
international ethical considerations;
 CRUD capabilities for search and export queries; 
 interfaces for specific clinical trials (e.g. EURINE-ACT); 
 freezer and aliquot management; 
8 www.ensat-cancer.eu
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 labelling and barcode support with manifest sample tracking allowing biomaterial shipments 
and tracking between centres;
 association with other related studies including cross-referencing and candidacy for other 
studies as a collaborative feature including re-use of registry data; 
 resource pooling and network collaboration, and
 statistical analysis interfaces with re-usability in mind. 
By October 2016 the ENSAT VRE had collected biomedical information from 91 research centres across 
Europe and internationally on more than 10,000 patients. This included clinical annotations and stored 
specimens in biobanks (see Figure 3-1). At this time, the ENSAT community ran a multitude of clinical 
trials from phase I to phase IV studies across the diagnostic and treatment continuum. EURINE-ACT 
was one example of a diagnostic trial, which aimed at the development of tools for accurate 
differentiation between malignant and benign tumours to improve the early detection of recurrence 
of ACC and to better understand the biological processes that take place that lead to hormonal excess 
in adrenal tumours. To receive a prediction of the likelihood of an adrenal tumour, biochemical 
profiles of all relevant steroids were measured from 24-hour urine. The differentiation from malignant 
and benign tumours was carried out through learning vector quantization (LVQ) approaches (Arlt et 
al., 2011). The VRE also provided access to Cloud-based resources and high performance computing 
facilities (Sinnott & Stell, 2011; Stell & Sinnott, 2012).
Figure 3-1 ENSAT-CANCER Registry Summary (October 2016)
Given the scale and scope of ENSAT, data quality assurance methods are an essential component of 
the registry.
An additional data quality module was developed that correlated the user online behaviour and 
patient record quality in the context of specific studies including EURINE-ACT. The EURINE-ACT study 
had specific standard operating procedures on the registry data that needed to be monitored by the 
presence of certain forms, e.g. availability of biomaterials. By combining information from the registry 
data and the meta-information drawn from the log analyser, a survey of the completeness and 
accuracy of information within the study was undertaken and a “Data Quality Score” (DQS) assigned 
that offered an important metric when interpreting the results of the study. These metrics used
captured data that represented the needs of the end-user scientists, however it was recognised that 
a balance between usefulness of data and requirement for excessive data input was needed. Thus not 
all data was needed for particular trial objectives. The DQS accuracy utilized the comparability, 
timeliness and validity of the entered values.
For the assessment of data completeness within the ENSAT-Registry, a graphical interface was 
developed to show researchers the overall completeness of the data that was available in the registry. 
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To support this, all records were assessed separately and results typically displayed as bar charts. 
Figure 3-2 shows an example graph for pheochromocytoma records from a particular centre.
Figure 3-2 Data completeness bar charts in the ENSAT registry
3.1.3 PMT Study
Headaches, dizziness and sudden sweating that occur without physical exercises can be signs of high 
blood pressure. The reason for high blood pressure (HBP) is rarely investigated by general 
practitioners, due to the fact that the treatment of HBP is less expensive than the diagnosis. In 0.2-
0.4% of all cases, the reason for such symptoms is a pheochromocytoma - a metanephrine producing 
tumour. Metanephrines are metabolites of the catecholamines adrenalin and noradrenaline. The 
PMT-Study (Prospective Monoamine producing Tumour) is a diagnostic trial that investigates such 
tumours to find biomarkers that can improve the diagnosis for pheochromocytoma (Reisch, Walz, 
Erlic, & Neumann, 2009). The primary objective of PMT is to identify new and improved biomarkers
for the therapy and diagnosis of pheochromocytoma and paraganglioma (PPGL). Another goal is to 
stratify different groups of PPGL with the help of biochemical profiles. In the majority of cases 
overproduction of hormones causes secondary hypertension (Darr et al., 2012).
The PMT Study is a full phase 1 to phase 4 trial performed within the ENSAT consortium. Data collected 
in the study is captured in the PMT-eCRFs that are linked directly with the ENSAT-CANCER registry. 
Clinical information collected in PMT can be transferred into the ENSAT-Registry (and vice versa). In 
addition to the collection of demographic and disease related information, all patients undergo a 
standardized blood withdrawal and 24h urine samples are also collected. The PMT registry includes 
around 500-1100 data items per patient (depending on whether they enter phase 2-4). Many of these 
data items, e.g. demographic data, originate and are transferred directly from the ENSAT-CANCER 
registry. The PMT Study enrols all patients with a current finding or history of pheochromocytoma, 
but also patients with secondary hypertension (hypertension not caused by an identifiable underlying 
causes). Of specific interest to the PMT Study are those patients where the cause of their hypertension 
is through possible pheochromocytoma. A new Horizon 2020 project ENSAT-HT is focusing specifically 
on this topic.
A total of 2400 subject were planned for enrolment into the PMT study protocol. The trial design was 
split into four phases. All patients that meet the inclusion criteria enter the trial in phase 1. Here, a 
diagnostic screening for increased plasma and urine metanephrines was performed. If the test was 
negative, a hormone-secreting tumour in the adrenal medulla was excluded and the patient would be 
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called again after 2 years to verify the test results (Phase 4a). In case the metanephrines were strongly 
increased, a pheochromocytoma was likely and imaging procedures to detect the tumour were 
conducted (Phase 3). If the extraction of the tumour tissue was possible (benign pheochromocytoma) 
the patient would undergo surgery and regular follow-ups would be scheduled (Phase 4b). However, 
there is also the chance that the results of Phase 1 are only slightly increased, hence a differential 
diagnosis in form of a clonidine suppression test needs to be performed to confirm the suspicion of a 
pheochromocytoma (Phase 2). In case of a positive clonidine suppression test is the patient assigned 
to phase 3, otherwise a pheochromocytoma is excluded and the patients is assigned to phase 4a.
Figure 3-3 shows the flow chart associated with the PMT Study including the statistical power analysis 
of subjects needed to meet the criteria for all phases and hence to realize the study objectives.
Figure 3-3 Flow chart PMT-Study
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Centralised monitoring is essential for quantification of data quality and the associated empirical work. 
Centralised monitoring has been a key focus of the PMT Study. The majority of all quality indicators 
typically need to be adjusted when evaluating data quality in clinical (cancer) registries. The 
assessment considered in the PMT Study included comparability of metanephrine values and the
validity, timeliness and completeness of these data sets within the ENSAT research registry.
PMT Comparability
Crucial data items for the PMT Study include the results of blood tests that prove the existence of 
metabolites from metanephrines, normetanephrines and methoxytyramine (MTY), a metabolite of 
dopamine. To determine the normal range of such blood results, blood was drawn from a healthy 
cohort (n=300). Because of the importance of the correctness of these values in relation to the 
diagnosis of PPGL, a comparison was performed between the blood test results from healthy patients 
and those with suspected PPGL. A study within the healthy cohort discovered that some centres had 
several outliers for MTY (see Figure 3-4). 
Figure 3-4 Outliers in a healthy cohort for blood tests in the PMT Study
Figure 3-4 was reported to the local investigators who subsequently refined their processes in how 
they performed blood sampling in accordance to the SOPs. 
As shown, Centre A is hosting the principal investigator of the PMT Study and hence provides ‘clean 
data’. All other centres show a larger range of values with three to four statistical outliers. These 
inconsistent results were reported to the centres and it was discovered that Centre B, Centre C and 
Centre D were not following the same Standard Operation Procedures (SOPs) for blood tests and 
subsequent processing of samples for presence of metanephrines (see Table 3-1). 
Table 3-1 Summary SOPs for Blood Withdrawal (BW)
SOP Blood withdrawal
… the patient is 30min before and during the BW in a supine position;
… the patient has fasted 12 hours before the BW;
… the patient has not taken paracetamol within the last 4 days;
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… the patient has not taken tricyclic antidepressants within the last 2 weeks;
… the patient was not physically active before the BW, and
… the patient has no renal insufficiency.
The trial-related SOPs for blood withdrawal clearly states that the patient has to rest for 30min in the 
hospital before blood is extracted. Furthermore, the patient has to fast for at least 12 hours before 
the sampling and the blood has to be withdrawn in a supine position (Därr et al., 2014). It was reported 
that some patients arrived with a bicycle and the blood withdrawal was performed immediately after 
their arrival in the research centre. During an onsite monitoring visit, it was discovered that every 
centre had different hospital related standard procedures for their routine blood sampling collection
processes (e.g. not in supine position or not after 30min rest).
PMT Validity
Data validity consists of three major quality indicators: completeness, accuracy and plausibility. While 
completeness provides information as to whether the data item exists in the data set, data accuracy
is often used to apply special ranges or values that are expected, e.g. has the patient consented for 
the study or do they meet the inclusion criteria. Plausibility assesses whether data items are logical, 
e.g. ‘female’ patients are unlikely to have “prostate cancer’ in their records. For the PMT Study, just 
one plausibility check was performed. Specifically, if the patient was enrolled into the study protocol 
with a history of PPGL, i.e. they had known genetic mutations or therapy resistant (secondary) 
hypertension, then the associated information in the eCRFs must include these details. 
In the PMT Study, centralised monitoring of all Phase I patients require that 45 data items were 
defined as compulsory. As shown in Table 3-2, centres with separate research units (Centre A and 
Centre C) achieved lower error rates. It was further discovered that Centre B and Centre A created the 
majority of their PMT records in the ENSAT registry (Centre B 51%; Centre C 55%). The transfer of such 
records into the PMT Study eCRFs resulted in data loss. Furthermore, it was identified that some data 
items (identification and genetic information) were discovered in the ENSAT registry, but not in the 
PMT Study eCRFs.
Table 3-2 Results PMT data validity
Centre
Centre A Centre B Centre C
Records 85 59 91
Completeness errors 8 31 15
Validity errors 5 13 3
Plausibility errors - 2 1
Total error percentage 0.34 1.73 0.46
PMT Timeliness
The evaluation of timeliness for the PMT Study focused on the period between data entry and date of 
consent of the patient. In clinical research, the patient needs to be fully informed of all aspects of their 
participation in a trial and that this is voluntary in accordance to GCP Guidelines and the Declaration 
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of Helsinki. Furthermore, the patient should be able to ask questions and the possibility to withdraw 
from a study at any time without any disadvantage in the clinical care that they receive. The first visit 
of the patient, the initial date of data collection and when consent was obtained are important time-
points to be captured. The PMT registry has two different data items that allow for the calculation of 
the period between data collection and actual data entry. One assumption that was explored was that 
the longer the time between the first patient-visit and data entry, the more inconsistencies would
appear in the eCRFs.
The period of data collection (date of consent) and data entry of Phase I data of all patients in the 
different research centres was calculated. Results showed that the centres with a lower error rate 
entered the data within the first four days after the patient was initially seen. This confirms the 
hypothesis that the longer the time between data entry and data collection, the more errors are likely 
to appear in the eCRFs (see Table 3-3).
Table 3-3 Results PMT data timeliness




Average days of data entry after 
data collection (Standard deviation)
Total errors in % 
(see Table 3-2) 
Centre A 224 57 3.9 (53.26) 0.34
Centre B 588 59 10.0 (20.74) 1.73
Centre C 184 91 2.0 (10.44) 0.46
The results show, that Centre A needed an average of 3.9 days to enter data after the data collection, 
but with a very high standard deviation. In contrast, Centre C needed 2.0 days with a low standard 
deviation. Compared to the validity, centre C also had a very low rate of total errors in their data set 
(0.46 %). It is noted that for a small sample size a large variance is expected.
Completeness of the research registry
The primary objective of this assessment was to provide an insight as to whether the research centre 
enrolled all patients available in their region. This calculation was based on an experimental approach, 
since checking the registry completeness would require that other comparison registries were 
assessed to draw conclusions. This assessment explored whether centres enrolled a balanced group 
of patients or only specific groups of patients. As a result, a comparison of inclusion criteria was 
performed as shown in Figure 3-5. 
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Figure 3-5 Comparison of inclusion criteria in the PMT Study
The analysis shows that 23 patients from Centre 2 were entered with no inclusion criteria. All records 
transferred from the ENSAT Registry to the PMT database. Centre 1 and Centre 2 recruited the 
majority of their patients via information gathered during routine care (history of PPGL). Also both 
research centres enrolled patients with incidentalomas (benign, non-hormone secreting adrenal 
tumours). The results show that there was no general trend in the subject recruitment. This might be 
due to the fact that Centre 1 and Centre 3 are both specialist adrenal tumour centres and researchers
have their own lists of patients with known pheochromocytoma. 
In summary, registry completeness, timeliness, validity and comparability are data quality dimensions
that should be measured in clinical research registries. To draw significant conclusions more patient 
information is needed for assessment of registry completeness. In discussions with ENSAT researchers, 
an overall score or values that show the data quality for one specific study was requested by both the 
principal investigators and the clinical research fellows. This score provided an arithmetic mean of 
quality indicators that impacted directly on the future research results of this trial and the ability to 
translate the results of the study into a clinical setting.
It was also identified by the researchers, that another important improvement was in relation to 
modifications to the web-based PMT Study user interface to support the re-use of data and increase 
the data completeness. Due to the multiple forms that are mandatory or non-mandatory for the 
diagnostics of PPGL, users need to easily determine whether the form has been completed (green), is 
incomplete/empty (red) or only partially complete (yellow). This information has subsequently been 
supported via a coloured bullet point in the record list (see Figure 3-6). 
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Figure 3-6 PMT Study Completeness Visualisation for Phase 1 Patients
Exploration of the evaluation of data quality and modifications of the user interface of the PMT-Study 
provides important results for further investigation. The remainder of this chapter considers the 
evaluation of data quality for the EURINE-ACT study. Here a data quality score was calculated to 
motivate the researcher to increase the data quality when entering compulsory data into the study 
specific eCRFs.
3.1.4 EURINE-ACT Study
A systematic centralized data monitoring study was undertaken to review the data completeness and 
data accuracy of the EURINE-ACT study using data derived from the ENSAT-CANCER registry. This case 
study was supplemented by on-site monitoring visits involving six selected ENSAT centres to better 
understand the potential reasons for data inconsistencies and overall data quality. 
In a clinical context, there can be many reasons for incomplete information that can only be found 
through a local (face-to-face) investigation of data processes (on-site monitoring). To gain further 
insight, interviews with the investigators and the local data managers need to be conducted with 
regard to low data quality and potential reasons for incomplete data sets. In total, eight on-site 
monitoring visits involving 8 local investigators and 7 data managers responsible for ENSAT registry 
data entry were undertaken in 2014.
In these visits, researchers provided insights into their work, which typically involved combining 
routine clinical care with biomedical research. Researchers from Italy and France identified that there 
was no governmental funding for research on benign diseases. Studies such as EURINE-ACT thus 
provided no direct funding (salary) for researchers. This is unlike ENSAT-CANCER, which had direct EU 
FP7 funding. Therefore, the motivation to enter research data after 8-10 hours routine care a day is 
important to understand. Furthermore, based on the researchers that were interviewed, the majority 
were young female clinicians at the start of their career. Their private lives (family), and continuous 
need for residency or sub-speciality training impacted directly on their availability and motivation for 
additional research work. A second problem that appeared during the structured interview was, that 
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data managers typically were unaware of the actual objectives of the trial. Rather, they were just 
tasked with entering (incomplete) data by the lead investigator at that site without fully knowing the 
reason for doing so.
To tackle these problems as part of the face-to-face meetings that were conducted, every staff 
member was introduced or reminded about the study protocol and the aims and the outcome of the 
trial. This was done to show the bigger picture of the study objectives. The initial results of a first data 
quality evaluation were presented with suggestions on how to face the data challenges of each of the 
visited centres.
Table 3-4 shows selected compulsory items from the ENSAT dataset and the EURINE-ACT eCRFs. Here 
ACTH (Adrenocorticotropic hormone) is a hormone that is measured during a Dexamethason Test 
(DST), a test that checks if an adenoma is hormone-secreting (Nieman, 2010). The dataset also includes 
information on whether imaging was undertaken or not and if yes, more related characteristics were 
required to be entered. It is recommended to perform a DST for every patient including those patients 
with suspected ACCs (Terzolo, Bovio, Pia, Reimondo, & Angeli, 2009). The data set showed the 
example where the data manager entered the value ‘Not Done’ for ACTH. Such an entered value can 
be defined as complete. However, ACTH is an important criterion for external judgment about the 
behaviour of adrenal masses and can provide additional information regarding routine care. Similarly, 
CT Density ‘Not Done” is not clinically useful information and should generally be avoided.
Table 3-4 Example Calculation of NAPACA Quality Score
Item Value Completeness Accuracy
ACTH Not Done ✔ ✖
24h Urine Cortisol [Select…] ✖ ✖
Imaging Form <exists> ✔ ✔
Imaging Method CT ✔ ✔
CT Density Not Done ✔ ✖
Ki 67 1% ✔ ✔
Weiss Score Not calculable ✖ ✖
Score 5/7 = 0.71 3/7 = 0.43
In the given example in Table 3-4 the record for the selected items show a completeness score of 71% 
and an accuracy score of 43%. Using an arithmetic mean of both values, a basic DQ score can be 
calculated through the steps outlined below. It is important to note that for this result, every item has 
the same importance. Compulsory items are represented in the Record Eligibility Score (see below), 
which should be part of the data accuracy feedback.
Report of Data Completeness
Data completeness determines whether all necessary clinical trial information is entered into the 
study-specific eCRFs. It does not measure/record whether the entered data is actually correct. Rather 
it gives information regarding the rigour of performance of data collection and the assiduousness of 
data entry personnel at particular research centres. When data completeness is low, critical gaps 
should be identified and resolved in the data collection and data entry processes. This can for example, 
require improvements in local training requirements. 
In the first completeness calculation, only the most important imaging, pathology and identification 
items of the EURINE-ACT eCRFs were considered. The analysis was performed for ACC and NAPACA 
records separately.
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The data completeness of ACC records showed a lack of pathology information. It is assumed that 
every patient without metastasis will undergo surgery and therefore will have information about the 
tumour tissue. A simply plausibility check was added, if the item ‘Distant metastasis’ is ‘No’, then the 
Weiss Score and Ki67 must have a value entered. Of the 193 patients without metastatic spread of 
cancer cells, only 68% of pathology information was entered. Nearly all records showed no 
information about imaging (see Figure 3-7).
Figure 3-7 Overall ACC Data Completeness
Benign lesions must also have imaging information. It is the case that all NAPACA tumours are detected 
and ultimately classified as benign – this is the specification of a NAPACA tumour. The entered values 
must therefore reflect this decision, e.g. so that an external reviewer can make a similar judgment 
based on the entered characteristics. Compared to ACC records, NAPACA records showed a better 
overall completeness, but mandatory items regarding the detection of the tumour were still missing 
in every third case. The data completeness assessment indicated that in nearly 30% of all patients, no 



























Figure 3-8 Overall NAPACA Data Completeness
Report of Data Accuracy
Each monitoring visit includes an interview with staff members that are responsible for performing
data entry. This is followed by source data verification steps and the direct witnessing of local 
biomaterial sampling for EURINE-ACT. For every site visit, one and a half days were scheduled to assess 
local processes and organisational structures (Donabedian-model). For the outcome quality, all 
EURINE-ACT records were checked as to whether they could be confirmed as EURINE-ACT. For this,
inclusion and exclusion criteria were checked. NAPACA and ACC records were assessed separately. For 
NAPACA the records had to meet the following five criteria:
 biomaterial was received in the investigator site;
 imaging reference standards were entered;
 tumour growth was lower than 20% within 6 months;
 in case of surgery, the Weiss score and Ki 67 were checked, and
 imaging follow up information was included.
An additional four mandatory NAPACA registry items were also monitored: tumour size, DEXA 
Suppression Test, Imaging information and if CT information was entered, then the Hounsfield Unit 
(HU) must be reported.
ACC records had to meet the following four criteria:
 the timestamp of the biomaterial collection (sampling) was required;
 whether the patient received chemotherapy or mitotane had to be documented;
 checks were required on the biomaterial availability in the biobank, and
 the patient follow up status had to be checked.
The ACC items were also checked with regards to tumour size and if the patient had no metastasis, 


























Once a range check was applied on every single compulsory data value, an accuracy score could be 
calculated. In addition to the data accuracy calculation required for EURINE-ACT, it was necessary to 
check whether the record met the eligibility criteria for the study. Patients with adrenal tumours that 
participate in clinical trials are entered into the ENSAT registry. Rules apply on these patient (registry) 
records, whether they meet the recruitment criteria for EURINE-ACT.
As outlined in Figure 3-9, once a record has been flagged as NAPACA, the biomaterial must be received 
and stored in biobank. If this condition is fulfilled, then it needs to be checked as to whether an imaging 
characteristic was given in the patient (registry) record. Imaging characteristics are mandatory for 
every patient with an adrenal mass and hence information about the existence of a CT, MRI, PET or X-
Ray must be given (Blake, Cronin, & Boland, 2010). The next check was whether the patient underwent 
surgery. If this is the case, it is important to identify whether this record was marked as an Adrenal 
Cortical Adenoma (ACA) or not. In the case of an ACA, it is mandatory to record information about the 
Weiss score and the associated Ki67 must be entered and be correct. These pathology scores serve as 
an external review indicator that are used to determine whether the patient has a benign or malignant 
adrenal tumour (Arlt, 2011). If all conditions are met, the record can be confirmed as eligible for 
EURINE-ACT. If one or more of these criteria are not met, then it might be due to the data entry person 
not having this information at the time of data entry, or their lack of rigor or a variety of other possible 
causes. The resolution of such data quality issues is essential to understand and processes instigated 
to identify and resolve such future issues.
Figure 3-9 NAPACA Eligibility calculation
After the calculation it was discovered, that just around 59% of all entered NAPACA records could be 
confirmed as eligible for EURINE-ACT. However, the majority of records did not have information 
about imaging characteristics. Additional problems also appeared in patients who underwent surgery, 
e.g. there was no information about pathology given. 
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Also considered in the accuracy score were plausibility checks. As an example for malignant (ACC) 
tumours, it was checked if the patient with selected “No Metastasis” underwent surgery. It is highly 
recommending that every patient with a malignant tumour (diameter >0.5cm) should undergo 
surgery, to prevent spreading to other organs. If no surgery and/or pathology information was 
entered, an error was given to this record.
Report of the Data Quality Score
Data quality in this chapter was considered as the combination of data completeness and accuracy. In 
later chapters we consider other aspects of timeliness and comparability that should be included in 
this calculation. A threshold must be also defined for every individual score to detect conspicuous and 
non-conspicuous values. In the present version, a total score was added in the feedback, so that the 
site could identify whether they achieved a score below or above the average (compared to other 
centres). Centres with less than 10 NAPACA records where not considered in Table 3-5. The displayed 
DQS is the mean of data completeness and record eligibility.














It was discovered, that the majority of the records achieved a completeness of above 60%. In contrast 
to this, the accuracy for two centres (n=2) with less than 10 entered records were calculated to be 0%. 
It was assumed, that when sites want to actively contribute, they mark the records as trial related, but 
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they do not always add any other study items, i.e. trials that they are not involved in. This underlines 
the need for training of local staff and processes in data quality management, but also need for better 
data management tools.
3.2 Monitoring Visits
Clinical monitoring can be based upon centralized monitoring or decentralised (on-site) monitoring 
visits. Such visits are used to assess predefined quality indicators that can have an impact on the 
overall data quality. Nahm (2012) described six major components that are mandatory to inspect 





 Documented work processes, and
 Consensus on data quality requirements.
For example, the assessment of ‘personnel management’ includes checks on staff training and 
relevant documents, job descriptions, employee feedback through to overall performance 
evaluations. To identify issues and inconsistencies in data quality processes, quality initiators need to 
be defined. For the PMT and EURINE-ACT clinical studies on-site monitoring visit indicators focused 
on all data process levels that could have an impact upon data quality. For every level a quality 
indicator was assigned (see Table 3-6).
Table 3-6 Quality indicators for on-site visits









Collection in accordance to SOPs
External reports (Pathology/Surgery)
Funding schemes
Infrastructure of research unit
Recruitment methods
Data capture Process
Access to devices to enter data
Time of data capture
Hardware and software issues
Method of data capture
Data analysis Outcome Data quality
On-site visits were performed in three German PMT participating research centres (Wurzburg, Munich 
and Dresden). For the EURINE-ACT study, international monitoring was demanded and the on-site 
visits included Wurzburg, Munich, Paris, Birmingham, Padua, Turin, Florence and Athens. To allow fair 
comparison of these centres, the national health services for routine care and research policies as well 
as their associated funding schemes was considered. Every hospital has its own SOPs for routine care. 
Similarly, every European country has different approaches with regard to data capture and 
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processing in hospital systems including the adoption of technologies and heterogeneity of IT 
solutions. In this context, we consider how the monitoring visits could be compared. 
3.2.1 PMT On-site Monitoring Visits
Wurzburg and Dresden both used paper-based (non-digital) sources for data capture and patient 
information management. Similarly, all trial related information of patients is stored on separate 
paper documents in clinical trial-specific folders. Munich however uses digital clinical data 
management systems provided by the hospital as their primary information source. When data items 
are requested for a particular clinical trial or study such as PMT, the user who enters the data into the 
PMT eCRFs has to search the hospital patient records for the relevant data items and enter them 
(copy/paste) into the PMT eCRFs. Furthermore, all centres have a separate folder (paper/digital) 
where they store the trial master file and related documents like ethical approval and forms for 
Serious Adverse Event (SAE) reporting. All three centres have an assigned data manager (research 
assistant) to support the actual capture and entry of data into PMT eCRFs. 
It was identified that the data managers in Wurzburg and Munich have multiple (seven) other trials 
where they are expected to enter data, whilst the data manager in Dresden was just assigned data 
entry needs for the PMT, EURINE-ACT and ENSAT registry. The research unit in Munich also specialised 
in several endocrine disorders (secondary hypertension, Diabetes type I & II, Conn syndrome, 
osteoporosis, Cushing’s syndrome, PPGL, ACC, Incidentaloma). This site is different to the research 
facilities of Dresden and Wurzburg where the focus is primarily on disorders of the adrenal gland.
The recruitment type and technical forms that are used is also important for data quality assessment. 
For comparability, a homogenous group of patients is important criteria for good clinical research. All 
centres have a long history of adrenal research and have data that they have collected – often over 
extended time periods. Often this is through Excel spreadsheets for former patients with a history of 
PPGL. Such spreadsheets are a key source of recruitment for registries and studies (subject to 
consent). Furthermore, in every research centre, all clinicians conduct endocrine-related outpatient 
clinics. Through such clinics they know first-hand, the inclusion and exclusion criteria of particular trials 
and if patients they see match the criteria for particular studies that might arise. A third possibility for 
recruitment type can also be through high values of metanephrine in central biochemical analysis 
laboratories of the hospital. Due to security regulations and the approach taken within ENSAT-CANCER 
for aggregation of data, a direct search of people that match the PMT recruitment criteria is typically 
not permitted across all of the hospital clinical data management systems. Such heterogeneity of 
systems and processes in individual healthcare facilities is common and remains a challenge for 
improved overall health care.
In conclusion, all centres can be considered as having equal conditions with regards to structural 
quality. All centres have experience with adrenal patients and have several possibilities to recruit 
patients. Special assigned data managers are available that have similar data entry training. 
Furthermore, every office where the patient is seen has direct access to the PMT eCRFs. Only Munich 
uses a direct manual transfer of data from the electronic hospital records to the PMT registry. This can 
have impact on the data quality, but a more detailed analysis will be described in chapter 4. 
3.2.2 EURINE-ACT On-site Monitoring Visits
For the EURINE-ACT on-site monitoring visits, the experiences from PMT were adapted and a general 
SOP monitoring protocol was developed (see Appendix I). In addition to the PMT structure and data 
processing assessment, a source document verification (SDV) of 3-5% of the records was performed. 
This sample size is in accordance to European recommendations (ECRIN, 2010). 
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Centralized data monitoring provided an overview of the data items with low data completeness in 
the EURINE-ACT eCRFs. Pathology and surgery information was rarely entered. Therefore, all data 
processes with regards to tumour tissue sampling and analysis was assessed. Every visit was started 
with a presentation to local investigators and associated research staff regarding the centralized 
monitoring results. Information about the overall trial objectives was also discussed. After the 
presentation a guided tour was performed. This included tours of the wards where the patients were 
enrolled into the protocol and the laboratory where biomaterial was aliquoted and analysed. The most 
important discovery was that all patients that have a suspected tumour in France are hospitalised for 
a one or two overnight stay. This has the added advantage for sampling of overnight urine – which is 
key to the needs and demands of the EURINE-ACT study.
Another important outcome identified was that different countries have different hospital SOPs and 
funding structures. In France, only malignant tumours are funded by the government, whilst in 
Germany, a general funding scheme exists for the treatment and support of all tumour types. In Italy 
all users that enter the data are young female clinicians that have routine care from 8am to around 
6pm. It was identified that they enter data into the registry only after their day-jobs. It was also 
discovered that their research related work was also not financially covered. Therefore, only limited 
individual motivation was discovered through personal interviews. It was identified that data 
inconsistencies and low completeness rates of surgery and pathology information were caused by 
diverse reasons. For example, the centre in Paris conducts research that assesses tumour tissues and 
directly interacts with the researchers who enter data into the registry. In all other cases, pathologists 
and associated laboratories were not located in the hospital and instead they received (via post) the 
tumour samples for analysis. 
3.2.3 Conclusions
In conclusion, visiting the centres provided detailed feedback and insight into the practices and 
processes related to data quality. The auditors gained insights into local processes, how data 
inconsistencies had developed and the day-to-day reality of data collection and data entry. A primary 
issue stemmed from the data processes of external providers and stakeholders that analyse 
biosamples. A secondary issue was the motivation of the data entry user and the realities of data entry 
often being in addition to the day job (mostly unfunded). While funding and the combination of 
routine care and research is typically overly cumbersome for the scientist that has to care for patients 
and trial subjects, their staff also and the roles they are actually funded for do not always reflect the 
needs and demands of good quality data entry into international disease registries and trials such as 
PMT and EURINE-ACT.
It was identified that the visits were overwhelmingly beneficial because of the background 
presentations about EURINE-ACT and highlighting of the results of the centralized monitoring. 
Experiences of other centres could be shared and small problems in the local data process could be 
resolved. The on-site monitoring shone a spotlight on day-to-day challenges facing all sites with 
regards to data entry.
In this context, it is essential to understand the role of motivation and the way in which technology 
can help in improved data quality capture. Staff members who are overworked and underfunded can 
easily be demotivated, if they see that they are performing less well than other centres. The roll out 
of technical solutions was thus carefully orchestrated to ensure that all aspects of data entry processes 
and reasons for potential issues were understood. 
3.3 Other Examples of Data Quality Assessment from other Studies
Data quality feedback is not a new approach in the scientific literature. The novelty here is to apply 
selected quality indicators to motivate researchers to increase the overall data quality in disease 
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registries and eCRFs to increase the usefulness of the data. Key factors to understand are what quality 
indicators are best for particular research environments and how can they be optimally reported to 
researchers.
Data quality reports should be continuously updated and fed back to data entry personnel and the 
research (clinical) collaboration protagonists. Ideally, tools that are used by everyone should be 
adopted, e.g. mobile phones or laptop/PC. By far the most important ubiquitous technology is the 
mobile phone, which provides a model for always-connected research and the ability to receive 
targeted notifications. Therefore, an approach for data quality reports should ideally focus on 
notifications, email reminders or alerts. Ideally data management systems should be accessible via 
mobile applications (apps) in accordance to data security standards.
Little research has been published in the field of feedback reporting and its efficiency. Stausberg et al. 
(2006) described feedback as ”periodic reports about data quality provided to those […] doing the 
input” (Stausberg, Nonnemacher, Weiland, Antony, & Neuhäuser, 2006). A literature review published 
by de Lusignan in 2005 listed ten characteristics for the improvement of data quality in primary care:
 Motivation of professionals to have a positive attitude of their structured computer data;
 Working with lead clinicians receptive to evidence-based quality improvement initiatives;
 Respect for the “clinical judgement” (phronesis) of experienced clinicians;
 Using informatics as an enabler of quality improvement;
 Using education as an appropriate change agent;
 Data quality feedback using parameters with a positive predictive value and high sensitivity;
 Personally provided feedback, by a skilled facilitator, within the workplace;
 Professionally led programmes, supporting local clinical champions;
 Alignment with national, evidence-based, quality improvement programme, and
 Financially incentivised data of higher quality. (Simon de Lusignan, 2005)
In all of these areas tools are needed that support clinicians that allow to keep them continuously 
aware of the importance of data quality with focus on the implementation of professional data 
management systems that meets standards and improve data interoperability (Simon de Lusignan, 
2005). 
Feedback systems in CDMS should support quality improvement purposes. There are a variety of 
feedback mechanisms published in the medical literature, that provide quality feedback during data 
entry and via email reminders (Herzberg et al., 2011; Porcheret et al., 2004). In the literature feedback 
also refers to the term ‘reminder’, that informs the user about missed documentation, displays 
summary reports and provides real-time/immediate feedback (Nair, Newman, Peterson, Wu, & 
Schwid, 2010; Wurst, Lamia, Schlundt, Karlsen, & Kuhn, 2008). Summary reports can be delivered to 
the research community that count as a reward that encourages the researcher to enter higher quality 
data. It was also discovered that passive cues during data entry increase the compliance with data 
entry more than hard stops (Nielsen, Peschel, & Burgess, 2014). 
The effectiveness of such processes in the domain of clinical trials with manual data entry and dual 
source systems (which is the situation in the majority of cases) has not been extensively investigated. 
This research has focused on a simple and generalizable method to improve the data quality by 
proposing to distinguish feedback into real-time feedback, investigator feedback and community 
feedback. In combination with suggestion/reminder features, the research has explored whether
feedback can improve data quality in research registries. To give a lay description of the three 
feedback mechanisms we identify:
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 For data entry users - real-time feedback, a user receives feedback during the data entry about 
the entered data and whether it meets the minimum research requirements, 
 For local investigators - investigator feedback, where all information about the current 
usefulness of data is given to reveal potential data inconsistencies of the captured data from 
the given sites, and
 For all researchers - community feedback, where quality reports are provided to the research 
community to encourage the staff to collect higher quality data than other sites.
Each sort of feedback will report its own selected type of quality dimensions. The feedback collectively 
can serve different purposes to increase the overall data quality and user motivation.
3.4 Demonstrating that Data Quality Increases through Feedback
To determine whether data quality improves based on encouragement of quality assurances, a final 
calculation was performed three years after the first centralised monitoring. Here, an investigation of 
data completeness of all phase one records was performed. The first evaluation was performed 2 
years after the start of the study protocol (October 2013) and the second evaluation performed 3 
years after the first calculation (October 2016). Several data items were changed during the three 
years, which resulted in a new data completeness calculation for October 2013. It is noted that not all 
research centres were included in the analysis, since they have no reference value, or they did not 
participate in the PMT-Study in October 2013. 
Results showed that two centres (including the centre of the principle investigator – GYDR) decreased 
their data completeness (DC), but entered more than 200 records in the registry. Whilst the overall 
data completeness of PLWW is below the average, they increased their data completeness slightly and 
entered 597 records within the three years (see Table 3-7). 










GYDR 91 291 200 0.88 0.81 -0.07
GYLU 2 36 34 0.39 0.83 0.43
GYMU 71 263 192 0.61 0.76 0.15
GYWU 92 313 221 0.84 0.50 -0.33
ITFL 9 9 0 0.30 0.30 0.00
PLWW 503 1100 597 0.58 0.61 0.04
TOTAL 768 2143 1375 0.64 0.66 0.02
This evaluation of PMT provided an explorative case study to gain insights into data quality evaluation. 
Feedback was given just to the principal investigator (investigator feedback), who planned quality 
control procedures to improve data quality. An example was given with the assessment of outliers in 
a healthy cohort. This calculation detected that GYWU, GYMU and PLWW were not performing the 
blood withdrawal in accordance to the study SOP. If regular feedback to the research community and 
to the principal investigator works, we should see a similar trend calculation for EURINE-ACT.
To assess the efficiency of the performed case studies, the data quality of EURINE-ACT was monitored 
for 6 months. In April 2014, the first quality report was sent to the research community via email. This 
score was developed in March 2013 and implemented in EURINE-ACT in November 2013. One year 
later, the ENSAT-Consortium met for a general Assembly in Nice and results and trends of the DQS 
were presented. For this purpose, a trend/efficiency of the DQS was calculated. Here two quality 
dimensions were calculated separately to build an arithmetic mean in the form of an overall DQS. First 
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it was investigated how the completeness, accuracy and overall quality scores changed through the 
year.
Table 3-8 Trend of Quality Scores
Apr-14 May-14 Jul-14 Oct-14
Data Quality .60 .64 .69 .73
Data Completeness .76 .82 .83 .86
Data Accuracy .45 .46 .55 .59
As shown in Table 3-8 the overall data quality increased. After the implementation of a data quality 
score, the overall quality of record information increased by 13%, while the accuracy changed by 14% 
and DC grew slightly by 10%. The slow increase in data completeness was caused by adding more data 
items over the time period of the implementation. The ability to strike the balance between overall 
completeness and quality should be aimed at encouraging good behaviour of site staff entering clinical 
data. The more items included in the data completeness calculation, the increase in effort required 
and the danger of potential lower data accuracy scores. Alternatively mandating that all data is 
compulsory and has to be completely accurate is often difficult to enforce: many registries and studies 
can contain thousands or tens of thousands of data items per patient. A balance is thus needed. In this 
review of ENSAT centres a spectrum of data quality was discovered. It should be noted that only 
centres with a data quality score over 50% showed interest and asked for more support in how they 
might improve their data entry processes.
To more closely investigate whether data quality issues appear in reporting or other data processes, 
an error count per sub-record (diagnostic, imaging and pathology) was conducted (see Figure 3-10). 
Counting errors or calculating an error rate is an established method in quality assurance in clinical 
trials to discover problems in data processes (Rostami et al., 2009). It was revealed that imaging and 
diagnostic problems could be resolved by improvements to data quality. However, pathology errors 
did not decrease over the given timeframe. One major reason why reports about Weiss Score or Ki 67 
could not be entered by local teams was due to funding problems and missing centralized pathology 
reviews. Furthermore, it was often not possible to obtain these values retrospectively.
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Figure 3-10 Trend of selected sub-records
In conclusion and importantly for this thesis, EURINE-ACT showed a data quality increase. Feedback 
on a regular basis to the investigator encouraged the majority of sites to improve their data entry 
practices and data entry processes. This improvement was the result of a combination of feedback, 
monitoring visits and interactions via email. Thus we have established that direct/manual feedback is 
one way of improving data quality. However, such improvements are expensive. This is especially the 
case with site visits in international settings. In the rest of this thesis we thus explore whether such 
improvements can be achieved by automated (web-based) feedback. 
Additionally, given the above case study, whilst community feedback encouraged some hospitals and 
users to increase the collected data quality; tools for user motivation and improving data quality were 
not fully established. That is, whether all three combinations of feedback were fully effective could 
not be shown by EURINE-ACT since real-time feedback was not available given the nature of the 
EURINE-ACT study.
3.5 Chapter Conclusions
The evaluation of data quality in the area of European adrenal research has provided important 
insights for the development of a data quality score. Researchers agreed that the data within the 
ENSAT registry needed to be more useful for other research initiatives. Therefore it was proposed that 
increasing the data quality with ongoing data quality feedback would increase the usefulness of data 
to facilitate other clinical trials. A data quality score that quantifies the usefulness of information 
entered into disease registries or eCRFs of a clinical trial is highly beneficial. We discovered a significant 
impact in both investigator and especially community feedback with regards to data quality. 
Community feedback needs to address intrinsic and extrinsic motivational factors of data entry users. 
Additionally, we identified that the development of a record eligibility score was important to show 
the community compulsory trial items. Presentations and discussions related to this score received 
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considerable interest in regards to data quality in clinical data management systems from the ENSAT 
community at international meetings. Quantifying quality is an important method for quality control 
of clinical trials. 
The analysis undertaken in this chapter was based on centralized monitoring augmented by on-site 
monitoring visits. We have demonstrated that face-to-face feedback works and has been quantifiably 
demonstrated, however traveling to all centres, giving presentations, interviewing and training 
researchers is both very costly and time consuming. On-site monitoring can motivate the users to 
improve the performance in regards to information processes. However as shown, the motivation did 
not last very long. Again as shown, on-site monitoring efforts can help to discover just 5-10% of general 
data quality inconsistencies. The majority of all errors can be detected via centralised monitoring tools. 
Issues about travel costs, spent time and short lasting motivation leads to the need for other models. 
In the remaining chapters we describe the extent that web-based applications that give automated 
feedback to the data entry user, the investigator(s) and the research community involved in the study 
collaboration can be used to replace the human-driven and expensive local on-site monitoring efforts.
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4 CHALLENGES TO SUPPORT AUTOMATED FEEDBACK
This chapter explains the challenges that automated feedback needs to address in data management 
systems. Most importantly are criteria associated with end users and their motivations for data entry. 
To understand this, a survey was performed within the ENSAT consortium to gain insights into 
motivational factors that could influence the quality of data entered into the ENSAT systems by data 
entry and related personnel. As noted previously, data quality is crucial for registries that ultimately 
need to provide useful data for current and future clinical trials and researchers with diverse research 
interests. An assessment of users of the ENSAT registry was performed with specific focus on 
determining whether data completeness of special tumour types for registry data was better (more 
complete) than those associated with ENSAT-CANCER related clinical trials such as PMT or EURINE-
ACT. Independently, from the result, methods of data quality reporting have to be addressed to 
understand how users can be motivated, e.g. by leaderboards, graphs or dashboards, and ensure that 
any kind of feedback is not demotivating. Finally, this chapter discusses how research registries with 
data quality feedback can improve the data quality and thereby improve the quality and conduct of 
registry-related clinical trials.
4.1 Survey
In order to prepare for EURINE-ACT onsite monitoring visits, a survey was conducted to identify any 
causes that might influence the data quality during data entry motivation. The survey was developed 
with the open-source GoogleForms platform. This application provided the option of a personalized 
survey development without subscribing to a website or company. The final survey was easily 
accessible to all users that have the survey link, even without registering with Google or having Google 
accounts. The users were also able to access the service on all platforms (Android, Windows, Mac, 
iOS) and on all general bowsers (Chrome, MSIE, Firefox, Safari). As such, all participants were able to 
submit responses.
An email was sent to all active ENSAT-members, with an invitation to participate in the survey to 
investigate their local data entry processes. The survey link was also provided to all users on the 
internal ENSAT registry start page (after the user login). It was assumed that the persons that 
answered the survey within the first few days were highly motivated to improve the ENSAT registry. 
The survey was anonymous, i.e. the names of the respondents were not requested or given however 
the centre that they are data entry personnel for was required. 
A specific identified bias of the survey was the possibility that a user could submit a survey more the 
once or that other non-ENSAT individuals could have completed the survey if they discovered the link.
This could have been countered with the possibility that every user had to log into their Google 
account (or set up a new Google account). The former option was not considered since it was 
identified that the login could be a barrier of users completing the survey. Also due to the presumed 
high motivation of every researcher in the ENSAT consortium it was assumed that there are honest 
and submit just one survey. It was also felt that any non-ENSAT user would be unlikely to want to 
complete the survey.
4.1.1 Evaluation Method
The survey was conducted with multiple choice and open questions to verify the cause-effects 
displayed in Figure 4-11. The primary purpose for the survey was to answer questions related to 
potential low data quality in clinical institutions or indeed understand why certain institutions have 
higher data quality. There are several hypotheses that were tested through this survey. Specifically, 
we considered that data quality could be influenced by:
(1) The individual’s personal characteristics such as their age and gender;
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(2) The specific individual role in the project and whether they are explicitly funded for data entry 
or not;
(3) Whether the centre is a clinical trial centre or a participating trial centre and is thus aware of 
the importance of data quality;
(4) If the centre is participating in registry-related clinical trials or not and if so, whether they have 
to enter data into clinical trials-related eCRFs;
(5) The type of source documents (paper or electronic);
(6) The time length of data capture;
(7) The time between data collection and data capture, and
(8) Whether the same data had to be entered multiple times in other registries.
The survey was concluded by two open questions focused on the individual’s personal motivation for 
using the registry and recommendations about features that should be added to the registry to help 
improve the data entry processes and ultimately improve data quality. 
To encourage the user to complete the survey, where appropriate, the questions provided default 
suggestions to elicit user responses such as "it is my job" or "I want to cure cancer". In case these 
default answers were unchanged, the responses were ignored in the final analysis for the survey. Open 
questions were analysed in a recursive process using an approach based on thematic text analysis 
(Braun & Clarke, 2006).
4.1.2 Survey Results
The survey was analysed after 28 days. In total 220 ENSAT participants received the first email 
requesting them to complete the survey. On day 19 after the initial announcement, a reminder was 
sent to all participants. In total 45 responses from the participants were submitted, giving a response 
rate of 19%. The peak response periods of the submission were the two emails that asked for 
participation (day 1 & day 9) and the first Monday (day 4) when the survey went live (see Figure 4-1). 
Figure 4-1 Timeline of Survey responses
The largest groups that submitted completed surveys were clinicians, investigators and research 
assistants (see Table 4-1). It was identified that the largest group of ENSAT registry data entry users 
were female clinicians between 30 - 49 years of age (n=9). 
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Table 4-1 Overview of Survey Participants
Female Male Total
Age
16-29 5 0 5
30-49 19 12 31
50 and older 5 4 9
Role
(Local-) Investigator 4 5 9
Research Fellow 2 2 4
Clinician 12 9 21
Lab Assistant 0 0 0
Research Assistant 7 0 7
Nurse 2 0 2
Data Entry Assistant 2 0 2
The participating centres that submitted the most surveys were Munich, Wurzburg and Florence (see 
Table 4-2). These centres were also visited during the EURINE-ACT monitoring visits. All three centres 
were identified as highly motivated to enter high data quality and involved in the conduction of the 
majority of clinical and biomedical trials associated with the ENSAT research network.
Table 4-2 Participating Centres (number of submitted surveys)
GYMU (6) GYWU (3) ITFL (3) NLNI (3) GYMV (2) BZSP (2) SBBE (2) ITTU (2)
FRPA1 (1) FRST (1) GBBI (1) GBDD (1) GRAT2 (1) GYBN (1) GYBN2 (1) ITBR2 (1)
ITMI2 (1) FRLY2 (1) ITTU2 (1) NLEI (1) NYBE (1) PTCO (1) CRZA (1) SPMA (1)
SPSV (1) TRIZ (1) GBED (1) GYDF (1) PLKK (1) PLWW (1)
EURINE-ACT and ADIUVO are the trials where most survey participants confirmed their ongoing 
involvement and contribution. Both of these trials recruit the majority of their patients from the ACC 
component of the ENSAT registry, while EURINE-ACT also has a large control group with NAPACA 
patients that are recruited from the ENSAT registry. Other trials of relevance include PMT and FIRST-
MAPP, which have a focus and demand on data quality for patients with NAPACA and Pheo/PGL 
respectively. In the case of PMT, NAPACA data is used as a control population to the ENSAT-registry. 
Importantly PMT supports bidirectional data transfers, i.e. data from the registry can be used 
(imported) into Phase 1 of the study, and other data collected throughout the trial can be fed back 
into the registry. The survey confirms the proportions of records as discussed in the adrenal research 
background, i.e. NAPACA, Pheo and ACC have almost equal amounts of patients in the ENSAT registry 
and these are used by and associated with the largest number of multicentre trials in the ENSAT 
research consortium (see Figure 4-2).
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Figure 4-2 Overview of current ongoing clinical trials associated with ENSAT (October 2016)
The final analysis of the survey data should ideally provide a correlation between the data 
completeness in the registry and the survey answers. For this, survey questions were ranked. The 
answers were scaled between 1 and 3, where “3” indicates the worst possible way to receive good 
(complete) data quality and “1” shows that the environment provides the optimal approach for data 
entry and ensuring best data quality (see Table 4-3). 
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Table 4-3 Ranking of Survey Questions
Rank 1 2 3
Question 1 (Q1): 
“Where do you access the 
ENSAT-Registry and enter 
patient related data?”
“in the office, where you 
meet the patient”
“in an office on the 
ward/unit where you 
meet the patient”
“in an office in your 
research facility”, “at 
home”
Question 2 (Q2): 
“What is the Source of the 




“Paper Based Records” “you know the patient 
and enter the data out 
of your mind”
Question 3 (Q3):
“In your opinion, how long 
does it take for you to enter 
a new patient record into 
the registry (with clinical 
information)?”
“under 10min” “10-30min” “more than 30min”
Question 4 (Q4): 
“In your opinion, how long 
after the patient visit do you 
enter the data?”
“within 30min after the 
visit”
“on the same day” “within the week”, 
“later”
Question 5 (Q5): 
“How many registries are 
you entering the patient 
data?”
“1” “2” “more than 2”
Survey exploring data completeness confounders
Figure 4-3 compares ‘good conditions’ and ‘bad conditions’, where ‘good conditions’ consist of 
answers with rank 1 and ‘bad conditions’ answers with rank 2 and 3. After ranking the answers (Q1-
Q5), every centre with more than 10 ACC records was matched to their own achieved data 
completeness levels at the time of the survey (see Figure 4-3). The results show that there is only a 
relatively insignificant correlation (p<0.05) with the number of patients in the registry. This indicates 
that centres that enter patient data in more than one research registry generally achieve lower data 
completeness levels. Despite the p values of 0.08 and 0.11, a trend is seen in the time of data entry 
and the age of the individual undertaking the data entry. Thus the longer the data entry time and the 
younger the data entry user, the lower the data completeness levels that were observed. There was 
no correlation discovered based on t-tests related to the gender, time of data entry (how long after 
the data was originally collected collection was the data entered in the registry), nor any relation 
regarding how many trials the centre participates in or whether the source documentation, i.e. the 
original medical record, was electronic or paper based.
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Figure 4-3 Correlation of a range of structural confounders for the ENSAT network
The survey was performed within ENSAT and so the results may not be generally applicable to other 
studies and trials. Furthermore, whilst 45 participants responded, this was a relatively small samples 
size. In summary, the results show that there is little or no direct correlation of data completeness and 
associated environmental factors and related confounders (R2=0.007). Even in the analysis of 
individual questions related to data completeness, there was no apparent correlation (R2 between 
0.02 and 0.48). Nevertheless, the survey as a whole provides insights into ENSAT and importantly 
systematically explores various quality control considerations that need to be incorporated to improve 
data completeness and data quality more generally in clinical registries. 
Assessment of Data Processes 
Possible issues related to analysis of confounders for data completion could be recall biases of the 
participants about the perceived and the actual length of time for data entry. A second bias could be 
the truthfulness of the response, e.g. whether the participant knows the trials objectives or not may 
seem to imply a lack of expertise and domain knowledge. During the initial on-site monitoring audit 
of the PMT-Study that took place in two different centres, three clinicians and two data entry 
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assistants admitted that they did not know the objectives of PMT and/or EURINE-ACT studies. As 
discussed in Chapter 3, linkage between the knowledge about trial objectives and the reasons and 
motivation for entering data was discussed with participants. Insight into the specific trial objectives 
clarified why the study was being conducted and it is presumed, motivated the data entry user to 
participate in entry of better quality clinical data. The survey showed that only members of the centres 
at Munich and Athens identified that they did not know the specific objectives and intended outcomes 
of the trials in which they were participating. These centres were also participating in several trials 
and studies including PMT, FIRST-MAPPP, MIBG Impact and Lysosafe, hence it is quite possible that 
the data entry personnel would not be fully aware of a given specific study needs, demands and the 
intended outcomes. 
The survey provided an overview of individual data processes. Specifically, these included questions 
related to where data is entered? What source is used for the data entry? How long it takes to enter 
the data and when the data entered is actually entered into the ENSAT registry? Answer choices where 
given in a hierarchical order so that if the first criteria did not meet the actual process, the next criteria 
might match. As an example consider Q1, which focuses on where data entry takes place. Is the data 
entered either in the same room where the patient is met, or somewhere on the same floor of the 
research facility or some other more remote location, e.g. at home. If the first possibility does not 
match, the survey participant should understand the hierarchy of the possible answers and choose 
the place where the clinical data entry actually takes place.
To present an overview of the data processes that are currently taking place, a graph was developed 
in accordance to the general data processes described in chapter 3. Case studies showed, that EDC 
methods are less complete but more accurate to manual data entry (Arts et al., 2002). The survey 
investigated the manual data transfer from electronic medical records (EMR) and paper-based records 
to the ENSAT registry. More data entry users transferred information from existing EMR (electronic 
medical records) compared to paper-based records to the ENSAT registry. Using EMR as the source 
document achieves a slightly higher data completeness level in ACC records (+1%). The average time 
for data entry and data capture after the patient visit was calculated based on the mean of the 
answers. Data entry users that use paper-based records enter that data around 17 days after the 
original information collection and the data entry user need 5.1 minutes less time for data entry 
compared to the electronic medical record centres (see Figure 4-4). 
Figure 4-4 Data Process Assessment
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Given these results, both methods deliver an approximate equal overall data completeness score for 
ACC records. This phenomenon is also confirmed by combining ACC and NAPACA records (both 
sources achieve an overall data completeness level of 74%). From this it can be concluded that the 
type of source document has no significant influence on data quality based on manual data entry. The 
use of the average mean for the period of time between the time of information collection and time 
of the data entry in the ENSAT-registry, allows for a comparison between both types of document 
sources. Data entry users that have EMR as their source document, enter the data around 2 days later 
than users with paper-based records. This provides an indication that the availability of paper-based 
records motivates user for earlier data entry. This is somewhat surprising; however, one possible 
explanation might be that the users are keen to move from paper-based records as soon as possible. 
Open Question – Motivation 
In 2012, interviews that took place during on-site monitoring visits for the PMT-Study showed that co-
authorship and/or recognition at international ENSAT meetings motivated users to enter better 
quality data into the registry. Questions related to this topic and the incentives that might be used to 
improve data quality were thus included in the survey. 
Results of the open questions were analysed through qualitative text analysis. The answers were 
categorised through an iterative process. For this, all 45 answers were divided into three categories. 
Each category was analysed and further decomposed to reassess and harmonise the categories. As an 
example, one participant entered: “It’s necessary to improve the research in these rare diseases”. This 
text entry was first categorised as “progress in rare disease research”. After the decomposition, the 
text was categorised as “support researcher/science/network in rare diseases” because the statement 
matches a larger category and a single statement on its own has no significance in the overall text 
analysis of the survey. 
Another example was the statement that “research is necessary for my patients”. First this was 
categorized as “importance for patients”, but ultimately re-categorised to “improved medical 
standards and treatments”, because the patient centres view was also shown in improved medical 
therapies. Some answers also provided multiple motivation factors. A second researcher verified 
these categories independently.
After the final iteration of the text analysis, ten categories were identified (see Table 4-4). Generally, 
multicentre research focuses on collaborative research goals, however as can be observed here, the 
primary focus of the survey participants was related to the patients themselves. Multiple answers 
identified the need for better care, treatments and standards for patients with adrenal tumours. Other 
answers focused on knowledge improvements and on international collaboration that can only 
realistically flourish through collaborative adrenal research. It was identified that international 
collaborations could have a far deeper impact with co-authorship of research articles for data entry 
personnel, especially for publications with high impact. However, the term ‘co-authorship’ was not 
used by all participants. This may be due to the fact that many data entry personnel are not 
academically motivated or indeed judged by their publication track record with regards to their career 
progression.
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Table 4-4 Motivation for Data Entry based on text analysis (subgrouping)
Category Count of Answers
Patient focused (improved medical standards 
and treatments) 11
Knowledge focused (learning about 
endocrine cancer) 9
Collaboration focused 8
Data mining focused 7
ENSAT focused 6
Support of science 6
Study participation 3
Support young researcher 1
Just a single researcher from Sao Paulo, Brazil, identified the importance of supporting young 
researchers in their career. Specifically, the researcher motivation for using the ENSAT registry was to 
build “new avenues for future young investigators”. 
The second researcher identified 6 categories and went through 3 iterative cycles of decomposition. 
Similar categories were defined, while the majority of answers were labelled with the term 
‘collaboration’ (see Table 4-5).
Table 4-5 Motivation for Data Entry based on text analysis (grouping)







Open Question – Recommendations 
For many the most important motivation is the collaboration itself, which provides outcomes for 
patients and for researchers. The advancement in treatments and procedures are also important 
motivational factors to enter data into the registry. 
The last survey questions asked for general recommendations, e.g. how could the registry be 
improved? In principle, these features reflect the actual needs of the community and what would be 
required to improve the data quality in the registry. As such they are fundamental to this thesis for 
improvements to processes and procedures for improved quality of data. A qualitative text analysis 
was performed but somewhat limited since 20 of the 45 responses entered “no”, or “not yet”. It was 
noticed that 9 of the answers were given by clinicians, compared to research assistants and principal 
investigators that have clear expectations what features should be added to improve their own 
research needs and demands.
All other responses comprised individual answers with different categories. Participants that did enter 
recommendations typically requested special features like support for web-based comments, easier 
login or logout, easier data entry including improvements to the user interface and support for web-
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based chat. However, there was no general consensus on these recommendations and no categories 
or community-wide agreed enhancements could be determined. 
It should be noted that only one principal investigator (from Munich, Germany), asked explicitly for 
the implementation of quality control into the registry. Another participant asked for e-mail reminders 
for compulsory trial related data. Before the survey was sent to the participants, the motivation 
question was expected to show consensus on the need for data quality assurance. Despite wishes for 
various new features, improved data quality could not be identified as an explicit demand from the 
community through the survey. These insights from the community feedback were subsequently used 
for a more structured assessment in accordance to data quality indicators and especially those that 
could lead to lower data quality. All answers and a google developed summary of the survey can be 
found in Appendix II.
4.2 Quantifying Motivation
Research in the field of motivation and data entry focuses on human behaviour in use of computer 
systems. Key terms that are used in this context include motivation, participation, engagement and 
contribution. Motivation can often include other criteria like funding of research staff members, 
authorship, regulations and external barriers in data collection. Tools and feedback processes can 
directly improve the motivation of the user, but it is recognised that these are not likely to be the full 
list of external influences. A perfect web-based user interface is unlikely to convince a researcher that 
has no vested interest in using the system.
Motivation is a key driver of a human that ‘moves’ them to something. We can make a distinction 
between intrinsic and extrinsic motivation (see Table 4-6). While intrinsic motivation emerges from 
the individual’s own challenges, enjoyments or interests – extrinsic motivation is given by external 
influences to the person. The driving factors could be grades, rewards and pressures. Internalisation 
of motivation has the highest value, because the human can self-regulate and self-motivate for a given 
activity (Ryan & Deci, 2000). 
Table 4-6 Taxonomy of human motivation (adapted from Ryan & Deci, 2000)







Intrinsic motivation is the main driver of user behaviour to use an information systems (H. M. Huang 
& Liaw, 2005). During the data entry process, users need insights into the contribution they provide 
that are associated with their data entry. A case study discovered that feedback about data 
contribution led to an increase in the motivation levels of participants in the research objectives 
(Rashid et al., 2006).
In addition to the factors that can increase user motivation, another approach for the improvement 
of data entry focuses on dynamic entry forms. The form changes due to a learning process by a 
probabilistic models and adapts the data entry forms accordingly. This method orders items during 
data entry and re-asks items if their input looks inaccurate and reformulates or adjusts answers to the 
plausibility of the entered values. This data-driven data entry approach purports to support an 
avoidance of data cleaning and reduces the expense of double data entry (K. Chen et al., 2011). 
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Another important aspect of (de-)motivation is the form of data entry related to the interface. This 
refers particulate to a clear interface, the ease of use and especially if and how double data entry 
(DDE) must be performed as part of quality control (Wang & Strong, 1996). In regards to monitoring 
purposes, DDE is considered to be the gold standard for record validation. However DDE incurs huge 
time, effort and increased monitoring costs (Day et al., 1998). One way to minimise these costs is to 
randomly selected records that should be re-entered or values that appear to be incorrect during the 
data entry (Brandt et al., 2006; K. Chen et al., 2011; Ohmann et al., 2011). Quality tools like tracking 
systems can also be applied (Tudur Smith et al., 2012). Research has shown that automated form 
processing with “check boxes, numerical codes and no dates” increases the quality of data (Paulsen 
et al., 2012). 
In summary, motivation is a key factor for data quality. Without motivating the user, data entry and 
research contributions can be drastically reduced, especially over the time period of a trial or study. It 
is therefore imperative to keep the community continuously aware about the level of data quality of 
data that is being entered to assess and increase the motivation of data entry personnel.
4.2.1 Increasing Motivation for Participation
Any given multicentre clinical trial depends on the information that is entered in the trial registry by 
the researchers and data entry staff. However, a fundamental question is, what drives every person 
to entry data into a repository? As discussed previously, a key aspect of increasing data entry quality 
is to understand what motivates users that enter data. Ideally data entry should provide an intrinsic 
value for the users and clearly show the impact that data entry can have for significant conclusions in 
biomedical research. Research has shown that a combination of intrinsic values with gamified 
activities, like rankings, badges or user levels increases the motivation for participation. Examples are 
Khan Academy, RibbonHero, HealthMonth, EpicWin, Recyclebank, FoldIt and StackOverflow 
(Deterding, 2012). Even popular resources and applications like Amazon, Ebay, LinkedIn and Duolingo 
use elements of gamification to increase user interests (Herger, 2014).
As an example, StackOverflow is an online Q&A (Question & Answer) platform for programmers. It 
has three main criteria: everyone can ask questions, everyone can answer questions and users can 
vote for the best answers. Every user receives points and badges for special interactions on the site. 
With this earned ‘reputation’, the user gets increased access to special actions like editing or deleting 
posts. Users are placed in a ‘league' to compete with each other to increase their overall reputation. 
A case study investigated the user activity related to earned badges and the results showed “strong 
empirical evidence […] of gamification in stimulating voluntary participation” (Cavusoglu, 2015). 
StackOverflow is an example of an online community that relies on the help of users to increase the 
quality of software development by programmers. This aspect can be transferred to the biomedical 
domain, where the research consortium can motivate clinical and biomedical researchers to increase 
their own quality to achieve a particular trial objective. 
Gamification is an approach to apply game elements in non-gaming contexts. It was shown, that the 
interaction of online users can aid in the development of building enzymes, motivate participation and 
improve collaboration to achieve a goal (Fernandes et al., 2012; Khatib et al., 2012; McGonigal, 2011; 
Reeves & Read, 2013). Cloud-based software companies provide services that use aspects of 
gamification that benefit from application of gaming mechanics on user activities. Established 
examples include Badeville and Bunchball (Deterding et al., 2011). McGonigal (2011) describe four 
fundamental elements that a game and gamified applications require: a goal, rules, feedback system 
and voluntary participation (McGonigal, 2011). Examples of methods that are used to increase the 
motivation of users in online communities include points, leader boards and league tables, 
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achievement/badges, levels, stories/themes, clear goals, feedback, rewards, progresses and 
challenges (Hamari et al., 2014).
The benefits of gamification are not well studied in a biomedical content. It is proposed that three 
criteria are related to the success of gamified elements: (a) the social environment (planned 
behaviour), (b) the nature of the system (either utilitarian or hedonic) and (c) the user involvement 
(cognitive or affective) (Hamari et al., 2014). A case study investigated effects of gamification related 
to age, sex and usage. It was discovered that gamified tools do not affect age, but women are more 
aware of gamified mechanics than men. Furthermore, women admire the social interaction of these 
tools and appreciate this method as more ‘playful’. It was shown that the motivation over time fades 
and users between the age of 20 and 29 show a stronger loss of motivation in using such services than 
those aged 30 and beyond. This research also considered aspects of networking that showed a positive 
correlation between usage time and newly acquired contacts (Koivisto & Hamari, 2014).
To summarize, gamification is not a well-studied process in the domain of biomedical informatics. It 
provides motivation to increase scores of a user in a domain, but this motivation is not permanent. 
Furthermore, gamification alone cannot increase data quality. The environment must provide 
suggestions and self-improvement strategies to gain maximum benefit. This in turn requires a creative 
and dynamic data management system coupled together with intrinsic motivation factors for the 
participants that are involved.
4.3 Data Quality in the ENSAT Registry and associated Studies
An important aspect of data entry motivation for clinical registries such as ENSAT is whether the 
researcher is also expected to enter data into clinical trials systems (eCRFs) for general use or to meet 
specific trial objectives, i.e. is there an expectation of double data entry. Clinical research registries 
need to be driven by data quality, however they are research oriented. It is important to distinguish 
between data needed for research purposes and data used for clinical care. Ideally there should be no 
difference, but this is typically not the case and different steps and processes have to be adopted. 
In a research setting, a multidisciplinary board is typically needed to guide the discussion related to 
which data items can be used for the life cycle of the research initiative. The ENSAT registry has large 
sets of data with all information needed related to specific tumour types. The registry has also grown 
to include data sub-sets required for individual trials that are ongoing across the research consortium. 
Multidisciplinary groups involving experienced researchers, research assistants and software engineer 
discuss the items that need to be included and excluded in the core data model. Importantly, being 
involved in a trial can directly impact on the quality of the data in the registry itself (intrinsic 
motivation). To understand the impact of this, we consider the ACC component of the ENSAT registry 
and the EURINE-ACT clinical study. 
A comparison of ACC and ACC EURINE-ACT records showed that trial data subsets don’t have more 
information entered than the whole registry. We consider here the records from Germany used in the 
registry, noting that German centers have an especially long history of ACC records and associated
expertise in large adrenal research and hence are assumed to have high motivation for entering high 
data quality. In total 1152 ACC records were assessed in the ENSAT registry, which included 288 
records affiliated with EURINE-ACT. In comparison to ACC records, EURINE-ACT has more information 
entered in three of the seven record types (Biomaterial, Follow up, Mitotane). Biomaterial and Follow 
up information is a crucial part of clinical research and therefore more information is entered in this 
record type. Other parts of ACC records that are not affiliated to clinical trials such as EURINE-ACT, 
have more information in Diagnostic Procedures, Tumor Staging, Surgery and Pathology (see Table 
4-7).
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Table 4-7 Incomplete items (errors) per record from ENSAT ACC and EURINE-ACT
ACC EURINE-ACT +/-
Diagnostic Procedures 5.10 (1152) 7.10 (288) -2.00
Tumor Staging 4.10 (1152) 5.22 (288) -1.12
Biomaterial 167.85 (426) 160.49 (281) 7.36
Surgery 22.16 (1037) 22.29 (260) -0.13
Pathology 81.47 (1087) 85.89 (260) -4.42
Follow Up 485.19 (1081) 476.69 (263) 8.50
Mitotane 92.51 (798) 92.38 (222) 0.13
Around 860 ACC non-EURINE-ACT records have more information about pathology and surgery 
entered. This information was entered without a specific research objective, i.e. it is provided to other 
researchers to allow them to conduct further trials with this data. Quantifying data quality is also an 
important tool to show user contribution and the benefit and impact of entering data on behalf of the 
research community. A key aspect to consider is how best to provide this feedback?
4.4 Visualization of Data Quality Feedback
The research group of Timmermans published an adaption of a centralized data quality monitoring 
method in clinical research and health registries (Timmermans et al., 2016). Statistical methods for 
data quality assurance have to be used for centralized data monitoring to aid in the detection of data 
inconsistencies through the help of statistical methods (Venet et al., 2012). Venet and other 
collaborators developed a centralised statistical monitoring (CSM) tool for statistical monitoring 
applied to research trials (SMART). Timmermans et al. (2016) adapted this tool for the evaluation and 
report of data quality in clinical trials. Although the analysis discovered no inconsistencies that had an 
impact on the outcome of the trial, the method and the research used was novel. They categorised 
data errors into four groups: 
a) Data inconsistencies related to reporting;
b) Data inconsistencies related to data tendency;
c) Data inconsistencies related to visit-to-visit evolution, and 
d) Data inconsistencies related to days (see Figure 4-5). 
To report data errors, the authors used bar charts with calculated p-values. Only extreme values were 
investigated and further quality assurance processes were conducted to investigate the origin of these 
inconsistencies. An overall score (“Data inconsistency score”) was calculated for every centre to report 
an overall data quality indicator to local researchers (Timmermans et al., 2016). Using scores and bar 
charts displaying extreme values should support both community feedback (data quality scores) and 
investigator feedback (reports to conduct additional investigations to improve overall quality).
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Figure 4-5 SMART p-value calculation with pseudonymised centres (Timmermans et al., 2016)
Puttkammer et al. (2016) performed a qualitative/quantitative case study investigating data quality 
priorities from health stakeholders. In the quantitative analysis the researchers discovered 13 
mandatory data quality indicators for data completeness (n=7), accuracy (n=5) and timeliness (n=1). 
For every indicator they defined a rule set to support the decision as to whether the items were 
inconsistent. While completeness covered the primary interests of the stakeholders, e.g., if the item 
existed, accuracy rules were defined for age, sex, visit dates, medication plans and lab results (range 
tests). Timeliness was calculated for late data entries (3 or more days after the patient visit). While 
the analysis results were very specific for developing countries, the researcher concluded that “A 
dynamic, interactive “DQ dashboard” […] could bring transparency and motivate improvement” 
(Puttkammer et al., 2016).
Another case study used a survey and a literature review (of articles from 1985-2014) to define 
“strategies for fraud and misconduct detection” (Knepper et al., 2016) in the area of industrial 
research. The study was primary conducted to show the performance and resources of TransCelerate, 
a non-profit organisation providing tools to improve translational research. The survey identified that 
site monitoring was still the most commonly used method to detect quality issues. Statistical analysis 
and/or centralized data monitoring were less of a focus of the survey. The authors (who worked for a 
large pharmaceutical company) discovered that the most used tactic to discover data inconsistencies 
was to detect extreme values in data trends (outliers) (n=11 of 47 answers), followed by detecting 
duplicates and confirmations of patient existence (n=8). In the literature review, the author discovered 
primary motivations (important for the community feedback part of this research), was on “prestige 
and financial rewards”, whereas academic researchers were primarily driven by publishing high impact 
research articles (Knepper et al., 2016).
With regards to data quality feedback, one group implemented data quality feedback into a food 
questionnaire-based trial. They distinguished between data input feedback and data analysis 
feedback. This data quality tool was dynamically adjustable for each user and they could define their 
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own data quality requirements with assigned weights (Weber et al., 2015). Another group investigated 
the increase in data quality in a randomised controlled trial. The improvement of health information 
was aided through motivational short message service (SMS) and by the combination of motivational 
SMS and data quality feedback. The authors discovered no differences between the two groups, but 
they noted that the study was underpowered (Joos et al., 2016). 
4.4.1 Implementing Data Quality Reports
Considering the breadth of data quality dimensions, a reporting framework should ideally support the 
calculation and reporting of completeness, accuracy, timeliness, comparability, record eligibility and 
the calculated overall quality from those scores as they pertain to and support biomedical research 
(see Table 4-8). All dimensions have different purposes, yet collectively they are fundamental to 
improving the overall quality of data and importantly, the processes that are used to improve data 
quality.
Table 4-8 Suggested Data Quality Dimensions related to the Feedback type
Quality Dimension Real-Time Feedback Investigator Feedback Community Feedback




Record Eligibility X X
Overall Data Quality X X
Reporting Feedback
Generic data quality tools should consist of several feedback considerations and support a range of 
features. Specifically, we identify and consider support for data quality considerations of the user, the 
principal and local investigator(s) and the research community (see Figure 4-6). Real-time feedback
can be applied during data entry and is suitable for the data entry user to allow them to gain insights
to the actual quality of the entered data. Investigator feedback can include items that are generally 
reported after monitoring visits and that are possible to report upon in comparison to previously 
entered data. The community feedback considers leaderboards of users and their associated centres 
in relation to their entered data and the achieved data quality. These tools should give advice related 
to items and processes that could or should be improved. This can be reported in several ways: it can 
be reported to the user via email or during the login as a daily task list; it can be regularly presented 
to the investigator to obtain an overview of items with low data quality, so that processes to improve 
the items in general or for specific trials can be initiated. The approaches can also benefit from 
reminders and notifications of progress in data quality as a whole to ensure that where benefits have 
been observed (increases in data completeness) then the users are actively encouraged.
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Figure 4-6 General Data Quality Tool Architecture
Real-time Feedback 
Identifying errors or data quality issues in real-time data entry implies that every data field must have 
precisely defined units and ranges. Real-time feedback should provide completeness and quality 
values related to the form/record that is created and/or updated. This information can be augmented 
with average quality values of the user and/or the community. A case study showed that real-time 
feedback doesn’t improve data quality immediately, but improvement was only seen in combination 
with reminders and ongoing training (Nair et al., 2010). In another study, real-time feedback was 
described as a “check for data integrity”, where collection inconsistencies, data errors and “illogical 
entries” were detected during data entry (Shiloach et al., 2010).
In summary, real-time feedback must include:
 Current value of quality;
 Comparison of quality with other users;
 Errors in data fields, and
 Reminders of missing compulsory data.
All these features must be combined with clear data field definitions. Real-time feedback influences 
the user interface presented to data entry personnel. During data entry the actual data completeness 
can be reported in real time with reminders and messages related to compulsory data not being 
entered and/or statistical feedback regarding the completion of the data that has been entered. A 
patient calendar can also serve as a reminder that follow-up, examination or tests are expected 
and/or, have potentially been missed. Consortium-wide networking and trial/consortium related 
news feeds can also be implemented to encourage users to regularly log in to the database and enter 
data.
Investigator Feedback (Monitoring/Audit Platform)
Investigator feedback can include quality reports that are periodically sent to research centres with 
the aim to inform them about their achieved data completion and accuracy. These reports can include 
information about record eligibility, patient follow-up times, specific information about treatment 
(dose, time and interval) all of which can represent the main objectives of the registry or trial. Every 
91
category can be reported with a score and the data threshold that must be achieved (Sandman et al., 
2006).
Investigators receive feedback after auditing or monitoring events. However clinical on-site 
monitoring visits can cost up to 30 percent of the total cost of a clinical trial (Davis, Nolan, Woodcock, 
& Estabrook, 1999). Therefore, Investigator Feedback should ideally include:
 Record eligibility for the trial;
 Overview of (Serious-) Adverse Events (SAE/AE);
 Current status of trial objectives and associated endpoints, and
 Information about staff efficiency (data entry/time/data quality).
Investigator feedback consists of information about data quality that is provided to the principal 
and/or local investigator associated with a particular centre. To reduce costs this report may consist 
of results related to possible investigations that would normally be carried out during an on-site 
monitoring visit. Through such reports, the investigator can determine how best to improve local data 
processes. Little research has been done in this area, but investigator feedback is critical for the 
reduction of costly on-site monitoring activities. This feedback needs to display critical data and 
processes that lead to low data quality. Such reports should:
(a) Assess and display the eligibility of all trial marked records. This eligibility can be calculated by 
a range of inclusion and exclusion criteria as well as through investigator defined mandatory 
items. Records that do not meet the minimum trial requirements should ideally be provided 
in a list with the information that needs to be entered (Suggestion list). These values will be 
compared with the community.
(b) Calculate the recruitment ratio and the aim of required subjects for the study;
(c) Provide an overall comparison of achieved data to study endpoints (if applicable);
(d) Display inconsistencies of demographic data and other data, e.g. laboratory results of new 
patients and compared them to other centres;
(e) Check if every record was marked with patient signed informed consent;
(f) Provide statistics for staff members (activity, quality, quality trends) for training purposes;
(g) List any adverse events in the trial (all centres);
(h) List any missed follow-up events, and
(i) Performance differences between the sites.
Those reports should be provided to the investigator on a regular basis. This can be achieved through 
several mechanisms, e.g. through a website, via the registry or simply via email. The information 
requires that detailed logging information and associated metadata are collected, e.g. showing overall 
statistics of the amount of time that the data entry personnel spent entering data. These suggestions 
can include FDA/GCP standards and requirements as well as recommendations from the literature. 
Instead of using only lists or tables, graphs and charts can also be used. For example, the report of 
performance differences may include a RICC vs. R2 plot. By clicking on the specific item a box-plot 
appear or table may appear that reports side-by-side differences (see Figure 4-7 & Figure 4-8).
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Figure 4-7 Example report of item related performance 
differences (adapted from Wynants et al., 2013)
Figure 4-8 Example report of side-by-side comparison of 
an item (adapted from Guthrie et al. 2012)
Community Feedback (Motivation/Competition Platform)
Reports to the whole research community aim to update all researchers regarding accomplished data 
quality results, trends and issues that appear during the course of a trial or establishment of a registry. 
Reports should ensure that the goals of the work as a whole are transparent to all participants. Reports 
should also empower users to increase their knowledge about the study and the problems that may 
arise. These are common aspects of transformational leadership that “inspire followers to change 
expectations, perceptions, and motivations to work towards common goals” (Burns, 2003). 
Motivation is key in this type of feedback. For the collection of high data quality, as noted, motivated 
users are the best way to increase the efficacy of the clinical databases. Therefore, it is highly 
recommended to use aspects of motivation related to user interfaces and reports. Staff members 
need to have an insight of the trial, including its overarching objectives as well as ways to understand 
and tackle their problems. Community feedback must therefore:
 Empower every research/user to understand the collaboration objectives including 
potential record eligibility for clinical studies and related issues;
 Motivate users to increase their own and/or their centre performance, and
 Motivate users to increase participation and improve the overall quality of data – even if 
the data that is to be entered does not directly benefit them.
Community feedback can also be construed as ‘naming and shaming’. In a gaming context, users 
compete with others. The possibility of a research assistant to appear on a leaderboard in the first 
position and to be recognized by the research community could be an intrinsic motivation factor that 
encourages them to participate in a registry and enter high data quality including increased user 
activity. Every user who is responsible for data entry in an international research consortium needs to 
contribute with the highest possible quality of data. To achieve this, gamified applications can be 
supported in the web-based research environment. Four main elements of such a system need to be 
considered in the biomedical domain (see Table 4-9).
Table 4-9 Elements of Community Feedback in Biomedical Research
Goal Support biomedical research through high quality datasets;
Rules Enter data of the highest quality and sustain this over time;
Feedback System During data entry, statistics should be available with associated 
encouragement and/or benchmarking with other personnel/centres, 
and
Voluntary Participation The user should be able to decide whether they accept the challenge to 
compete with others or not.
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The primary goal of this feedback is to assess why and how data quality is actually measured. These 
aims are to improve research using quantifying errors of datasets (assessment); to design actions to 
reduce errors (plan); to improve the quality of the dataset (do); to evaluate the inconsistencies (check) 
and ultimately to achieve a higher overall data quality (act). This is an iterative process related to the 
PDCA quality cycle that can be used to fulfil quality control aspects (see Figure 4-9) (Deming, 2000).
Figure 4-9 PDCA Continuous Improvement Cycle (adapted from Deming, 2000)
Rules are defined that allow the user to “unleash creativity and foster strategic thinking” (McGonigal, 
2011). This creativity emerges out of the will to achieve a better place on a scoreboard or to receive a 
higher user level in the research environment. It was noted in chapter 3 that some users simply cannot 
achieve high data quality. This can be due to a variety of factors: funding issues; local processes that 
lead to incomplete clinical information, e.g. lack of imaging facilities or lack of patients at that centre. 
As such, such factors should be considered when scoring data quality. These scores will be activity and 
quality improvements or rankings where troubling items (e.g. pathology and imaging information) can 
be excluded from the user competitive rank. 
To consider the design of community leaderboards, it has been identified that six aspects should be 
considered: centred views, filtering, aggregation, multiple leaderboards, points and metadata 
(Ventrice, 2013). Reviewing user statistics can be embarrassing and confusing. Therefore, users have 
to see their scores in the centre of the interface or at the bottom of the screen so that an immediate 
comparison with other users and centres is possible. This provides the opportunity to establish how 
much of an improvement is needed to overtake other researchers in the leaderboard for example. 
Ventrice (2013) also suggests multiple scoreboards, related to teams (centres) scores and individual 
scores (see Figure 4-10). 
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Figure 4-10 Example of a leaderboard that covers a simplified view of the user and the scores in different boards 
(individual, team and community)
For voluntary participation it is important to establish the motivational affordances for particular 
studies and trials. This motivation could be co-authorship on papers; involvement in grants; clinical 
decision improvement and/or recognition as part of the job description that could have an impact on 
the individual’s career. A further incentive is community recognition, e.g. through rewards/prizes 
honouring the contribution made at collaborative meetings.
4.5 Continuous Data Quality Assessment
As described previously, European funding schemes have accelerated clinical research. ENSAT has 
benefited greatly to other adrenal research initiatives worldwide through its collaborative funding 
model. With collaborative funding, challenges of clinical data quality arise. To identify as early as 
possible any low data quality issues, primary indicators for data inconsistencies must be identified. A 
range of commonly accepted quality indicators was developed by Avedis Donabedian in health care 
(Donabedian, 1988). These include structure, process and outcome quality. 
To map a range of possible causes for low data quality, a cause-effect diagram (Ishikawa diagram) for 
data processed within EURINE-ACT was developed. The starting point for the analysis is the 
information delivered by the patient to the individual who captures the data for research purposes 
either by pen and paper or electronically. Primary data quality issues can stem from several areas: 
environmental issues, by human, by hardware or data management software. 
It was discovered that the main issues are often the human resource (see Figure 4-11). Other common 
problems are time and funding as well as low motivation to enter medical related information into 
clinical databases outside of the immediate healthcare setting. 
95
Figure 4-11 Cause-Effect Diagram for Causes of Low Data Quality (own figure)
This research is conducted using qualitative and quantitative research methods. The central concepts 
of the method are based on the PDCA Cycle (Plan-Do-Check-Act) or Deming-Cycle, which is well 
established in health care quality assurance (Deming, 2000; Taylor et al., 2014). This process is used 
as a quality control method and supports continuous improvement of the tools and processes that 
should be adapted (see Figure 4-12). Such a concept is often mandatory due to the heterogeneous 
processes that are adopted during translational research (American College of Medical Quality, 2010). 
Figure 4-12 Quality Assurance Cycle
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To explore possibilities for improvement of data quality in the biomedical and translational domain, a 
detailed literature review was performed in the initial phase of this research. The general search was 
performed using Google Scholar and Medline Database with the words “evaluation of data quality” 
and “medicine” between the years 2000 to 2013. The year 2000 was used because translational 
medicine was first identified in the literature in this year (Sung et al., 2003). During the review process, 
leading questions were:
• What methods are used to improve data quality in the translational domain?
• What requirements need data management systems for quality assurance purposes 
especially in clinical trials and studies?
• What dimensions of data quality are currently discovered and used?
• Are there any published documents that elaborate on the effectiveness of data quality 
feedback in academic research?
• How can researchers be motivated to enter higher quality data in an external research 
data repository?
To supplement the search, papers referenced by other papers and authors known by reputation were 
considered and included in this review. 
To illustrate the needs for data quality and the importance for feedback, a case study was performed. 
The EURINE-ACT trial within the ENSAT Consortium was used to gain insight into translational research 
and to provide feedback about the requirements on research data sets and data quality for principal 
and local investigators. Initially all compulsory data was used to calculate a data completeness value. 
This value was reported to centres. A range of rules where applied to the calculation, including 
plausibility checks and a novel eligibility confirmation check for adrenal tumours. With these values 
an overall Data Quality Score (DQS) was calculated and reported to every centre.
After the first reports, feedback from every site was analysed and the DQS adjusted accordingly. Each 
month, new mandatory items were added to the completeness score to encourage every site to enter 
higher quality data. In addition to this process, on-site monitoring visits for six selected centres was 
conducted. 
In the trial, two of the proposed feedbacks were introduced. Community feedback aimed at
encouraging the study site to improve their captured data and to be better than other sites with 
regards to data quality. Investigator feedback should provide an overview of captured values of the 
centre and allow a comparison with other centres to determine, if values are comparable or if 
inconsistencies exist. The effectiveness of both feedback mechanisms were analysed to evaluate 
difficulties and possible improvements (see chapter 3.1.4). 
The overall data quality (data quality score) calculated for EURINE-ACT is a specific quality score for 
adrenal cancers. It is mandatory to show the usability and effectiveness of quality scores across other 
biomedical communities. The PDCA method is an iterative process and the cycle restarts and the 
experience gained in EURINE-ACT can be applied to other studies and trials. Here, all feedback types 
were analysed, including whether it was possible for user motivation to enter high quality data to be 
increased.
4.5.1 Proposed Structure of Quality-driven Research Registries
Research platforms in biomedical research typically don’t need long-term motivation since studies run 
over a given time window, e.g. a few years based on the research funding. Furthermore, since data 
collection already happens during routine care, the ongoing motivation to enter data into research 
databases is important. It could be argued that data entry should not be for enjoyment and simply 
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part of the formal job description. In many (most) cases however, research funding is inadequate for 
full time data entry personnel.
While reporting feedback, it is important to keep users motivated. Therefore, it is advisable to 
implement feedback features in stages. There are two different scenarios of data quality feedback 
requests: either at the onset of a new study/trial or during the conduct of a particular study/trial. Data 
feedback at the end of a trial is not considered to be feedback. Rather it is more a retrospective 
evaluation of data quality.
Continuous data quality assessment during an ongoing trial is essential. A researcher or an EDC 
method enters/feeds data into the study database ideally with data quality tools giving immediate 
feedback to the researcher with reports that can be generated for the community and investigator 
(see Figure 4-13). 
Figure 4-13 Quality-Driven Data Quality Feedback during a trial
Another purpose of data quality reports is to support the onset of new trials and studies, where the 
investigator defines the study objectives and compulsory and optional data items. This information is 
entered into the clinical database and eligibility scores should be identified and subsequently 
captured. This includes how many records fit the study and what records need to be updated with 
information to be confirmed as eligible for the trial (see Figure 4-14). 
Figure 4-14 Quality-Driven Data at the onset of a new trial
4.5.2 Development of Automated Data Quality Feedback 
A data quality-reporting framework is essential for exploring and analysing the results of quality 
control methods and quality dimensions that need to assessed and adjusted with continuous user 
feedback to optimally motivate data entry personnel. 
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In this situation, the trial is initiated by a principal investigator responsible for defining compulsory 
and optional data items that need to be collected during the trial (as part of the clinical trial protocol). 
During the set up phase of a clinical research trial, queries should be run to ascertain the quality of 
the data in the registry. This quality should encompass how many mandatory data items are required 
(according to the clinical protocol) and how many new items are required (in the eCRFs to be 
developed for the trial). 
As part of this process, the data manager performs the evaluation of data quality in accordance to 
centralized monitoring guidelines. As discussed, general accepted quality dimensions are data 
completeness and data accuracy (validity) of data in the registry. Additionally, as shown in EURINE-
ACT, a record eligibility score can be calculated to show the investigator, how many records can be 
confirmed as eligible for the trial. The next step is the selection of reporting methods, i.e. how the 
data manager reports the data quality to the data entry personnel, principal and local investigators 
and the research community. 
There are several tools and features mentioned in the previous chapters that are useful for these 
steps. Data entry users can receive real-time feedback during data entry, as well as possible query lists 
with suggestions regarding what data items are missing in records to support their eligibility for a trial. 
The investigator receives regularly quality reports in the form of a dashboard page of the registry 
and/or clinical study with an overview of trial performance and if the primary items are collected in 
accordance to clinical trial SOPs (if applicable). 
Finally, the research community can be set into a competition with one another, where individuals 
and centres gain rewards by obtaining high quality values or entering many patients over defined time 
periods. These extrinsic motivational factors can encourage data entry users to be better than others. 
At the end of the iterative cycle, the data manager will assess if the data quality has indeed improved. 
If the data quality improves the feedback works, if the data quality does not improve, the loop starts 
again with a discussion of data items in an expert group between the principal investigator and data 
manager (see Figure 4-15).
Figure 4-15 Automated data quality feedback loop
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This feedback loop will be supported with notifications that can be delivered via a range of 
technologies. This can be email notifications of missing compulsory items or when trial milestones are 
reached for example.
One other dimension underpinning this work is the notion of trust and honesty. When awards are 
made through ranking and leaderboards, it is possible that end users may be pushed to enter the 
highest quality data on the registry and where the data itself is manufactured. In this thesis and work 
as a whole, we treat data entry personnel as honest citizens that work within organisational 
frameworks that such falsifying of data would result in severe reprimands. Nevertheless, encouraging 
data quantity and quality should be directly augmented with data auditing capabilities to ensure that 
such issues do not arise.
4.6 Chapter Conclusions
The previous chapter has showed a practical and theoretical approach for systematic evaluation and 
improvement of data quality. It identified that reporting data quality and data completeness are an 
ongoing process that should ideally motivate the involved personnel. While PMT and EURINE-ACT 
showed an improvement of data quality through investigator and community feedback, this does not 
indicate that data feedback alone is the cause of that trend. There can also be performance bias and 
hence monitoring visits should not be replaced completely. Rather this approach can be an aid in the 
reduction of monitoring visits to improve data quality.
It is also known that for the continuous improvement of data quality, ongoing training of data entry 
personnel should be mandatory. To clearly demonstrate the impact of feedback, it is necessary to 
investigate whether there is indeed a positive effect of feedback on data quality. This can be achieved 
through observational studies. The following chapter provides a study design to investigate whether 
automated feedback can indeed improve data quality. For this a stage-wise research framework will 
be developed, that has to be implemented into the data management system. This framework has to 
assess intrinsic motivation (self-motivation) and extrinsic motivation (pressure from outside). 
Feedback can provide feedback about the individual performance and a comparison to other users. 
Both intrinsic and extrinsic motivational factors can increase the quality of data entry. A comparison 
of data quality before and after the implementation of feedback will detect whether data quality 
feedback works. This aspect is explored in a different disease research registry and explained in the 
following chapter.
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5 REALISATION OF WEB-BASED AUTOMATED FEEDBACK
This chapter applies the framework of the previous chapter in the context of data quality demanding 
disease registries. With this case study we aim to assess if automated (web-based) feedback during 
data entry actually improves the overall quality of the data that is entered into clinical data registries
or not. We also consider the use of the systems more generally and whether the adoption and use of 
the systems encourages an uptake of data quality. Specifically, we track patterns of user behaviour 
through web-based registries and discuss the utilisation patterns and whether there are any indicators 
that might increase the motivation of end users to enter more data and/or data of higher quality.
5.1 Case Study on the International Niemann-Pick Disease Registry
5.1.1 Niemann-Pick Context
Niemann-Pick Disease (NPD) is a rare metabolic disease that is caused by an accumulation of fat cells 
in the liver, spleen, bone marrow and brain. NPD is categorised into three types (A, B, C). There are at 
present no specific cures for this disease, just symptoms that can be partially treated (Schuchman, 
2007). Researchers from six centres (Prague, Barcelona, Udine, Birmingham Children’s Centre, 
University of Birmingham and Dublin) collect disease specific information as part of the EU funded 
International Niemann-Pick Disease Registry (INPDR9) to gain a better insight into the basic biology 
and clinical management of the disease. The registry captures extensive data about clinical symptoms 
and results of diagnostic tests.
The data that is captured can have different processes used for data capture. The INPDR supports 
manual data entry by clinicians and associated researchers – along the lines of ENSAT, however INPDR 
also captures data from patients directly through web-based systems and mobile applications. Mobile 
apps for INPDR patients used for capturing data for diagnostic purposes was presented in Sinnott et 
al. (2015). The registry captures a range of items clustered into several categories: demographic data, 
biochemical results, family history, clinical history, treatments, disability scale, further investigations 
and completed visits. While “further investigations” and “completed visits” are non-mandatory, such 
information supports the clinicians and research community by providing insight into the progression 
of the disease. Visits support longitudinal data covering laboratory results, treatment plans and 
disability scales. At the beginning of the evaluation and feedback period, INDPR included 142 NPD 
Type C (NPC) patient records and 18 NPD Type B (NPB) patient records. This work thus focused 
primarily on NPC patient data only. 
To commence the work a baseline analysis of data was conducted. It was identified that the centres 
with the highest baseline completeness data were ITUD2 and CZPR1. However, the 21% completion 
rate of ESBA needs to be viewed in relation to their contribution of more than 100 patients into INPDR. 
Taking a closer look, the lowest scores are shown in treatment along with the visit information. 
Excluding ESBA, all scores would be 7-10% better (see Table 5-1). ESBA has far more patients entered 
however it has a lower overall data completeness level. 
9 www.inpdr.org
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ITUD2 2 0.90 1.00 0.96 0.67 1.00 1.00 0.00 0.82
CZPR1 8 1.00 1.00 0.96 0.54 1.00 1.00 0.00 0.81
IEDU1 3 0.67 0.89 0.71 0.11 0.90 1.00 0.00 0.66
UKBI1 3 0.67 0.67 0.64 0.00 0.67 0.67 0.58 0.61
UKBI2 23 0.93 0.91 0.89 0.13 0.17 0.15 0.06 0.53
Total 142 0.73 0.79 0.73 0.26 0.66 0.68 0.13 0.57
5.1.2 INPDR Study Design
To explore the benefits of real-time data quality feedback and community data quality feedback a 
staged observational study was developed to assess data completeness trends and the impact of data 
quality feedback categories (see Table 5-2) of the INPDR. 
Table 5-2 Study Design - 2 Stages of DC Feedback
 Stage I - No feedback (data collection)
 Stage II - Data Completeness feedback to the user
 Stage III - Stage II feedback with users average Data Completeness
 Stage IV - Stage III with community average Data Completeness (see Figure 5-1) 
 
Figure 5-1 Stage IV Data Completeness Feedback
During data entry, every user receives warnings and alerts if the data entered is implausible (see Figure 
5-2) or compulsory data is missing (see Figure 5-3). Within INPDR, the basic demographic patient 
information is captured when a patient record is initially created and this is all compulsory data. This 
includes a data element confirming that patient consent has been obtained. The actual compulsory 
(demographic) data is a very small subset of the total data that is to be captured within the INPDR 
however.
Figure 5-2 Warnings in INPDR
102
Figure 5-3 Missing compulsory data
This staged approach is in accordance to the motivation scale described in chapter 4.2. The human is 
driven (‘motivated’) by intrinsic and extrinsic factors. While intrinsic factors rely on self-motivation, 
extrinsic factors are based on pressure from outside with expectations that have to be fulfilled. Stage 
II & III assess whether the user is primarily driven by intrinsic factors. Stage IV assesses if the user is 
driven by comparison with colleagues. As noted, this could also be construed as ‘name and shame’.
Every stage needs a separate assessment. Ideally, each stage should go live after a fixed time window, 
e.g. 2 months, or after a given number of patients were entered, e.g. at least 50 patients were entered 
into the INPDR. Unfortunately, between January and August 2016 only 35 records from 7 different 
centres were entered into the registry. This amount of patient information is not useful to draw 
significant conclusions. A power calculation indicated a minimal recruitment of 358 patients within 6 
months. However, an analysis of data completeness scores can identify trends of quality and whether 
real-time feedback can reduce data inconsistencies or motivate the data entry user to enter better 
data.
Due to the low recruitment rate, Stage III went live after Stage II was live for 2 weeks. After both stages 
were combined in the final analysis. Data completeness of Stage II & III was analysed after 3 months 
and data completeness of Stage IV analysed after 3 months of Stage II & III (see Figure 5-4). 
Figure 5-4 Time of data export and analysis from INPDR
The results showed a general increase of data completeness in five of six centres. CZPR1 entered just 
one record within these seven months (before stage II), which was more complete than the average 
records. ESBA1 entered five records and slightly increased the data completeness, but this was caused 
by the entered record information, not by the data quality feedback. IEUD1 showed a significant 
increase of data completeness before Stage II by improving existing records. ITUD2 had a dramatic fall 
of data completeness, caused by entering more incomplete records into INPDR. UKBI1 reduced data 
completeness by around 6% between stage I and II&III, by entering one incomplete record. UKBI3
entered no records and updated one patient record in stage IV (see 
Table 5-3 where the number in brackets is the total number of patients entered into the registry at 
this time).
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Stage II & III
1-Aug-16
Stage IV
CZPR1 81.23 (8) 81.40 (9) 81.40 (9) 81.40 (9)
ESBA1 30.93 (103) 31.37 (106) 31.35 (107) 31.89 (108)
IEDU1 66.00 (3) 72.67 (3) 72.67 (3) 73.17 (3)
ITUD2 81.56 (2) 38.51 (17) 38.51 (17) 38.51 (17)
UKBI1 61.08 (3) 61.08 (3) 55.31 (4) 68.10 (6)
UKBI3 53.17 (23) 53.17 (23) 53.52 (23) 53.61 (23)
INPDR Conclusions 
The results of analysis of INPDR showed an increase of data completeness of existing records, however 
this needs a much larger sample size. To gain further insights into the DQF and a user’s 
intrinsic/extrinsic motivational factors, the study needs to be extended with more patients and patient 
related information. 
5.1.3 INPDR Discussion
This INPDR study design is a classical quasi-experimental study with a one-group pre-post test design. 
There is no actual control group because the data quality was measured from the same group before 
feedback was implemented into the data management system, i.e. there was a large collection of data 
entered into the INPDR before the feedback mechanisms were implemented. However, this study was 
performed to exclude a possible confounders related to data manager/data entry personnel that want 
to increase the data quality without using data quality feedback. Such confounders have the 
characteristics that they are directly associated with the outcome (higher data quality) and the 
exposition (data quality feedback). Monitoring increases the feedback rates that are reported to the 
data entry users and monitoring directly encourages the users to enter more data (see Figure 5-5).
Figure 5-5 Confounder: Monitoring visits
Confounders can be detected through various mechanisms. One example of a confounder in medical 
cohort studies is the age (high age influences an exposition and the outcome) of the subject or the 
gender (Rothman, Greenland, & Lash, 2008). Research in medical informatics can be biased by, 
ambiguous temporal precedence, selection of wrong conditions, events that happen concurrently 
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during the observation, maturation, regression of scores due to multiple interventions (features), 
attrition, testing, instrumentation and interactive effects (Shadish, Cook, & Campbell, 2002).
In such case studies, there are two ways to exclude confounders in the final analysis. Cohorts like the 
INPDR research community need to be stratified in two groups: one group that had monitoring visits, 
and one group that had no monitoring visits. A comparison of both groups could subsequently detect 
and exclude the confounder. A second possibility is a restriction, e.g. considering just users without 
monitoring in the final analysis. Other possibilities that deal with confounders that could not be 
applied in this particular case study are randomisation (one group with feedback and one group 
without) or matching of cases with controls (case-control study) (Rothman et al., 2008; Rothman & 
Monson, 1973).
This case study could also be influenced by events that impact on data completeness. One expected 
event is the entry of imaging, pathology or laboratory results. For example, such capabilities and hence 
data are not available due to local clinical processes, or where the results can only be collected and 
entered after a certain amount of time. Such localised processes can have a major impact on the 
evaluation and data quality and completeness, especially where potentially minor improvements 
through web-based feedback are lost in the noise of major local organisational data access and usage 
issues. 
5.2 Tracking and Monitoring User Online Data Entry Behaviour
To understand the data entry habits and impact of data quality feedback, it is also important to 
understand how often users are accessing the system; what records they are editing and how long 
they stay online for. This can be achieved through web-based logging tools. It is obvious that feedback 
only works if the systems are actually being used. 
Logging is not a new feature. Companies with medium and huge traffic on their webpages typically try 
to improve interfaces and design their application with support of logging and/or metadata 
information. One popular public user logging example is Google ‘My Activity’. In case the same Google 
account is registered on multiple devices (phone, PC, laptop, car navigation system), this approach 
offers a very detailed log of the use of various systems by a given user (see Figure 5-6).
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Figure 5-6 Example Google Logging
The literature describes the use of logging information in regards to the quality dimension of 
timeliness, which is also often referred as currency. In the clinical context, logging tools can track 
whether patient information is entered into the registry within a reasonable time period after the 
original data collection (Weiskopf & Weng, 2013). As a biomedical example, the translational research 
platform REDCap, a metadata-driven research registry, uses a ‘Data Logging Module’ to show every 
user data entry transaction and to provide a platform for data auditing during the lifecycle of the usage 
(Harris et al., 2009). ECRIN (described in previous chapters) provides a research network offering 
standards and frameworks for biomedical research in Europe, has addressed logging as minimum 
quality criteria for importing and uploading data into a research registry. It is also used “to maintain 
accuracy in identifying outstanding data” (ECRIN, 2010, 2013).
The majority of logging systems in clinical applications that are not used for security purposes are 
developed for event tracking. Patient events are tracked and clinical pathways suggested, often 
utilising other data (Z. Huang et al., 2014). Agosti, Crivellari, & Di Nunzio (2012) defined two research 
sources of general user logging: they focused on what the user actually entered and with regards to 
the preferences of the user. While the first point in this research is the evaluation and report of data 
quality, the second point is the analysis of user interaction with logging tools. One widely accepted 
tool is the Java-based library log4j. With this logging utility several levels of logs can be created. These 
level can be turned on/off or used to report debugs, fatal errors, report warnings, user interactions, 
or capture and report all information (Gülcü, 2012). This information is typically stored in a text file on 
the server where the web application is hosted (although this need not be the case and as a security 
issue it is generally preferred to store log files on other servers). Such log files can be analysed with 
other tools. Due to the volume of logging information that can be captured in large scale web 
applications, services like CouchDB and ElasticSearch can be used to clean and process the log files 
and subsequently identify events, e.g. logged in; edited record #23; logged out. The successor project 
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to log4j, LOGBack was designed by the developer of log4j (Ceki Gülcü). LOGBack is a more dynamic 
solution than other logging tools like log4j or SLF4J (Simple Logging Facade for Java)10.
Studying user interactions based upon log information provides the possibility to track the efficacy of 
implemented data quality tools and the possibility to draw conclusions about the user knowledge and 
motivation of data entry.
5.2.1 Logging in ENSAT
One of the tools developed during this research for the ENSAT registry has been a log analyser. Key 
actions within the registry that indicate interactions with the data need to be recorded (record 
creation, modifications, deletion, reads, etc.) A typical log file is shown in Figure 5-7. Understanding 
who has accessed and used the registry is an important part of the auditing demands of the VRE but 
also part of data security standards. The log analyser uses a combination of a custom log-parser 
software system with cloud storage and a NoSQL database supporting Map-Reduce based 
visualisation. The scale of the logging information can be very large (many Gb per year) especially for 
ENSAT with over 170 registered user accounts and an average of 10 extended visits per working day 
(a typical research user can spend around one-hour interacting with the application), and many 
significant actions within a given web session can occur. Efficient cloud storage and rendering 
solutions were therefore required so a NoSQL database was chosen as a high volume, scalable and 
easy-access data repository solution. This system was deployed on the National eResearch 
Collaboration Tools and Resources (NeCTAR11) Research Cloud – the national academic research cloud 
across Australia.
Figure 5-7 ENSAT Log file output
The MapReduce visualisation application provides a variety of views to interpret the record histories 
– through patient IDs, centre codes, individual users (see Figure 5-8). It then renders the information 
through different graph representations (timelines, pie charts, bar graphs, etc.), again with efficient 




Figure 5-8 Tracking ENSAT user activities through log analysis
The architecture of the ENSAT log analyser provides information for users and internal/external 
auditors (see Figure 5-9). All internet-based access attempts are logged (successful and unsuccessful) 
and all activity inside of the ENSAT registry is captured. The logging data itself is periodically sent 
through a CronJob to the log analyser, which parses and processes the raw log file data. The log 
analyser application utilises CouchDB, ElasticSearch and MapReduce on the NeCTAR cloud to support 
converting the log data into understandable (human readable) content. The visualisation itself uses a 
timeline library (timeline.js), HTML, Jquery, AJA, CSS, JS and the CouchDB API (all software languages 
and libraries are deployed on the NeCTAR servers to ensure scalable and robust processing of logging 
information. Auditors have access to all of this information. The logging itself encompasses a range of 
key user tracking features:
 user movement or activities within the registry, e.g. navigation;
 interactions of users with the registry, e.g. searching;
 creating records;
 updating records;
 user logins, and
 access to and use of (specific) patient records.
The original log analyser was implemented by Effendy and its architecture and performance are 
described in Effendy (2014).
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Figure 5-9 ENSAT registry logging architecture adapted from Effendy (2014)
The visualisations of the logging features are accessible to all members of the ENSAT research 
consortium. Dashboard, timelines and bar charts provide insights into user activities, their interactions 
and a record of the registry use as a whole. 
It is important to note that the logging information provides two key services: to capture the history 
of the use of the ENSAT registry and to show the longitudinal history of the data that is collected on 
particular patients. Such a history is shown in Figure 5-10. This shows the history of editing of a 
particular patient (from Munich, Germany). The timeline shows all logged information from the 
original surgery and diagnosis in 2008 through to multiple treatments and follow up that have 
occurred throughout the patient’s clinical care. This information flow captures the editing information 
captured in a log file. Similar capabilities exist to show the patients that are accessed and used the 
most in the registry, e.g. in search terms, although it is noted that this information is often limited by 
the security settings related to the individual patient records.
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Figure 5-10 Visualisation of patient longitudinal information captured in log files
5.2.2 Google Analytics and ENSAT
Google analytics is a service to track user interactions with websites. The typical data that is collected 
includes country of origin, city of origin, session times and redirects. Such information can be used for 
features like budgeting and cost planning. It is traditionally used for benchmarking of web pages. For 
clinical research, Google analytics provides direct possibilities to monitor user interactions, session 
times and calculate a count of pages visited during a particular user session. This information is similar 
to logging tools, but Google provides this service for free for all registered users (see Figure 5-11). 
Figure 5-11 Example of Google Analytics Interface for ENSAT
It is important that data from services and platforms such as Google analytics is interpreted to 
contextualise clinical user patterns (Crutzen, Roosjen, & Poelman, 2013). For instance, how long does 
a user stay on a site, how long does the user need to complete a particular record? Whilst a useful 
model to understand the global access and use of the ENSAT website, such information does not allow 
finer-grained access to information on use of the registry and user/session related information, e.g. 
how long particular users log in for and whether are frequent accessing the system. Nevertheless, 
tracking of information on the web site gives another dimension of the uptake of the ENSAT systems 
more generally.
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5.3 Log Analysis Results of User Activity
5.3.1 ENSAT Log Analysis
The first assessment of the user logs provides a range of insights into the practical handling and usage 
of the ENSAT registry. In the observed time period, a genetic researcher within the ENSAT consortium 
recorded 32.7% of all activities when updating patient records (see Figure 5-12 and Figure 5-13). 
Figure 5-12 ENSAT updated records (user)
Figure 5-13 ENSAT Updated records (centre)
The research centre in Spain was by far the most active centre over the observed time. The centre in 
Spain receives biosamples and tumour tissues of adrenal tumours from all ENSAT centres to analyse 
genetic information. This information is entered into the genetic record of every subject that is 
captured in the ENSAT registry. Other centres did not show any significant activity in the observed 
time period. This may be because no patient information was entered or the centres only participated 
in biomedical basic science. For example, other centres like NLEI resample tumour tissue only for local 
research purposes. 
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Such data can track user activities that can inform data quality feedback and interaction. Logging 
provides the possibility to contextualise and inform the assessment of the efficiency of data quality 
feedback. Google analytics also provides key features that can be used to assess the overall utilisation 
and external (international) visibility of the system.
5.3.2 ENSAT Google Analytics Analysis
For the evaluation of user interaction within ENSAT, the year 2014 was chosen. In 2014, the EURINE-
ACT case study with investigator and community feedback was performed. Centres were visited from 
January to May; reports were mailed to the community between March to September and the 
consortium was updated about the data quality assessments in April (Investigator) and November (all 
ENSAT members).
In 2014, an average of 435.67 sessions occurred per month. After the initiation of the ENSAT data 
quality project at the end of January, the user activity increased by 200 sessions (see Figure 5-14). 
Three German centres were visited at the end of January/beginning of February. By mid-February, the 
largest ENSAT centres that provided ACC information in Paris were visited, followed by three visits in 
Italy at the beginning of April. Unfortunately, the statistics showed no direct correlation between the 
data quality and the user activities. There were also no other events in the research consortium at this 
time (increased patient entry, new record forms, new clinical trials), so it was only possible to detect 
a correlation between the monitoring visits in Germany and France with regards to increased user 
activity. Specifically, we consider the motivation and data entry associated with the EURINE-ACT study. 
There was no increase in user activity detected after the visits to Italy, which might be due to the fact 
that the Italian centres where mainly focused on genotype data and the work/research balance for 
young medical scientists is unfavourable as explained in chapter 3.2.2.
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Figure 5-14 ENSAT Registry User activity 2014
Google analytics of the ENSAT registry commenced in January 2014, and no comparison data prior to 
this year is available. Nevertheless, we observed that in 2015 there was an average user activity of 
694.08 sessions per month performed up to January 2016, and a further 1299.78 sessions per month 
up to September 2016. This is most certainly caused by the increased number of users and study 
activities. It is noted that the average activity was increased in the month of February and March 2014. 
This leads to the conclusion that monitoring visits and regular feedback forms a factor in the increase 
of user activity.
5.3.3 INPDR Log Analysis
Log analysis in INPDR was performed with Apache text analysis tools and use of a MySQL database
(Rui, 2016). Every new session was logged and the number of actions performed on each record was 
recorded and subsequently analysed. In this analysis the time was measured and the pages through 
which the user performed particular actions. A typical example showing the creation, 
edit/modification and deletion of information is given in Figure 5-15. It is worth noting that the actual 
identification of records in the log files was made possible through the REST-based architecture, where 
http commands such as PUT, POST specifically included the record end-point (the uniquely identified 
record identifier such as NPC-UKBI-12).
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Figure 5-15 INPDR log analysis
The figure shows that some centres only performed search queries, i.e. discovering patients that meet 
particular criteria. Such queries take little time to run and the user sessions are often far shorter, e.g. 
1 minute or so. Other centres (Lyon, France) entered data for NPA and NPB patients that took of over 
3 hours of online data entry time (Rui & Sinnott, 2016). 
Similar to the data completeness analysis and primarily due to the lack of adoption of the platform 
(compared to ENSAT), no significant conclusions can be drawn from the INPDR log analysis. The users 
have a range of usage patterns showing that they have only sporadically used the system for data 
entry. This makes any detailed results difficult to establish. One other dimension to data entry is 
through the patients themselves. INPDR has developed a range of game application on mobile devices 
to help improve the diagnostics of children (Sinnott et al., 2015). Other mobile apps targeted to 
specific quality of life questionnaires are also being completed. It is hoped/expected that these will 
improve the quality of the data and the usage of the systems more generally.
Finally, it is worth discussing the importance of non-technical considerations on data quality. What 
makes a community such as ENSAT flourish whilst others such as INPDR struggle to truly galvanise the 
international community. A large part of this is getting to a critical mass of data, but it is also important 
that the clinicians and researchers themselves have extrinsic motivation. In ENSAT this is often through 
the very many clinical trials and studies that are taking place that demand and drive use of the registry 
to improve the data quality. For INPDR, at present no clinical trials have yet been established. It would 
be expected that when this arises, the usage and quality of the core registry data would increase 
considerably.
5.4 Chapter Conclusions
Unfortunately, for INPDR no significant conclusions can be drawn in regards to the impact of feedback 
on data quality. The primary cause of this is insufficient data and record entries within the observation 
period. Still, INPDR is a fully working platform that went through all of the proposed feedback stages. 
It was intended that Stage 2 should be as long as all other stages, however due to the observed low 
data entry, this stage was combined with stage 3 which itself went live after 2 weeks of stage 2. The 
justification for this was that both stages assess intrinsic motivational factors. Therefore, no other 
outcome could be detected in stage 2 than in stage 3. 
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Furthermore, it was shown that defining mandatory items works for improvement of data 
completeness in ENSAT and to a lesser extent in INPDR (where only a small number of data items have 
been defined as compulsory). It is expected, that all optional data items depend upon improvements 
to user motivation. Therefore, data completeness of mandatory items can be more readily increased 
and actually enforced than data completeness rates of optional items. 
ENSAT logging and INPDR case study explored whether the patterns of use and impact on motivation 
of the data entry impacted on the overall data quality. The results here were mixed due to the amount 
that INPDR was used over the time period. Furthermore, it should be noted that to generalise the 
results, research hospitals and research units need better access to novel technology and solutions
should be equally applicable to those centres in rural areas or in third world countries. Researchers
needs to be more motivated to participate in research by showing them their impact on the research 
and clinical study objectives. 
User logging information and general uptake is a key for the assessment of the efficiency of data 
quality feedback. Logging information is a rich source of information both for auditing and for 
visualisation purposes. During the logging analysis of INPDR and ENSAT technical solutions were 
developed to explore many factors of the usage. A more detailed analysis of the visualisations and the 
impact they have on data quality combined with resultant data quality scores is important to 
understand.
One major challenge with the INPDR analysis was the fact that once centre (Barcelona) has entered 
the vast majority of data into the registry with a low overall data completeness rate. Specifically,
Barcelona entered 108 patients with an average completion rate of 31%. As a comparative example,
Prague has entered 9 patients and an average completion rate of 81%. The interpretation of any 
meaningful results from the feedback systems that were put into place needs to be carefully 
understood.
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6 USAGE AND ROLE OF PATIENTS ON DATA QUALITY
This chapter considers other usage patterns and their impact on data quality of disease registries. We 
also consider other dimensions of motivation and the impact that they can have on data quality in 
clinical registries. Specifically, we consider the impact of patients entering data themselves. We 
hypothesise that patients that have a disorder/disease will be more motivated to enter better quality 
data to help researchers and clinicians find cures for particular diseases. Given the ubiquity of mobile 
devices, we explore the role of such technology for data capture and investigate whether patients 
achieve higher data quality than researchers themselves. This chapter considers the example of the 
Environmental Determinants of Islet Autoimmunity (ENDIA12) project and the mobile applications that 
have been made available for patients to enter their own information. 
6.1 Mobile Health
In 2007, Steve Jobs, former COE of Apple Inc., introduced three new products to the public: a new 
“widescreen iPod with touch controls”, a “revolutionary mobile phone” and a “breakthrough internet 
communicator”. His team put all of these devices in one mobile device, the iPhone. The following year 
changed the way in which mobile phones evolved into mobile communication devices that supported 
all aspects of communication: speech, video and text. Mobile devices are now an integral part of 
everyone’s life. With the constant access to news, information, games and apps that support daily 
activities, new dimensions of data collection are now possible. This includes apps that can be used to 
collect daily information that can support the clinical and biological data typically collected in disease 
registries.
Nearly 75% of the world now has mobile access and developing countries have more mobile coverage 
than the developed world (ICD, 2012). The approach to support health related circumstances with 
mobile applications – so called mobile health (mHealth) offers many potential opportunities to 
capture and indeed deliver health-related data. mHealth has no general definition nor a primary public 
health related context that it can be applied to (World Health Organization, 2011). According to Kay 
et al. (2011) “mHealth is being applied in maternal and child health, and programmes reducing the 
burden of the diseases linked with poverty, including HIV/AIDS, malaria, and tuberculosis (TB)” (World 
Health Organization, 2011). Mobile health applications (apps) have been developed and applied to 
multiple disorders including developmental disorders, cognitive disorders, substance-related 
disorders, psychotic disorders, mood disorders, anxiety, eating and sleep disorders. Many apps have 
been developed for collecting data automatically from device sensors, e.g. tracking users mobility (or 
lack of mobility) through the location-based services that many devices now support whilst others 
have been developed for targeted data entry to collect information specific to the condition of interest 
(Luxton, McCann, Bush, Mishkind, & Reger, 2011). 
Several systematic reviews showed that mHealth has a high potential to improve treatments or 
diagnostics of diseases, but more research must be performed (Catalani et al., 2013). In HIV research, 
a systematic review investigated mHealth applications that support the prevention, care and 
treatment of HIV. In 62 analysed articles between 2001 and 2011 they discovered that the majority of 
all studies were evaluation studies (56%), while they categorised all studies into monitoring, 
operational and evaluation research. Catalani et al. (2013) concluded that mHealth applications have 
to be implemented into the HIV treating cascade and that “the overall rigor of mHealth research […] 
needs to be improved …” (Catalani et al., 2013).
Similar findings can be confirmed through other systematic reviews, which investigated the impact of 
mHealth applications in chronic disease management. The authors selected 107 articles between 1980 
12 www.endia.org.au
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and 2014 that met the inclusion criteria and described mobile applications that support diabetes 
mellitus, cardiovascular diseases, chronic lung diseases and hypertension. The research team 
identified several used tools: SMS, video messaging, applications or devices that added extra 
capabilities to the phone such as blood pressure monitors. They defined “mAdherence” as the core 
motivation whereby the patient is actively involved in the care of their disease through such mobile 
apps. It has been shown that, in 15 out of 27 randomised controlled trials mAdherence has directly 
impacted on patient’s adherence behaviour. On the other hand, the authors conclude, that there is 
no strong evidence that mHealth improves patient’s adherence. Recognition that more research has 
to be performed regarding low patient motivation through mobile devices was discussed in (Hamine 
et al., 2015).
A third systematic review by Aranda-Jan et al (Aranda-Jan et al., 2014) investigated the advantages 
and disadvantages of mHealth projects in Africa. Of the 44 research articles reviewed the authors 
discovered eight mHealth research categories: adherence, motivation/training of staff, evaluation 
research, stock management, patient education, surveillance, data collection and mHealth overviews. 
The review of articles classified as staff training, support and motivation (n=2) described two pilot 
studies that supported rural care scenarios and giving easier access to clinical information and 
facilitating data sharing between physicians. Research articles also described the impact of mHealth 
on data collection, transfer and reporting (n=10) where it showed that the use of SMS for data 
collection improves the overall data quality. However, several issues need to be addressed: low 
technology skills of staff members, high setup costs and risk of theft. The authors conclude that the 
“evidence remains poor” regarding the positive impact of mHealth applications in Africa (Aranda-Jan 
et al., 2014).
All three systematic reviews performed a literature analysis review of mHealth technologies applied 
to developing countries settings, to chronic diseases and to important infectious diseases. Whilst all 
three research groups established a positive impact of mHealth on the treatment, patient adherence 
and goals of data collection, they recognised that further research needs to be performed that can 
evaluate the findings and show a more general and more significant impact of mHealth technologies. 
Tomlinson et al. (2013) summarise this as, there is “insufficient programmatic evidence” of mHealth 
applications. The authors also recommend improvements of current standards and development of 
new standards and guidance for mHealth solutions. This is needed to scale-up mHealth in low and 
middle income countries, to implement factorial designs, to focus on user behaviour and to establish 
an open mHealth architecture (Tomlinson, Rotheram-Borus, Swartz, & Tsai, 2013). 
The research group of Deborah Estrin (University of California) proposed an open mHealth 
architecture13, which supports the interconnectivity of multiple mHealth apps (C. Chen et al., 2012; 
Estrin & Sim, 2010). The idea is that every user generates their own data with various applications 
running in the Cloud, which is managed by a centralised system (Estrin, 2014). Several applications 
could focus on special medical fields such as rheumatic diseases (Say et al., 2015) or HIV (Swendeman 
et al., 2015). Many standards for the evaluation of mHealth technologies have been published (Kumar 
et al., 2013), but the concrete evaluation and uptake of these standards remains under-achieved.
Nevertheless, mobile technology is advancing and almost every human will have access to a mobile 
device. As such mHealth needs to support a wide range of stakeholders including health organisations, 
professionals and patients to improve the prevention, diagnosis and treatment of a spectrum of 
diseases. In the previous chapters the intrinsic and extrinsic motivation factors of researchers and 
clinicians was assessed through collaborative research registries. In this chapter we consider the 
motivation of patients in clinical trials and if patients are driven to offer better data quality given they 
13 www.openmhealth.org
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are the ones with the actual diseases or the risk of such diseases developing to themselves or their 
offspring.
6.2 Patient Incentives
The first approach to check whether patients can drive data quality is to assess the motivation of 
participation in clinical trials themselves. In a survey of 153 healthy participants of a volunteer drug 
injecting clinical trial, seven primary motivational categories were identified (see Table 6-1) (Fry & 
Dwyer, 2001).
Table 6-1 Motivation to participate in trials (healthy volunteers) (Fry & Dwyer, 2001)
Motivation % (n)
Economic gain (money) 46 (71)
Citizenship (for the community) 38 (58)
Altruism (help) 19 (29)
Personal satisfaction 17 (26)
Drug user activism 16 (24)
Seeking information/assistance 5 (8)
Non-specific 5 (8)
Other research showed that people participating (n=13) in qualitative research are driven by: 
subjective interest, enjoyment, curiosity, introspective interest, social comparison, as well as 
therapeutic, material and economic interest (Clark, 2010). 
Quilici et al. (2013) investigated the impact of using SMS technology after coronary stenting. The 
research compared the adherence of patients in a mHealth group with a control group and discovered 
that those in the mHealth group had a better completion rate than the control group (Quilici et al., 
2013). Another article examined the design of a mobile application for diabetes mellitus type 1 
patients (n=20, between 12-16 years). They implemented gamification features and discovered that 
frequency of blood glucose sampling improved, however they identified that more research utilising 
more data was needed (Cafazzo, Casselman, Hamming, Katzman, & Palmert, 2012). This research 
shows the significance of introducing mobile devices in daily care of patients and that they can indeed 
increase data collection, especially with some form of rewards. Other studies (Tatara, Arsand, 
Skrøvseth, & Hartvigsen, 2013) have confirmed these results with focus on type-2 diabetes patients. 
Their focus was on visualizing automated feedback from patients about blood glucose and their 
activity levels (steps walked) initially without data entry. Feedback was used to show the patient the 
journey to their goal (relation between blood glucose, physical activity and nutrition). During 
interviews, two of the 12 patients talked about a lack of motivation for self-management. The authors 
concluded that their qualitative study design only provided limited generalizable results, because the 
majority of all participants were highly motivated (Tatara et al., 2013).
In summary, technological advancement through mobile devices and apps are increasingly 
implemented into personalised health tracking, tracking movements like ‘quantified self’ and open 
mHealth platforms are increasingly required. They can be beneficial for the community and 
researchers, especially due to their always-accessible nature. Often they can be used for collecting 
data automatically, i.e. without explicit data entry through use of the accelerometer and the location-
based services now existing in mobile devices. Systematic reviews discovered improvements in data 
collection and motivation, but the evidence is not yet established about their impact on data quality 
due to the typically small population sizes. Furthermore, more research has to be performed regarding 
the behavioural change of users and the impact on data quality itself (Sinnott et al., 2015).
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To explore this, a case study was performed where the user interaction was logged and conclusions 
about the efficiency and quality of patient data entry explored. This was conducted in the context of 
the Environmental Determinants of Islet Autoimmunity (ENDIA) project.
6.3 ENDIA Context
The Environmental Determinants of Islet Autoimmunity (ENDIA) project was funded by the Australian 
National Health and Medical Research Council (NHMRC), the Juvenile Diabetes Research Foundation 
(JDRF) and the Helmsley Charitable Trust in 2013. The aims of ENDIA are to investigate the 
environmental factors that might be involved in the onset of type-1 diabetes (T1D) and specifically 
those related to pancreatic islet autoimmunity. ENDIA is a prospective cohort study across Australia 
(n=11 centres) with a recruitment aim of 1400 subjects. The inclusion criteria for participants include: 
age (less than 6 months) and where an infant has a first-degree relative with T1D. Mothers and infants 
are monitored before birth and subsequently followed until their early childhood. The trial aims are 
focused on the development of T1D during pregnancy, the microbiome during the first 3 years, weight 
changes and infections (Penno et al., 2013). The clinical databases include an extensive range of 
phenotypic data on both the parents and the pre-born and infant child. This includes extensive dietary 
information on the mother and more generally on the environment in which they live. This data is 
captured over an extended time period as shown in Figure 6-1 (for a small subset of the patients). 
Each column corresponds to a 3-month period (first trimester, second trimester, third trimester, birth, 
3 months, 6 months etc.). At each time period, an extensive amount of information needs to be 
collected.
Figure 6-1 ENDIA Phased Data Collection
Many of these data forms are especially data demanding and place considerable onus on the data 
entry personnel and indeed the study participants (mothers/fathers). For example, the dietary 
information guidelines alone are based on a 167-page manual that documents all of the dietary –
related data items that need to be collected and the processes that must be taken to collect the data. 
The actual number of patients entered into the system is shown in Figure 6-2 and the number of 
patients (involved) per site shown in Figure 6-3. 
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Figure 6-2 ENDIA Recruitment Actual (October 2016) and Target (September 2017) 
 
Figure 6-3 ENDIA Recruitment by Site
Audit information on access and use of the ENDIA database has been collected since the start of the 
project in 2013. The evaluation of data completeness was implemented in the registry, similar to 
INPDR. Analysis of data was conducted to detect potential data quality issues with specific focus on 
incompleteness and any identified data inconsistencies. A log analysis of the use of the registry was 
conducted through CouchDB using MapReduce and the Python API (see Figure 6-4). 
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Figure 6-4 Example of ENDIA logging information
All user actions (login, deletion, withdrawal, update or creation of information) were analysed. For 
visualisation the software d314 (data-driven documents) was used. D3 is a JavaScript based library 
suitable for a range of data visualisation scenarios. The advantage of D3 is that it does not require a 
“toolkit-specific lexicon of graphical marks” (Bostock, Ogievetsky, & Heer, 2011). As such, it can be 
used on a large variety of platforms because it selects the object not based on the mouse curser, but 
based on the data element, class attribute or tag names (Bostock et al., 2011). The library has a large 
amount of different layout schemes including calendar views, box plots, scatterplots, bar charts, 
geographical maps, hierarchical edge bundling and force-directed graphs.
A key aspect for understanding the quality of the ENDIA data is the patterns of data entry by data 
entry personnel – these are typically research nurses employed at the sites that are involved in ENDIA. 
Figure 6-5 shows the times of day that data entry personnel typically enter data into the registry. 
These results are obtained through running MapReduce algorithms focused on the specific time of 
day for any data entered into the registry. Importantly, through such algorithms it is directly possible 
to detect the statistical patterns of individual users and centres. For example, it is possible to 
understand how often do personnel edit the same records and at what point does this become the 
optimal – in terms of the quality of the data that is entered. Whilst one would assume that the quality 
and completeness of the data increases indefinitely as more edits are made, this is not typically the 
case. Since the amount of data that is to be entered follows a longitudinal timeline, different forms 
are activated at different time periods, e.g. when the infant has reached 6 months the 6-month data 
entry form is activated and available for editing. 
14 https://d3js.org
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Figure 6-5 ENDIA Timeline of Data Edits
It was detected, that users with at least 35 edits of the same record have the highest data 
completeness scores (see Figure 6-6). This is based on the completeness of the records that have been 
entered up to that point and not all possible data that might be completed up to the child reaching 30 
months (V10).
Figure 6-6 ENDIA edits vs. data completeness
The centre with the highest data completeness rates (up to October 2016) is the Women’s & Children 
Hospital in Adelaide. It is also noted that this centre has an average amount of edits compared to the 
centres with lower data completeness rates. This might be construed as data completeness is not 
influenced by average and total record edits of the centres. However, Barwon Health has only 10 
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subjects entered in the protocol and has achieved a data completeness of 73%. The Women’s and 
Children’s Hospital and Barwon Health can’t be compared because of the large discrepancy in the 
number of records entered into the registry (see Figure 6-7). 
Figure 6-7 ENDIA average completeness rates (centre)
This indicates that average numbers of edits do not automatically lead to higher data completeness 
rates – at least for ENDIA. Westmead Hospital in Sydney has the highest average but the second lowest 
overall completeness score. They have also entered less than half the number of patients (43) 
compared to the other centres, e.g. Mater Hospital in Brisbane (96). From this, one can conclude that 
data entry personnel in Westmead may require further training or guidance in using the system. As 
identified in previous chapters, this may also be an artefact of the local processes and environment in 
which study personnel are collecting data. A discussion with the principal investigator and the report 
of these findings may thus be advisable.
6.4 Can Patients drive Data Quality?
As shown in Figure 6-1, there are numerous (longitudinal) points where patients are expected to 
provide information. One of the key aspects of ENDIA is considering how environmental factors that 
can impact on the onset of type-1 diabetes for children. One of the major environmental 
considerations under investigation within ENDIA is dietary information. As noted, this information is 
extensive with 167-page manual covering all of the potential information that should be collected in 
the system. In the first two years of the project it was identified that the research nurses were not 
systematically collecting this data in their visits and discussions with the patients. To help tackle this, 
it was decided to develop mobile applications that could allow the patients themselves to enter their 
own dietary data directly. 
This mobile app was introduced in April 2016 and has a small cohort of users (n=20), however this is 
gradually increasing, as more patients are involved in the study. The app was delivered through both 
Apple iOS and the Android platforms and made available to all patients involved in the study. It is 
noted that whilst these apps are available within the iPhone AppStore and Google Play environments 
and hence downloadable by anyone (including those outside of the study). The app itself requires an 
activation code that is created by the ENDIA study personnel for the patients that wished to be 
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involved in using the mobile app. The app itself focused on a subset of the key dietary intake questions 
that were essential with 50 different data items to be entered each week. The app was developed 
through close interactions with the ENDIA study teams and evaluated initially with a few patients, 
before being made available more widely to the ENDIA patient cohort. Figure 6-8 to Figure 6-11 show 
some of the core functionality of the mobile application that was developed for dietary information 
collection. Figure 6-8 shows the initial opening screen of the application (after it has been activated). 
Figure 6-9 shows the weekly dietary forms that have to be completed by the patients. As noted there 
are no identifying information that tie the app to the specific patients themselves, e.g. their names, 
dates of birth etc. All patients are assigned a unique code (e.g. VIC-MEL-MEG-001 for the first (001) 
dummy patient from Victoria (VIC), Melbourne (MEL), Melbourne eResearch Group (MEG)).
A small subset of the data that is collected by the dietary form is shown in Figure 6-10. This can be 
sent directly to the ENDIA database (Figure 6-11) or saved and edited. Once the dietary information 
has been submitted for a particular week, the data is sent to the database and a local (non-editable) 
copy of the data stored on the mobile device. That particular week is then no longer possible to 
complete by the end users, i.e. the week is greyed out. 
The mobile apps also include feedback mechanisms (notifications) that can be sent to the patients to 
remind them to complete their dietary information. The apps also include a range of data quality 
enforcement capabilities directly. Thus the apps require that all of the data for a particular week is 
collected and they raise warnings if patients attempt to submit incomplete data. The apps also do not 
allow data to be entered in the future, however they do allow for previous (historic) non-completed 
or partially completed dietary information to be entered and submitted to the ENDIA database.
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Figure 6-8 Patient Select Figure 6-9 Weekly overview
Figure 6-10 Survey Example Question 1 Figure 6-11 Saving actions
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Before the ENDIA mobile app was developed for the patients, nurses and participants met directly 
(face-to-face) and patient related dietary information collected. In October 2015 it was identified that 
the data dropped by more than 20% - due it was presumed to the verbosity of the data to be collected 
and the fact that the data had to be continually collected each week. With the implementation of the 
mobile app in April 2016, it can be observed that the overall completion rate increased slightly (see 
Figure 6-12) although this is far from 100% completion rates as originally hoped/expected by having 
patients enter their own data at any time. This may be an artefact of new technologies needing more 
training time and support for patients to enter more data. 
Figure 6-12 ENDIA data completion rate
The overall completion rate for the dietary information has improved since the mobile app went live. 
However, the overall completion rate for ENDIA as a whole remains a challenge. Indeed, as with any 
major study such as ENDIA, the attrition rate of patients being initially enthusiastic and/or convinced 
to be involved can gradually wane as shown in Figure 6-13.
Figure 6-13 ENDIA dropout trend (September 2016)
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The evaluation of the ENDIA study and patient engagement through the use of mobile technology 
remains somewhat inconclusive. At present more patients and more time is needed to systematically 
evaluate the improvement in data quality achieved through patients being self-empowered to enter 
their own data. A further factor in this is the feedback that patients themselves receive. Simply asking 
patients to enter data with no reward may not be continually sustained. Feedback mechanisms 
currently under consideration include targeted reports to the patients that benchmark their baby with 
other babies involved in the study. ENDIA is also a great adopter of social media with Facebook groups 
established. This has shown direct correlations and engagement with the study with targeted 
recruitment activities resulting directly from the periodic updates to the Facebook groups (see Figure 
6-14).
Figure 6-14 ENDIA Social Media Engagement
This model of adoption of social media is another mechanism to keep the participants involved and 
motivated. Such models of using the web and targeted technologies offers another dimension to web-
based feedback proposed here that targets the specific needs of the patients and families (Moorhead 
et al., 2013; Nurse et al., 2014).
6.5 Chapter Conclusions
Through the technological advancement and the availability of mobile devices, nearly every human 
now has access to the Internet from everywhere. mHealth technologies are increasingly important 
and will be a key part of new research initiatives. There is still no significant evidence that the 
application of mobile devices in clinical care has quantitatively improved data quality and data capture 
processes. This chapter has presented an approach based on an experimental pre- and post-test 
regarding the change of data completion and data quality in the ENDIA project focused specifically on 
dietary information considering the research nurse (pre-) and the patient (post-). 
The results suggest that patients do capture slightly more data through the mobile apps, however they 
do not yet achieve the desired data completion rates. Furthermore, the study design needs to be 
improved regarding post-tests and longer observation times in order to draw significant conclusions. 
Thus ideally having patients enter the data themselves through the web application and then through 
mobile applications could be assessed and whether the mobile technology itself has systematically 
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increased the quality of the data in the registry. The data shows that there is an increased trend of 
data completion, which can in part be based on the learning curve of trial subjects. As time progresses 
and more data is collected, we would be able to assess more rigorously whether patients offer better 
quality data as they are directly (intrinsically) motivated.
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7 IMPACT OF INVOLVEMENT IN CLINICAL STUDIES ON DISEASE REGISTRY DATA
QUALITY
This chapter explores how involvement in clinical trials and studies can influence the quality of data in 
disease registries. We focus specifically on two clinical trials associated with the ENSAT registry: the 
Prospective Monoamine Tumour (PMT) study and the prognostic value of urine steroidobolomics in 
patients with adrenocortical tumours (EURINE-ACT) study. We assess whether centres that have a 
direct involvement in these clinical studies have improved the quality of the data in the data registry 
overall, and/or whether the data quality has only improved with regards related to the data required 
for the clinical trials themselves. We consider participating centres in the studies and the lead study 
sites and the role of vested interest. Thus in this chapter we seek to identify the extrinsic motivational 
factors that can improve data completeness and data quality. Implicit in this assessment is the 
relationship with the central disease registry and the associated clinical studies. This motivational 
factor can be considered directly when one considers that the data can flow from the disease registry 
to the clinical study and vice versa. We describe some of the capabilities and challenges in facilitating 
such data flows through ENSAT.
7.1 Data Interoperability
Key to the establishment of disease registries is the knowledge exchange between collaborators, and 
allowing others to take advantage of centralised and shared data for new trial intentions and allowing 
secure access to any associated biomaterials. Literature in this area of research is often labelled as 
‘data exchange’, ‘data warehousing’ and/or ‘data pooling’. Implicit in this is ensuring data 
interoperability and tackling data heterogeneity. 
For data interoperability several clinical data standards such as CDISC15 (Clinical Data Interchange 
Standards Consortium) or HL716 (Health Level 7) are now well established, both in industry and 
academia. These standards have been developed to enable interoperability of medical data in clinical 
care and medical research. CDISC has different data models. CDISC-ODM17 (Operational Data Model) 
is used for data interchange between regulatory submissions and (meta-) data collected in clinical 
trials. EDC systems can write ODM compatible files and thereby strengthen the network between 
clinical health records and CRFs (Ohmann & Kuchinke, 2009; Prokscha, 2007). Other CDSIC models are 
used for laboratory purposes (CDISC-LAB 18 ), study data tabulation (SDTM 19 ), analysis datasets 
(ADaM20), protocol representation (PRG21), standards for exchange of non-clinical data (SEND22) and 
case report tabulation data definition specifications (CRT-DDS). On the other hand, HL7 is widely used 
in healthcare data exchange (Ohmann & Kuchinke, 2009) with rich and extensive information models 
and associated messaging capabilities. 
Every standard has its own purposes and the implementation of any given standard is driven primarily 
by concerns about costs, quality, patient safety and knowledge transfer speed from bench to bedside 
(Richesson & Krischer, 2007). The Biomedical Research Integrated Domain Ground (BRIDG23) project 
developed a data standard for biomedical research that provides a semantic foundation for 











Biomedical Informatics Grid (caBIG) project focused on data exchange and processing in the cancer 
domain also supported similar functions (Buetow & Niederhuber, 2009). The stakeholders of these 
domains included CDISC, HL7, NCI and the US Food and Drug Administration (Ohmann & Kuchinke, 
2009). It is worthwhile noting that in 2011 a report on caBIG raised significant questions about the 
effectiveness and oversight, and its budget and scope were significantly trimmed. In May 2012, the 
National Cancer Informatics Program (NCIP) was created as caBIG's successor program (Mongkolwat, 
Kleper, Talbot, & Rubin, 2014). 
In these efforts it was shown that CDSIC-SDTM was a helpful tool for data warehousing and CDISC-
ODM was suited for clinical trial data and trial audit information (Kuchinke, Aerts, Semler, & Ohmann, 
2009). ECRIN requirements recommended the use of CDISC-ODM to target data especially in CSV or 
XML files. However, it was identified that, despite the advantages of single centre clinical trials, it was 
“impractical… to insist on the use of specific data standards” (Ohmann et al., 2011). In short, they 
identified the major challenges of data heterogeneity and IT heterogeneity across the clinical 
landscape: from primary care, to secondary care through to clinical research systems and databases. 
A multitude of hospital systems exist and mandating any given standard or solution was impractical 
and unworkable especially given the demands for sustaining existing (legacy) systems. However, many 
reports have stressed the importance of standards and harmonisation in large multicentre trials 
(ECRIN, 2013; Ohmann et al., 2011).
In this context, it has also been recognised that there is a lack of defined research data standards for 
descriptive information including the study design, the type of randomization, data blinding and 
standardised (or commonly accepted) coding of record forms (Richesson & Krischer, 2007). It was also 
shown that for clinical care - case report forms in areas of physical exams, medical history and 
eligibility criteria have typically no established named standards and ad hoc approaches are typically 
manifest (Richesson & Krischer, 2007).
The GCP Inspection Group recommended an implementation of described data standards into clinical 
research databases to simplify data exchange with hospital systems (GCP Inspections Working Group, 
2007). While the majority of volunteers in CDISC have a background in biotechnology (51%), only 21% 
have an academic or government-related background (Souza, Kush, & Evans, 2007). The GCP 
Guidelines suggest that long-term storage of essential trial-related documents and data has to be 
captured in study databases and subsequently address longer term storage and preservation demands 
(International Conference on Harmonization, 1996). Often heterogeneous data management 
solutions, even in the same institution, make new trials difficult to undertake or in certain cases, 
difficult to understand and interpret the results (Kuchinke et al., 2009). Ideally data standards such as 
CDISC-ODM for data exchange have to be applied on data sets in a more rigorous and widely adopted 
(ubiquitous) manner (Richesson & Krischer, 2007). It was further argued that this should be mandatory 
to achieve interoperability of clinical and biomedical datasets (Brandt et al., 2006).
Data standards are recommended for virtual (collaborative) research environments and especially 
those in multicentre research settings. In ENSAT, data has largely been defined by its purpose for the 
clinicians that are involved in the individual centres. Consensus and agreement has been a core 
achievement of the broader ENSAT network and whilst all hospitals involved have their own 
independent IT systems in place, agreement on the core data to be captured in the centralised 
databases has been achieved. In particular, every working group (NAPACA, ACC, PHEO, APA) defined 
their own relevant data needs (data variables) including the data field to be captured and the range 
and purpose of the data. However, not every data item is needed in every clinical trial. Therefore,
many more variables can be found in the ENSAT registry that are related to the type of tumour and it 
is typically the case that a subset of these variables may be relevant to particular trials. The trials 
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themselves will define their own data requirements as part of the study protocol and these will 
typically be far more demanding than the core data captured in the registry.
The following evaluation of “vested interests” and extrinsic motivational factors by involvement in 
clinical studies focuses on the ENSAT PMT and EURINE-ACT clinical studies. These studies are focused 
on the PHEO and ACC parts of the ENSAT registry respectively. In particular, we consider the extrinsic 
motivating factors that might influence the quality of the relevant PHEO and ACC data sets on the 
registry related to these clinical studies. Specifically, do sites with vested interest in clinical trials 
improve the quality of the data (in the registry) that is related to those clinical studies? 
7.2 PMT Study
7.2.1 Background
As noted, the PMT study (Prospective Monoamine Tumour study) is a four-phase clinical trial that 
tracks patients who exhibit clinical indications of suspected pheochromocytoma through any of the 
following criteria:
 Signs and symptoms;
 Therapy-resistant hypertension;
 Incidental finding on imaging for related condition;
 Routine screening due to known mutation or hereditary syndrome, and
 Routine screening due to previous history of pheochromocytoma
Patients are admitted to the study from the specialist clinics in Germany (Dresden, Munich, 
Wurzburg), Netherlands (Nijmegen) and Poland (Warsaw). These patients are then tracked through 
the four phases of the clinical trial, which includes screening, clonidine tests, characterisation, follow-
up. These data are collected throughout the trial and up to five years after the study. The clinical path 
of patient progress through the study is outlined in Figure 3-3. The full set of information captured in 
this study covers the sections outlined in Table 7-1. 
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Phase 3: Tumour Characterization
Medications
Biochemical tests (carried over from phase 2)






Phase 4A: Excluded Follow-up
Follow-Up
Medications




Resectable tumour: post-operative verification
One year follow-up: medications
One year follow-up: biochemical tests
One year follow-up: cardiovascular
One year follow-up: blood pressure
One year follow-up: echocardiography
One year follow-up: electrocardiogram
One year follow-up: metabolic
The tables that translate directly to the ENSAT registry exist primarily in phase 1 (Identification, 
Demographics, Tumour Details and Genetics). The PMT eCRFs were designed explicitly with similar 
parameter fields so that transfers between both the ENSAT registry (the PHEO/NAPACA databases) 
and the PMT clinical study could occur. As a result, patients that are recruited prospectively to the 
PMT study can subsequently be entered into the ENSAT (PHEO/NAPACA) registry and patients from 
the ENSAT (PHEO/NAPACA) registry can be recruited to the PMT study. It is noted that all clinical 
studies associated with the ENSAT registry have to apply for their own individual ethics approval and 
obtain consent from the patients that are involved. Thus the data flows are not completely 
automatically enabled but require strict adherence to the standard operating procedures and 
protocols that have been established throughout the course of the ENSAT project more generally.
In the case that a PMT patient has or had a metanephrine secreting adrenal tumour (PPGL) or 
hormonal inactive tumour (NAPACA), the record can be/has to be transferred from PMT to the ENSAT 
registry. With the transfer, data and biomaterial can in principle be available for all ENSAT researchers 
(provided the patient has signed the ENSAT informed consent form for biobanking and subsequent 
(physical) data exchange). 
To understand the information flow within the PMT and ENSAT systems, we describe a typical use 
case scenario that illustrates how patients with an adrenal tumour are recruited to a clinical study 
such as PMT. 
During a routine diagnostic, an adrenal mass is detected at the top of a patient’s kidney. Following this 
identification, the patient is referred to a local endocrine research unit. At this point, the patient is 
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interviewed and receives consent forms related to the PMT study including the trial aims and the 
treatment plan (PMT flow chart). Once the patient agrees to be involved in the PMT study, i.e. after 
they have signed the consent forms, they are introduced to a clinical researcher, who collects all PMT
Phase 1 related information. This information will be entered directly in the PMT eCRFs or captured 
on paper based case report forms (pCRFs) so that the data entry can be performed retrospectively. 
When registering the patient data, the patient is assigned a pseudonym. This is a unique identifier 
generated the PMT study system. Importantly this identifier is linked through the ENSAT registry 
through an incremental clock/counter-based system (Stell & Sinnott, 2012), e.g. if this patient is the 
6th patient from Dresden then they are assigned with a unique identifier by the ENSAT registry (ending 
with GYDR-006) where the prefix reflects Germany, Dresden. This central ID generation greatly 
simplifies the subsequent data management and data relationships between the registry and the 
eCRFs related to the clinical study. After the ID is generated, the information identified in Phase 1 of 
Table 7-1 can be entered (captured) into the PMT eCRFs. 
Data entry users have the possibility to transfer the patient information into the ENSAT-registry. The 
user can choose the level of access to the subsequent data (local, national, PMT study members or 
international collaborators) along with the ENSAT database (NAPACA or PHEO) depending on whether 
the patient has been confirmed with a PHEO or a NAPACA tumour. This data transfer web interface is 
shown in Figure 7-1. 
Figure 7-1 Data transfer from the PMT study to the ENSAT Registry
The same transfer possibility exists within the ENSAT registry and data flow to the PMT study database. 
Often this data flow correlates with patients that meet the criteria for recruitment to the PMT study 
and once consent is approved, they can be recruited into Phase 1 of the study with the pre-existing 
ENSAT data automatically transferred to the PMT database. Both ENSAT Pheo and NAPACA patients 
can be transferred into the PMT study. It is noted that the ENSAT registry data entry user has to select 
the specific inclusion criteria for transfer of the patient record to the PMT study (see Figure 7-2).
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Figure 7-2 Data transfer from the ENSAT Registry to the PMT study
The structure of the vast majority of data items in the ENSAT registry and those required specifically 
for PMT is different, since PMT is a single study related to the ENSAT database. It is noted that at 
present over 25 major clinical trials were ongoing and associated with ENSAT (November 2016). 
Furthermore, much PMT data is not required for ENSAT (for example very detailed medication 
information; history of cardiovascular diseases information or TMN classification). Registries and 
clinical studies differ in their goals and needs. Typically, a study will have much finer grained data 
requirements than a general disease registry. During data transfer, the data may need to be 
restructured so that it is compatible with the other database. Data validation on data transfer is 
essential in supporting such data flows.
7.2.2 Assessment of ENSAT-PMT Data Quality Exchange
PMT utilises a subset of the ENSAT data and requires different data items in each of the clinical trial 
phases (as outlined in Table 7-2). Importantly the data items entered into the registry can be used as 
the basis for determining whether a patient meets the criteria for the study and whether the minimum 
data required has actually been entered. The study has far greater demands on data quality and data 
volume. The core data items of patients in the PMT Study covering phase 1-phase 4b comprises around 
400 data items. However, it is important to note that these data items often repeat, e.g. multiple 
measurements are taken repeatedly at specific time points. Any given patient can have over 10,000 
individual data items in the PMT Study (where the items in Table 7-1 are typically repeated at each 
follow up visit)
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Table 7-2 PMT data items per phase






The ENSAT Pheo database itself has 339 core data items. However most of the PMT data items are not 
transferred or requested by ENSAT PHEO. For example, data items such as follow up examinations 
(Phase 2 Clonidin test, Phase 4a follow up information and Phase 4b) are not required in ENSAT Pheo. 
By calculating data completeness of all data entered for ENSAT PHEO patients, calculation of an overall 
average 291.8 errors per record, where here error is given by data that is not completed. ENSAT Pheo 
has 339 data items, which leads to an average data completeness of 14%. This data will subsequently 
be compared with PMT phase 1 patients – noting that all patients (tumour or no tumour) can be 
enrolled in PMT entered Phase 1. For the PMT Phase 1 patients, an overall average error rate of 60.1 
errors per record (based on missing data) was calculated. Based on a total of 112 data items, this leads 
to a data completeness rate of 46% (see Table 7-3). It is noted that such errors are calculated and not 
entered information.
Table 7-3 Data completeness of Pheo Datasets
Dataset Avg. errors per record Data items per record Data completeness
ENSAT Pheo 291.8 339 0.14
PMT Phase 1 60.1 112 0.46
An evaluation of just PMT records in ENSAT Pheo has no impact on the calculation, however the impact 
of the involvement of a centre in the study needs to be considered. It is also important to consider 
those patients that meet the inclusion criteria for PMT (or not). The data collection and data entry 
(data processes) will be the same for both scenarios, i.e. as discussed the ENSAT system is largely 
based on a best effort data entry effort. It is presumed that a comparison of centres that are 
participating versus centres that are currently not participating in PMT will have an impact on the 
evaluation and quality of the related data in the registry (see Table 7-4). 
Table 7-4 Data completeness impact of PMT
ENSAT Pheo Dataset Avg. errors per record Records Data completeness
Centres participating in PMT 292.6 1026 0.137
Centres not participating in PMT 291.6 1765 0.140
Principal investigator centre (GYDR) 299.94 50 0.115
Not participating (GBLK) 223.33 30 0.341
Not participating (SPMA) 234.41 165 0.309
Participating (NLNI) 260.38 245 0.232
Centres with the highest completeness rates and more than 10 records are reported for comparison 
purposes. The results show that the PMT study is not improving the overall data completeness of the 
common (overlapping) ENSAT Pheo data subset. However, the 12 PMT participating centres out of 60 
overall contribute an average of 85.5 records each compared to 36.7 records for other non-
participating centres. Results of both the ENSAT and INPDR registries showed that the more records 
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that are entered, the lower the overall data completeness. Furthermore, the difference between 
13.7% data completeness and 14% data completeness is not significant (p=0.90). There is thus no 
direct evidence that PMT is improving or not improving ENSAT Pheo. 
In a new assessment of PMT inclusion criteria, similar problems of data transfer appear. Specifically,
154 records out of 2149 (=7.1%) were not transferred due to inclusion criteria from ENSAT Pheo to 
PMT (marked red in Table 7-5). Also four inclusion criteria due to language issues (in Dutch) were 
discovered in the assessment that should be harmonized with the trial language English (see Table 
7-5).
Table 7-5 Distribution of PMT inclusion criteria
Inclusion criteria Total
doorverwijzing met feochromocytoom mgl maligne 1
doorwijzing feochromocytoom 1
Family History positive 1
gemetastaseerd paraganglioom 1
known malignant pheo 1
paraganglioom verwijderd in abdomen, onbekende mutatie, genetisch onderzoek 
loopt
1
Right adrenal tumor found in the USG and CT, signs and symptoms present 1
Routine 1
several glomus tumors 1
Excluded 6
Routine screening due to known mutation or hereditary syndrome 109
-- 154
Routine screening due to previous history of pheochromocytoma 181
Incidental finding on imaging for unrelated condition 422
Therapy resistant hypertension 473
Suspicion based primarily on signs and symptoms 795
Total 2149
This leads to the conclusion that transferrals from ENSAT Pheo to the PMT study have a 7% error rate 
with regards to inclusion criteria. The inclusion criteria is a mandatory criteria when transferring 
records from ENSAT Pheo to the PMT study. GYWU has 91 inclusion criteria from 317 entered patients 
(=29%). All other trial critical defined data items (e.g. biochemical assessments) could be correctly 
transferred. Nevertheless, the inclusion criteria are important variables for the final stratification.
7.3 EURINE-ACT
7.3.1 Background
EURINE-ACT is an international prospective study that examines the diagnostic and prognostic value 
of urine steroidobolomics in patients with adrenocortical tumours (ACC). Urine steroidobolomics is 
the combination of steroid profiling by gas chromatography/mass spectrometry (GC/MS) followed by 
data analysis by machine learning analysis. The focus of the work is to differentiate between benign 
and malignant adrenocortical tumours (ACC) by a simple urine test should have a higher specificity 
and comparable sensitivity than existing imaging techniques.
The EURINE-ACT data flow is shown in Figure 7-3. The study aims to recruit patients with any adrenal 
mass >1cm. It requires entry of the clinical information into the appropriate ENSAT database (ENSAT 
ACC for adrenocortical carcinoma and ENSAT NAPACA for any other adrenal mass/adrenal 
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incidentaloma). The required biomaterial consists of a 24-h urine, a spot urine, a serum and a heparin 
plasma sample. 
Figure 7-3 EURINE-ACT Flowchart
Patients with confirmed ACC can participate in the EURINE-ACT ACC follow-up arm that offers urine 
steroidmetabolomics every 3 months following apparent complete surgical removal of the primary 
tumour. This arm aims to assess the sensitivity of the approach for detection of recurrence in 
comparison to imaging and also allows analysis of steroid changes induced by mitotane treatment. 
Patients with an adrenal incidentaloma that are thought to be an endocrine inactive adrenocortical 
adenoma can participate in the EURINE-ACT ACA follow-up arm, with biomaterial required 6 and 12 
months after initial diagnosis and then annually. This arm aims to detect whether the adrenal 
incidentaloma shows evidence of potentially deleterious excess hormone production during the first 
three years after initial diagnosis. All patients with active ENSAT ethics or active local biobank ethics 
can participate.
Patients enrolled in EURINE-ACT are directly entered into the ENSAT registry and not into separate 
eCRFs like PMT patients. Compared to PMT, patients with a confirmed adrenocortical cancer are 
enrolled into the study protocol. In PMT, patients with therapy resistant hypertension or suspected 
adrenal tumour (the majority of cases are not confirmed during the study phases) can be enrolled into 
the trial. EURINE-ACT patients with a confirmed adrenocortical tumour are seen in an outpatient 
setting where they are consented and enrolled into the trial. Data is typically collected through a study 
assistant, study nurse or clinician. There is no treatment advantage (or disadvantage) for any patient 
participating in EURINE-ACT (or indeed in PMT).
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7.3.2 Assessment of ENSAT-EURINE-ACT Data Quality Exchange
Similar to PMT, EURINE-ACT uses a subset of the ENSAT registry data. Specifically, the study requires 
64 ACC related data items from the 142 ACC data items that are available. It is noted that the link 
between EURINE-ACT and ACC has direct advantages over PMT, because EURINE-ACT is not using 
external eCRFs. 
The results show that EURINE-ACT centres have a 3% higher data completeness level over centres that 
are not involved, which is not a significant difference (p=0.5). Despite the statistical insignificance, 
EURINE-ACT centres improve the ACC data sets with on average 3 errors less per record. In comparison 
to the best centres with the highest data completeness (for centres entering more than 10 records), 
the centres participating in EURINE-ACT have around 5 errors less per record entered into the ENSAT 
ACC data subset (see Table 7-6). 
Table 7-6 Data completeness impact of EURINE-ACT ACC
ENSAT ACC Dataset Avg. errors per 
record
Records Data completeness
Centres participating in EURINE-ACT 84.06 1940 0.41
Centres not participating in EURINE-ACT 87.49 664 0.38
Principal investigator centre (GBBI) 96.33 63 0.32
Participating (FRBO) 59.17 42 0.58
Not Participating (FRNA) 64.13 16 0.54
France
Participating 64.92 207 0.54
Not participating 74.03 480 0.48
Germany
Participating 86.49 1155 0.39
Not participating 119 2 0.16
Italy
Participating 82.97 328 0.42
Not participating 100.90 75 0.29
Great Britain
Participating 91.67 65 0.35
Not participating 101.93 71 0.28
It was observed that the majority of centres with higher data completeness were situated in France. 
Therefore, a stratified data completeness analysis of all ENSAT founding countries (with the greatest 
involvement and experience) and the country of the principal investigator (GBBI – Birmingham, Great 
Britain) was conducted. The results show that in every country, the centre participating in EURINE-
ACT achieved higher data completeness levels than non-participating centres. Furthermore, in France 
EURINE-ACT centres have 10 errors less per record, Italy – 18 errors less per records and Great Britain, 
10 errors less per record. The results of Germany can’t be used to lead to any significant conclusion, 
because the non-participating centres only entered two ENSAT ACC records into the ENSAT registry. 
All German centres are highly motivated to participate in research and have been involved in ENSAT 





Health informatics is the connection between biomedical science and information science. As 
explained in chapter 2, major subspecialties are clinical research informatics and translational 
informatics. Another important area of research is the focus on eHealth including spatial research. We 
consider this here since it provides a relevant example of data trustworthiness. Like every other field 
of science, spatial research relies on the quality of source data. One widely available form of spatial 
data is social media, e.g. Twitter. Web developers can use the Twitter APIs to receive data from 
(tweeted by) users and this can often include the geo-location of the tweet. Users of Facebook and 
Facebook messenger can also activate the option to share their location with others. Other open 
source web application like wunderground24 provide a weather forecasting app that provides users 
with the possibility to share their personal weather station data with others to improve the weather 
forecasting around their geo-region. However, in such scenarios, data can be wrong or misleading 
either deliberately or accidently and this phenomenon gives rise to the question: how much data can 
be trusted?
As an example of this, Nurse, Agrafiotis, Goldsmith, Creese, & Lamberts (2014) developed a 
trustworthiness score related to social media information. In a literature review they put forward that 
trustworthiness should consist of four categories that have to be weighted appropriately (see Table 
7-7).
Table 7-7 Categories of Data Trustworthiness (adapted from Nurse et al., 2014)
Category Weight
Competence of a source (i.e., they have been found not to be very competent) x5
Information recency (i.e. the information is up to date) x10
Proximity (i.e. the source is physically close to the event of interest) x20
Integrity (e.g. there may be concerns about the integrity of the information such as the 
origins of the data and the infrastructure where it is made available)
x10
The overall calculated scored is called data trustworthiness. The authors suggest to communicate this 




Figure 7-4 Example of data trustworthiness of social media data (Nurse et al., 2014)
7.4.2 ENSAT Data Trustworthiness
Data trustworthiness is a data quality dimension that has great impact especially in the clinical domain 
and for translational science. After the exploration of data eligibility scores presented previously, data 
trustworthiness is a second novel dimension that should be explored. Trusting data entered by 
potentially non-trusted personnel, e.g. collaborators involved in ENSAT places requirements on the 
data analysis. One example of such potentially untrustworthy data is from patients (or individuals 
more generally) that download mobile applications for their own data entry. One such mobile 
application - NAPACA app has been developed for ENSAT patients with focus on collecting data based 
on their quality of life. The app is available on the Android and iOS platforms. However, unlike many 
open mobile applications that can be used by anyone, the NAPACA app requires an activation code 
that is generated through the ENSAT server by the clinicians responsible for the patients. Hence only 
those patients that are being seen by ENSAT doctors can activate and subsequently use the app. This 
is unlike many other crowd sourcing efforts and social media activities, where there is no policing of 
the users or the data/tweets that they send. 
Within ENSAT it is assumed that through the process of a trial and the ongoing data quality assurance 
methods that are applied (investigator communication, data quality feedback, staff training and 
protocol amendments), the quality of data and the data completeness will improve over time. It might 
be considered that data entered at the beginning of a trial has more inconsistencies than data that is 
entered at the end of trial. 
The ENSAT registry captures the date when a patient was registered for research purposes by a 
contributing clinical centre. However, it is noted that this registration might well have been before the 
development of the ENSAT registry in 2010. Given this it might be suspected that older data are 
assumed as having lower trustworthiness than more recently registered patients. We consider this 
hypothesis in more detail through exploring the trustworthiness and completeness of the ENSAT data 
within the PMT and EURIN-ACT studies. Specifically, and for simplicity we assume a linear scale for 
data trustworthiness based on the date of entry of the data. To support the analysis and the 
visualisation, the source data and R script are given for both EURINE-ACT and ENSAT ACC respectively
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in Appendix III. The trustworthiness of PMT is measured in a similar to EURINE-ACT but Pheo-related 
source datasets are used. 
The final graph plots the data completeness of centres with their associated data trustworthiness. To 
show the different record contributions in ENSAT ACC, each centre will have a plot in relation to the 
entire set of patient records that have been contributed to the registry. Therefore, the source data is 
split into several dimensions: the centre; the completeness score; the trustworthiness score; the 
record rank for the visualization; whether the centre participates in the related trial, and the overall 
records for weighting the final calculation (see Figure 7-5). 
Figure 7-5 Calculation of ACC data trustworthiness (based on time of entry)
The column ‘completeness’ is a percentage value that represents the average entered values of the 
entire ENSAT ACC dataset. The ‘trustworthiness’ column is also a percentage value and is calculated 
as an average of all centres records based on the age of the records. This calculation was performed 
by assessing the difference between the record registration date and the data trustworthiness 
calculation. All records of the centre (displayed in ‘records2’) are assigned in 5 different categories. 
Centres with more than 300 records are assigned in the category 5 (n=1), centres with 300-100 records 
are assigned into category 4 (n=3), centres with 100-40 records assigned into category 3 (n=14), 
centres with 40-10 records into category 2 (n=11) and centres with less than 10 records into category 
1 (n=25). This category is displayed in column ‘records’ and is only used for visualization purposes. The 
column ‘EURINE’ is for those centres participating in the EURINE-ACT study (value = 1) or not (value = 
0). Not every record from a centre participating in EURINE-ACT or PMT is assigned to EURINE-ACT or 
PMT, however it is assumed that the data processes of non-trial records are similar to those of trial 
records.
For the visualization of the centres, the package RColorBrewer was used to allow larger centres to be 
visualised with larger circles and hence to better understand the data analysis. The code to achieve 
this analysis is shown here.




somecols <- brewer.pal(5, "Set1")
red <- col2rgb(somecols[1])
blue <- col2rgb(somecols[2]) display.brewer.all()
# transparency for dot plots
Transred <- rgb(red = red["red",],
green = red["green",], 
blue = red["blue",], 
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maxColorValue = 255, alpha = 60) 
transblue <- rgb(red = blue["red",],
green = blue["green",], 
blue = blue["blue",], 
maxColorValue = 255, alpha = 60)
dat$colors <- ifelse(dat$EURINE == 1, transred, transblue)
# relative size of the plotting symbol, color in new column
dat$cex <- dat$records/max(dat$records) 
oldpar <- par()
Using this code, we plot an ellipse for the overall visualisation. This ellipse displays the 95% confidence 
interval of centres that participate in EURINE-ACT and centres that do not participate. This ellipse is 
weighted by the overall records (see dataEllipse – weights command below).
layout(matrix(c(2,2,2,2,1,1,1,1,1,1,1, 1,1,1,1, 1,1,1,1,1, 1,1,1,1), nrow = 6, byrow = T))
library(car)
par(mar = c(5,5,1,0))
plot(0,0,type = "n", ylim = c(-10,40), xlim = c(60,105), 
ylab = "completeness in %", 
xlab = "trustworthiness in %", 
main = "",cex.axis=2, las = 1, cex.lab = 2, cex.main = 2, 
bty = "n", yaxs = "i", xaxs = "i")
# the maximum size of a plotting symbol is 8
points( dat$trustworthiness, dat$completeness, cex = 10*dat$cex, 
col = dat$colors, pch = 16) 
with(subset(dat, EURINE == 1),
dataEllipse(trustworthiness,completeness, weights = records2, levels = 0.95, add = T, 
center.pch = NULL, plot.points = F, 
col = red))
with(subset(dat, EURINE == 0),
dataEllipse(trustworthiness,completeness, weights = records2, 
levels = 0.95, add = T, center.pch = NULL, plot.points = F, 
col = 'blue'))
The last part of this code segment is the labelling of the graph, which is not further explained, since is 
it redundant for the data quality aspects explored here. The final graph for ENSAT ACC and EURINE-
ACT is shown in Figure 7-6 and Table 7-8. 
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Figure 7-6 Visualisation of ENSAT ACC Data Trustworthiness (based on time of entry)
Table 7-8 EURINE ACT Trustworthiness Regression estimates in a linear regression model (weighted)
(Intercept) (slope) p (EURINE-ACT vs 
no-EURINE-ACT)
EURINE ACT 157.40 -1.32
no-EURINE ACT 140.16 -1.08 0.52
The size of the ellipse illustrates a non-visible difference between the centres involved in EURINE-ACT 
and those centres not involved in EURINE-ACT. The graph is expected the show that both ellipses are 
not covering themselves (at least by the majority of their area) and the data completeness has a 
positive linear correlation with data trustworthiness. The results in Table 7-8 show that there is no 
significant difference in data completeness and data trustworthiness for centres participating in 
EURINE-ACT compared to those centres that are not involved in EURINE-ACT. This is caused by large 
centres (ITTU, FRPA2 or GYWU) who provide a large proportion of ‘older’ data with an average overall 
data completeness level (≈ 55%) versus newer and typically smaller participating centres that provide 
lower data completeness levels. 
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The same analysis was performed for both PMT and ENSAT Pheo and is shown in Figure 7-7 and Table 
7-9. 
 
Figure 7-7 ENSAT Pheo Data Trustworthiness (based on time of entry)
Table 7-9 PMT Trustworthiness Regression estimates in a linear regression model (weighted)
(Intercept) (slope) p (PMT vs no-PMT)
PMT 11.89 0.07
no-PMT 61.65 -0.52 0.067
In contrast to EURINE-ACT and ACC, the weighted graph shows a positive correlation for those centres 
participating in PMT compared to those centres not participating PMT with regards to data 
trustworthiness and data completeness. This confirms the hypothesis that new centres with newer 
data provide more complete information (of Pheo datasets) in the ENSAT-registry. It is also noted that 
the ellipse is narrower for non-participating centres, which implies that this assumption is more valid. 
In general, the overall data completeness is low, which indicates that the included data items in the 
registry should be discussed in the ENSAT working group meetings, and that very specific data is 
needed for research purposes, which is potentially not needed for other trials.
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To explore this further, a more detailed investigation of the assumption that there is a positive 
correlation between data completeness and data trustworthiness can be achieved through a linear 
regression analysis per record. The results of the linear regressions for the Pheo and ACC data are 
shown in Figure 7-8 and Figure 7-9, linear regressing values displayed in these figures are given in 
Table 7-10.
Figure 7-8 Linear regression ENSAT Pheo Figure 7-9 Linear regression ENSAT ACC






The linear regression shows a negative correlation coefficient in all cases. The slope of PMT, no PMT, 
EURINE-ACT and no-EURINE-ACT records shows a negative slope, which indicates that there is 
decreasing completeness with higher levels of data trustworthiness. This indicates that the data of the 
records do indeed have an impact on the ENSAT-registry, however new records (higher 
trustworthiness) have lower data completeness. This may be caused by too many redundant data 
items that are used for research purposes.
Furthermore, in ENSAT Pheo there are a large proportion of records in the region of 20% data 
completeness and 95% data trustworthiness. Inspecting only this area (trustworthiness 90-100%) a 
slope is seen for data completeness. The reason for this might be caused by an ‘information delay’. In 
other words, the records are created with baseline information of the patient. After a certain time, 
laboratory information, pathology information, follow up information is entered and the records are 
gradually made more complete. The data shows that this has indeed been the case since 2011. The 
same can be confirmed for ENSAT ACC, where a large proportion of records show a data completeness 
drop between 90% and 100% with regards to data trustworthiness.
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7.4.3 Conclusions on Data Trustworthiness
The assumption that more recently entered can be more trusted needs to be reconsidered. Factors 
such as the discovered information delay arise in ENSAT ACC and ENSAT Pheo and need to be 
considered. The assumption that data trustworthiness has a positive correlation on data completeness 
also needs further evaluation in other situations and with other registries. It is a logical assumption 
but the analysed data could not confirm this to actually be the case. 
In conclusion, data trustworthiness as a data quality dimension needs more attention, especially in 
clinical research settings. Data quality procedures improve data and the data can be more trusted and 
subsequently used in other research purposes, e.g. in other clinical trials. The performed analysis is a 
novel approach to investigate the relationship and correlations between two quality dimensions. 
There is a need to investigate dynamics between defined quality dimensions for clinical research. Data 
completeness is a well-researched data dimension for record eligibility for example, whilst data 
trustworthiness dimensions will have a growing impact in the era of mobile health and other citizen 
science data-oriented activities. 
In summary with regards to ENSAT, data older than 10 years (lower trustworthiness) is less complete,
whilst data from 2011/2012 is more complete. Conversely we find that more recent data (higher 
trustworthiness) is also less complete. Specifically, we observe that data has most ‘usefulness’ for 
research purposes, when it is around 3-4 years old, i.e. it was entered 1-2 years after the establishment 
of the ENSAT registry.
7.5 Chapter Conclusions
Data standards are an important tool for data exchange, for research interests and to achieve system 
interoperability more generally. So-called data warehouses must be built leveraging established 
standards. CDISC and Hl7 provide several modules for different study intentions. International 
platforms and research networks suggest to use data standards to improve data exchange between 
electronic health records or hospital health records and electronic case report forms (eCRFs). Due to 
policy and security barriers, ENSAT is not using electronic data captured from hospital records into the 
ENSAT registry. Manual data entry is the used method to complete eCRFs with standardised 
information. Here, no general data standard was used, but a standard that matches the intensions 
and purposes of the international network of adrenal tumour researchers. 
In this chapter we considered the research question as to whether PMT or EURINE-ACT improved the 
ENSAT registry with regards to data completeness of the overlapping data due to extrinsic 
motivational factors, i.e. by being involved in the trials. This was found to be the case for EURINE-ACT 
but not so for the PMT study. One reason for this result is, that EURINE-ACT is using the same data 
elements as the ENSAT registry and does not have its own eCRFs for data entry – thus its success 
depends on the quality of the data in the registry. It should be noted that these calculations were 
performed with just one type of tumour: pheochromocytoma for PMT and adrenocortical carcinoma 
for EURINE-ACT. Other ENSAT tumour types (NAPACA, APA) were not explored. The results suggest 
that data transfers to study-specific eCRFs do not in themselves lead to improvements in data quality 
of records in centralised registries. On the other hand, PMT is enrolling many patients (as controls) 
that do not have an adrenal tumour and these kinds of patients cannot be captured within the ENSAT 
registry. 
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8 CONCLUSIONS AND FUTURE WORK
High data quality is essential for translational research, especially in the clinical domain. The 
evaluation of data quality in clinical research is needed to improve scientific conclusions. It is also 
essential that data quality assessment is undertaken throughout the data collection and analysis 
phases of clinical research, and where required improve the behaviour of data collection personnel 
and their data entry practices. The intention of this thesis was to provide a framework realised through 
an automated web-based application that provided data quality feedback for data entry users
throughout the lifecycle of data collection and future use. As part of this aim an exploration of data 
quality dimensions and data entry motivation was conducted. This was undertaken in a range of 
national and international disease registries and included the patients themselves performing data 
entry through targeted mobile applications.
The following chapter summarizes the primary and secondary aims of this thesis and provides an 
overview of possible future research that may be followed to improve data quality in clinical research
settings.
8.1 Conclusions
This research has outlined the necessity for data quality in clinical research and especially for its 
translation into a clinical setting. We explored the state of the art approaches that have been adopted 
in the area of data quality with specific focus on clinical research demands. We articulated why clinical 
research especially relies on data quality based on the specific demands for accuracy and challenges 
in collecting data from patients, e.g. during patient visits or from medical devices. We discussed how 
data might be entered manually by data entry personnel or electronically through software systems 
leveraging pre-existing (digitised) clinical data. Both methods have their own advantages and 
disadvantages: manual data entry is more realistic at present given the heterogeneity of IT systems 
and standards for data that currently exists across the healthcare sector both nationally and 
internationally. It is envisaged that this situation will eventually be overcome through continued 
adoption of IT within the clinical sector. One example of this is the growing research field of mobile 
health applications. As US President Thomas Jefferson once said: “Information is the currency of 
democracy” (The Jefferson Monticello, 2016). In the internet age, a refinement of this quote is 
applicable: ”Information is the currency of the digital age” (Nurse, Agrafiotis, Goldsmith, Creese, & 
Lamberts, 2014). However, more information in itself does not necessarily indicate that more insight 
(knowledge) can be garnered. Whilst big data promises much for the future through data mining and 
advanced data analytics, it is still the case that clinical and biomedical research demands high quality 
data that is difficult to access and use due to the sensitivities that surround it, e.g. need for 
confidentiality and it’s heterogeneous ‘at source’ nature. In a clinical setting, it should be the case that 
“Information that matches the need of the user is the currency of the digital age”. This would imply 
that information is standardised and organised such that knowledge can be derived from it directly. 
As discussed in this thesis, this is still a fraught issue for breakthroughs in biomedical research due to 
the challenges in establishing sufficiently robust and accurate data repositories and/or providing live 
access to high quality data sets at source. Biomedical data registries represent one approach to 
overcome this. Such registries offer ways to establish targeted sets of data relevant to specific disease 
areas that support networks and communities of biomedical researchers. Such data resources can 
underpin clinical trials and biomedical studies more generally, but this demands that the data is of 
high quality.
During the exploration of the research hypothesis: “web-based feedback should be an integral part of 
data collection processes in disease registries that demonstrably improves the overall quality of data 
that is entered into such registries”, three key aspects were identified and explored in the thesis: 
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 how to measure data quality (data quality dimensions), 
 how to improve data quality (user motivation), and 
 how feedback can “be an integral part of data collection processes” (categories of feedback).
These aspects are concluded in the following chapters.
8.1.1 Exploration of Data Quality Dimensions
For the evaluation of data quality in clinical and biomedical research, the definition of relevant data 
quality dimensions is crucial. There are standard quality dimensions that are often measured in the 
majority of clinical trials. As discussed, these typically include data validity checks related to data 
completeness, data accuracy and data plausibility. 
This research covered in this thesis explored the five most used data quality dimension of clinical 
research (Weiskopf & Weng, 2013):
 Data completeness;
 Data correctness (here accuracy);
 Data concordance (here comparability);
 Data plausibility (here trustworthiness), and
 Data currency (here timeliness).
We discussed the recommendations and findings of each of these data quality dimensions in this 
research through case studies involving a range of international clinical disease registries and clinical 
trials. We summarise these findings here.
Data completeness
Data completeness is the most commonly used dimension for data quality evaluation. It is calculated 
based on the ratio of entered/given items of a (requested) dataset with all items of a dataset. Often 
these requested and given are based on web-based forms for data collection. NIH collaborators 
distinguish data completeness with overall completeness through ‘column’, ‘row’ and ‘ascertainment’ 
(record eligibility) completeness (Zozus et al., 2014).
Within this thesis it was highlighted, that data completeness needs to be adjusted depending on 
whether data is compulsory or optional for particular clinical studies. Making all data compulsory is 
typically unworkable in most settings: data items may not exist at a given time, and data entry 
personnel may be unwilling or unable to provide all such data. A more typical approach is to mix 
compulsory data with optional data. In this situation the predominant approach for data collection is 
based on best effort. The calculation of data completeness provides a general procedure that can be 
used to provide a generic form of data quality assurance in health based data registries. Literature 
suggests that percentage values of >90% for data completeness are recommended (Mathers et al., 
2005; Nonnemacher et al., 2014). Data completeness is generally reported as percentage values in the 
literature (Larsen et al., 2009). For the visualisation of data completeness, tables with percentage 
values and given (Hills et al., 2010; Hirdes et al., 2013; Porgo, Moore, & Tardif, 2016) or tables with 
arithmetic means (Köpcke, Trinczek, et al., 2013). Data completeness can also be visualized as bar 
charts (Herzberg et al., 2011) or as process diagrams with percentage values (Arts et al., 2002). 
Timmermans et al. (2016) also suggested using p-value dot plots to visualize data inconsistencies (see 
chapter 4.3). This thesis also suggests to weight every data dimension and to set a threshold, but these 
demand could not be explored within this research.
For this work, data completeness assessment provided the baseline information for the research 
hypothesis. The first data completeness evaluation was performed for the PMT-Study where all 
records for Phase 1 patients were analysed. Here data completeness was used to detect data items 
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that were not entered into the ENSAT-CANCER registry, but needed for the research hypothesis. In 
PMT data completeness was assessed as part of data validity, where the completeness was combined 
with data accuracy and plausibility checks. In the EURINE-ACT study, a separate data completeness 
evaluation was performed, since the dataset was incomplete and could not be used directly to assess 
accuracy and plausibility. In this case, data completeness was used as feedback to researchers to help 
to increase their motivation to enter more data. The resultant bar charts visualising the data 
completeness scores before feedback are presented in Figure 8-1 & Figure 8-2. 
Figure 8-1 EURINE-ACT NAPACA Data completeness 
visualisation example I
Figure 8-2 EURINE-ACT ACC Data completeness 
visualisation example II
Data completeness was also reported in tables as percentage values with errors per record also 
provided, where an error represents a non-entered value. In the literature data completeness also 
referred as data accessibility, availability, missingness, omission, presence, rate of recording or 
sensitivity (Weiskopf & Weng, 2013).
Data accuracy
As discussed in this thesis, data accuracy is often combined with data completeness to assess the 
overall degree of data validity. The completeness level of data in clinical registries is more readily 
reported than the degree of data accuracy. Data accuracy also has a much more diverse definition in 
the literature. Accuracy is also defined as the “extent to which the results of a method agree with the 
independent external citation” (Stone, 1986). Accuracy is often given in terms of possible transfer or 
transcription errors that arise when moving (transferring) data into a data registry (Datta, Findlay, 
Kortbeek, & Hameed, 2007). An example of such data accuracy measurements occurs in source data 
verification based clinical studies.
In this research, data accuracy was defined as the extent to which a data item agrees with the defined 
range for the item. Data accuracy was assessed in the PMT study, where every item of phase 1 patients 
was assigned with a range that was required to be fulfilled study. This excluded items that were not 
filled out or where default information was provided, e.g. an item with the possible responses “—“, 
“not done”, “no” or “yes” in case the item “—“ should be selected since otherwise it is assumed that 
no data entry was performed and hence the item is inaccurate (incorrect). A similar procedure was 
applied to EURINE-ACT for the data completeness calculation. The reason is that “—“ reflects non-
entered information and therefore where such a moot response is given, this corresponds to an 
incomplete data item in the dataset. 
As an extension (sub-category) of data accuracy, record eligibility was developed for the EURINE-ACT 
study. This quality dimension has the potential to be applied to other clinical trials. Records entered 
by the data entry personnel need to meet defined minimum criteria to be eligible for the final analysis 
and ultimately to be useful for research. The report of eligibility during a trial (e.g. a cohort study) 
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displays important information about possible issues in the data process. With regards to the EURINE-
ACT study, these issues included items such as pathology and surgery reporting problems (see Figure 
8-3).
Figure 8-3 Example of Record Eligibility Feedback
For EURINE-ACT, record eligibility and data completeness scores were combined to provide an overall 
data quality score. In a pre-post test study design (without control group) within the EURINE-ACT 
study, feedback of the record eligibility score increased the overall data quality within 6 months (see 
chapter 3.4). This was an essential fact that provided the basis for much of the experiments and the 
research hypothesis that has driven this thesis. Specifically, it was demonstrated that feedback works.
In this case the feedback was based on face-face meetings with the data entry personnel. The core 
thesis we wished to explore here was whether the human face-face feedback loop could be replaced 
with automated web-based feedback systems.
Data comparability
In disease registries, data comparability is often regarded as the extent of classification procedures of 
a registry that agrees with international guidelines. One example of this is ICD-10 (Bray & Parkin, 
2009). Such coding of data in a registry can allow it to be directly compared with other registries based 
on the common coding scheme and ability to compare directly. However, clinical registries often 
cannot be compared with other registers since the research purposes are diverse, and importantly the 
data itself is coding using many different coding systems. Comparison with other registries can be 
explained as challenges of ‘external’ comparability, whilst comparison with datasets derived from the 
same registry, e.g. data used to support particular clinical trials, can be considered as ‘internal’ 
comparability.
The optimal epidemiological practise for clinical trials is based on comparison with control groups. 
One example of such an approach is the PMT trial, which is used to improve pheochromocytoma 
diagnostics based on the measurement of blood-based metanephrines. Measuring blood-based 
metanephrines in a healthy (and similar) cohort offers a baseline assessment of what constitutes high 
and low levels of metanephrines. 
In the evaluation of the PMT data quality, data monitoring of blood sampling approaches detected 
statistical outliers (see Figure 8-4). A ‘health’ cohort had higher blood metanephrines levels when they 
did not fast, if they drank coffee, if they cycled or did sport more generally. The importance of standard 
operating procedures (SOPs) for blood sampling was thus essential, because SOPs forbid these actions 
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(Därr et al., 2014). Thus data quality and comparability is far reaching and goes beyond the data 
entered into a database. Rather it can involve the systematic approaches and procedures by which 
data is collected and analysed in a clinical setting. The graphical visualisation of such performance 
issues and deviance from the norm is one way that such issues can be addressed. This subsequently 
implies that clinical staff are subsequently trained to adopt best practices in blood taking. This is one 
example, but many others are essential for data to be truly comparable.
Figure 8-4 Box-Plot chart displaying outliers used to detect data issues in PMT
Another statistical approach for data comparability is the calculation of interclass correlation 
coefficients (ICC) and their visualisation, e.g. through boxplots. There are several propositions in the 
literature for such visualisation. Guthrie et al. (2012) display the value in a table where values are used 
to indicate a performance differences between centres. The display of ICC in boxplots or RICC vs R2 
(Wynants et al., 2013) is another possibility. With regards to investigator feedback, the usage of ICC 
or RICC vs. R2 was suggested (see chapter 4.1.1).
Data trustworthiness
Assessing data trustworthiness is often used to quantify the quality of the original source of the data. 
There is no general definition of data trustworthiness. Questions that data trustworthiness needs to 
address are: “Where did the data come from? How trustworthy is the original data source? Who 
handled the data? Are the data managers trustworthy?” (Dai et al., 2008). Alternative terms for data 
trustworthiness can be data provenance or believability (Weiskopf & Weng, 2013).
For this research the first approach taken was to assess data trustworthiness with regards to data 
completeness. Here the hypothesis was that data has high trustworthiness when it is recently entered 
into a research registry or into an electronic case report form (eCRF). It was considered whether older 
data would have lower trustworthiness on the premise that the data processes were not as 
established compared to more recent data or where the older data was based on evolving 
understanding of the data that was to be entered into the registry. 
Based on correlation with data completeness for the ENSAT-CANCER registry, it was discovered that 
data has higher completeness when it is 3-4 years old or when it is entered 1-2 years after the 
establishment of the registry (see chapter 7.4.2). As an example for the visualization, dot plots of every 
centre (see Figure 8-5) and for every record can be used (see Figure 8-6).
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Figure 8-5 Data completeness visualization by centre 
(example ENSAT Pheo & PMT)
Figure 8-6 Data completeness visualization by record 
(example ENSAT Pheo & PMT)
Data timeliness
In clinical research, data timeliness is a “benefit to health providers and researchers, and early 
provision of data usually enhances the reputation of the registry” (Bray & Parkin, 2009). This research 
defined data timeliness as a core indication of good data entry practice. 
To assess data timeliness, timestamps in the data sets that were entered was used. These timestamps 
were collected through logging tools associated with the data registries such as INPDR and ENSAT-
CANCER. Other important dates include the date of the original collection of the data, which is in the 
majority of cases different to the date of registration and actual data entry. Logging data can also be 
used to assess the need for staff training purposes and use of registries more generally. This can be 
used to better understand local processes, and where necessary to improve local data collection and 
data entry processes.
Another key capability that is often required for clinical research is the visualization of patient 
timelines. Longitudinal visualisations offer the ability to readily assess patient diagnosis and treatment 
to improve follow-up and generate feedback that can subsequently be used for advanced patient care. 
An example of this from the ENSAT-CANCER registry is shown in Figure 8-7. 
 
Figure 8-7 Visualisation example of longitudinal data timelines of a patient
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Similar analysis can be performed for researcher interactions with a clinical data registry. This can be 
used for data protection purposes but also for monitoring when data entry personnel have problems 
entering data. This assessment should be part of an overall data quality feedback process (see Figure 
8-8. 
Figure 8-8 Example of ENSAT visualisation of user logging information
Data Quality Conclusions
The data quality dimensions of completeness (all trials), accuracy (EURINE-ACT & PMT), eligibility
(EURINE-ACT), comparability and timeliness (PMT) were all explored in this research. Some 
dimensions need targeted correlations with data completeness, which is the most widely adopted 
data quality indicator currently used in clinical research. Other quality dimensions could not be 
statistically tested with other registries. For the INPDR data registry, there were insufficient data 
entries within the observed period to make any overall conclusions on data quality practices. Other 
registries where originally considered to be part of the final analyses of this work included registries 
focused on Polycystic Ovarian Syndrome (PCOS), however the research collaborators failed to utilise 
these resources (this work was tied to a research grant that was submitted, and whilst the PCOS 
registry and associated mobile applications were developed, the grant was unsuccessful and the 
subsequent use of the system did not materialise). 
A methodological disadvantage of the overall efficiency of assessing data feedback is that this is 
typically not based on use of a control group. Thus there are no known data quality measures that can 
be systematically applied. Instead each disease registry has its own communities and data collection 
practices that differ between one another. Thus comparing the data quality of ENSAT-CANCER does 
not immediately transfer to INPDR or PCOS for example. Nevertheless, the process of applying web-
based feedback is generic and can be applied in all cases.
As outlined in the introduction (section 1.2.3), the impact of user motivation with an overall data 
quality score could not be fully explored in this thesis. The reason for this was that only PMT and 
EURINE-ACT explored data completeness along with a second data quality dimension (for PMT – data 
accuracy and for EURINE-ACT – data eligibility). For ENDIA and INPDR only data completeness was 
assessed. This indicates that the impact of an overall data quality score (an arithmetic mean of all 
calculated data quality dimensions) still has to be investigated with regards to user motivation.
Data quality has an essential overall impact on the final conclusions of any given clinical study or trial. 
As a suggestion, all data quality dimensions can be given as feedback where single values can be 
reported in tables or visualised in bar charts, box plots, dot plots, timelines or pie charts. The overall 
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data quality itself can be reported in radar charts and targeted to specific users or specific centres 
involved in a given clinical collaboration as shown in Figure 8-9. 
 
Figure 8-9 Visualisation example of all ENSAT data quality dimensions
High data quality should be the goal of all clinical research collaborators: from data entry personnel 
through to data users including those beneficiaries involved in associated clinical trials. Data quality 
feedback can motivate and encourage collaborators to collect higher quality data. We have 
demonstrated that feedback works. Ultimately higher data quality is an essential cornerstone that 
provides the bridge between clinical research and clinical care.
8.1.2 Exploration of User Motivation
The second element that has driven the work in this thesis was evaluating user motivation. People 
have by far the greatest impact on data quality especially based on manual data entry processes 
(which reflect the vast majority of clinical research registries existing today). Following the literature 
review, a survey was performed and the responses to this survey were correlated with data 
completeness for the ENSAT-CANCER registry. It was found that data completeness was directly 
influenced by the number of other research registries that the (contributing) centres were involved 
with, and especially where the data entry personnel had to enter data from the same patient multiple 
times. Furthermore, the time of data entry showed an impact on data completeness rates. The more 
time spent by the user on data entry, the lower the data completeness – this is somewhat against 
intuition. It may have a relation with the usability of the system more generally, e.g. it requires a longer 
time based on unfamiliar user interface to the system for example. Non-significant results of the 
survey included a negative correlation with the age of the data entry personnel, or more specifically 
the trend showed that the older the user, the better the data. The survey results showed no relation 
regarding the time delay to actual data entry (i.e. the time between original data collection and data 
entry into the registry), the gender, how many trials the centre is participating in, nor the original 
source data type, e.g. paper or electronic based data forms. 
For the motivational question of the survey, users expressed that they have higher motivation when 
they see the impact of their data entry efforts on the treatment of patients or in supporting 
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international collaborations. Various tools have been implemented in the ENSAT-CANCER registry to 
motivate the users and centres to enter more and better quality data. These tools include leader 
boards and feedback features that dynamically inform the user about their own data quality and how 
it is tracking over time as well as comparing their data entry efforts with other user/centre data entry 
efforts. Other possibilities include badges and wards to help motivate better data quality efforts, 
however these have only been considered indirectly in the work conducted here and by and large, all 
of the registries are based on best (unrewarded) effort. 
For the PMT study, pre-post tests on data quality could not be performed (since the work had already 
commenced), but in structured interviews during monitoring visits, researchers had positive feedback 
on feedback features. One feature that was tested was the reporting of data completeness scores at 
varying levels of feedback. This was explored for INPDR in chapter 5). The study design was developed 
to distinguish between intrinsic (self-motivation) and extrinsic (external pressure) motivational 
factors. This included a variety of feedback mechanisms of increasing detail and comparison with the 
other data collected by collaborators. Unfortunately, no statistically relevant results could be seen, 
largely due to the limited amount of data entry during the time of observation to the INPDR registry.
It is worth noting that the technological underpinnings of ENSAT-CANCER and INPDR are largely similar 
and both deal with a rare disease, however the ENSAT-CANCER registry has galvanised global research 
into adrenal tumours whilst INPDR (at present) only includes the original collaborators involved in the 
Niemann-Pick grant. It is assumed that the ENSAT network has been key to this. A second major 
contributing factor is the number of clinical trials that are now supported through the ENSAT-CANCER 
registry. At present INPDR does not support any clinical trials, although several are being discussed 
with pharmaceutical companies. 
8.1.3 Exploration of web-based Feedback to increase Data Quality in biomedical 
Registries
The Good Clinical Practise Guidelines (GCP) define two mandatory criteria for clinical trials: to protect 
human subjects and to collect high quality data (International Conference on Harmonization, 1996). 
Other important standards and guidelines describe the need for ongoing quality assurance during 
clinical trials leveraging centralized repositories and on-site monitoring visits (U.S. Department of 
Health and Human Services et al., 2013). It is widely recognised and reported that quality assurance 
procedures are cost intensive (R. M. Califf et al., 1997). Furthermore understanding the cost-
effectiveness of clinical trials is challenged by the lack of reported information regarding the data 
quality, the data quality processes and their overall contribution to the trial performances (Macefield 
et al., 2013). There are efforts to improve centralized data monitoring with better bias detection 
(Baigent et al., 2008) and suggestions on how to perform cost efficient on-site visits with targeted 
focus on information collection processes (J. Bakobaki et al., 2012). The literature and the case studies 
undertaken in this thesis confirm that most problems stem from source-to-registry data transfer, 
which suggests that single source data pools with remote and quality-controlled data entry are the 
best way to improve clinical research (Glöckner et al., 2015). 
Data quality implies appropriate data management processes are in place and actually adhered to. All 
trial protagonists need to have an overview of the need for the data; for the subsequent collected 
data and its quality. All protagonists should be made aware of the impact of lower data quality on the 
study. As described, the defined data quality dimensions must focus on:
 Record Completeness feedback including statistical information on those records required 
with their associated values compared to those that were actually entered;
 Record Accuracy feedback focused on records with their validated values;
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 Record Eligibility which focuses on the data needs as they pertain to existing (ongoing) and 
upcoming clinical trials and studies;
 Record Timeliness related to the temporal information of records from when the data was 
originally recorded to when it was actually entered into the registry;
 Record Comparability allowing statistical consistency verification between centres, and
 Overall Record Data Quality feedback and how this can/should be calculated.
These dimensions should be assigned and reported to data entry personnel, to investigators and to 
the clinical research collaborators/community more generally (see Figure 8-10). Automated data 
quality feedback in combination with the improvements and suggestions conducted through this 
research should be an ongoing and key part of clinical trials to ensure that higher quality data is 
collected in a timely manner, and so that the data is subsequently useful for all parties involved in the 
clinical collaborations and the future researchers wishing to better understand the results of the trials 
that have taken place. Such repeatability of science is increasingly demanded and a focal area for many 
research activities, but it is especially critical in a clinical and translational setting. 
Figure 8-10 Suggested categorised targets for data quality feedback
This approach taken on data quality for the PMT and EURINE-ACT studies showed an overall 
improvement in data quality. However, this thesis argues that automated feedback for each of these 
dimensions should be supported with focus on community feedback, investigator feedback and ideally 
real-time feedback to the data entry personnel. A study framework was applied on INPDR to show the 
efficacy of the community feedback however the results cannot be generalised, primarily due to the 
limited data entry over the time of the observation. In general, data quality reports should be 
delivered through generic tools and processes that are not tightly coupled with any specific study. The 
basis for any clinical trial or study is the ethics and clinical protocol, which outlines the data that is to 
be collected and how it should be processed/analysed to achieve a particular outcome. Moving 
forward, a clear specification of the data quality requirements should be a key part of such protocols.
Data quality feedback mechanisms and tools need to be implemented, supported and considered at 
the beginning of any new trial, and indeed we argue that these need to be continuously and 
consistently applied with results shared between all study personnel. Analysis at the end of the clinical 
study is too late, but unfortunately currently the norm. This thesis has shown that tools and processes 
now exist to address this situation and should be more systematically adopted and applied.
8.2 Future Work
As already pointed out, some parts of this research were underpowered due to the limited amounts 
of data entry that occurred during the period under consideration (specifically with regards to INPDR 
and PCOS). The work on ENDIA and support for mobile applications for patients themselves was also 
in the early phases of adoption. To gain insights into user motivation and demonstrate clear data 
quality improvements through feedback, the proposed stage wise study design framework has to be 
applied to other clinical registries and trials. Data feedback showed an improvement of data quality, 
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but for good epidemiologic practice a comparison with a control group should ideally be performed. 
This can happen during randomization of patients in a particular clinical study for example where 
healthy individuals and used and compared (subject to appropriate randomization) with the actual 
disease group.
The thesis discovered a correlation of research success and research funding schemes with focus 
explicitly on adrenal research. Deeper research needs to be conducted to show any true causality 
however. This can be performed in other research fields (e.g. coronary or selected infectious diseases) 
with further detailed analysis on R&D spend by country for example. This would potentially show how 
important multicenter research and ultimately improved VREs could be establish to avoid research 
funding that does not deliver true value. 
Another aspect that needs further research is the impact of national health services on data collection 
for research purposes. The comparison of centres in a multicentre trial must also focus on comparison 
with national health policies. As stated in the ENSAT monitoring visit reports, Italy does not financial 
supporting research on benign tumours, hence patients that are enrolled into a given study protocols 
have to travel their own costs. More importantly, physicians are not payed for research. In France, a 
general patient hospitalisation of a malignant tumour is covered by the national health service, which 
consequently improves data collection possibilities for research purposes. Germany covers only 
routine care and hence all research must be carried out during standard diagnostics or treatment. 
Each European health system is different to the NHS in the UK. Germany has a multi-contributing
system, covered by the government and/or the individual (depending on insurance type). The UK 
provides health care services covered by the taxpayers through the NHS. Such differences in health 
service policies need to be explored and taken into account for the evaluation of data quality in 
multicentre international trials.
For further projects in the field of eHealth and/or mHealth technologies, this proposed stage wise 
framework could be applied to gain insights into the behavior of research collaborators, patients and 
health workers more generally. The work could also be used in other contexts and situations including 
for example the rising surveillance and case management research needs and demands of developing 
countries. It is obvious, that the behavior of end user researchers and data entry personnel in third 
world and developing countries are differently motivated and presumably under resourced compared 
to collaborators in more established settings, e.g. data entry users in North America, Europe or 
Australia/New Zealand.
Technology is continually evolving and mobile phones and applications are now a ubiquitous part of 
people’s lives and society more generally. The ENDIA study and the use of mobile apps for dietary 
information has demonstrated that the technology exists for patient-specific data collection, however 
again the clear demonstration that these apps have provided a step change in data quality remains 
largely unanswered. One challenge here is that the ENDIA apps are used for collecting an extensive 
amount of information from patients on their dietary intake. The amount of data that is to be collected 
is an important factor that can directly impact upon data quality. Future clinical data collection 
opportunities with associated data quality reports through mobile applications are expected to occur.
Furthermore, with increased technological advancement, increased importance on the data quality 
dimension of data trustworthiness will arise. Ensuring that only the mothers are using the ENDIA 
mobile application can be difficult to enforce (if someone else uses their mobile phone for example). 
This is issue can of course arise in a hospital setting, but the risk is increased given that mobile phones 
can be easily mislaid or stolen. Quality dimensions need to be continually adjusted to new research 
purposes and clinical trials. It should be mandatory that every principal investigator plans the 
employment of data managers with expertise in data quality assurance and software engineering, 
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however this can be a cost that may not always be afforded. Nevertheless, detailed training should be 
a key part to all personnel involved in clinical research and data entry. As shown by this research, 
people are by far the greatest factors on data quality. Whilst automated data quality feedback can 
support improvements in data quality, this will have little impact for those with direct intrinsic or 
extrinsic motivational challenges. 
In conclusion, high data quality is an achievement, which is reached by the collaboration and 
motivation of all researcher in a research community. Data quality feedback encourages collaborators 
to collect high quality data. Therefore, high data quality will be the tool to improve the efficiency and
translation speed of findings in clinical research into clinical care.
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